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Elizabeth A. George Cisar, Ph.D. 
The Rockefeller University 2009 
Bacteria use receptor histidine kinases to sense extracellular cues and 
convert them into intracellular signaling events that allow them to respond to 
their environment. In Staphylococcus aureus, each individual cell must sense the 
size of its overall population in order to synchronize virulence factor expression 
with the entire population. This task is carried out by the accessory gene regulator 
(agr) quorum sensing system. The agr autoinducing peptide (AIP) pheromone 
activates the AgrC receptor histidine kinase, resulting in downstream 
modulation of virulence factor expression. As S. aureus is a dangerous pathogen, 
understanding virulence regulation is of great interest, and the agr system has 
been extensively studied. However, little was known about the mechanism of 
ligand-induced signal transduction by AgrC at the outset of this work. Moreover, 
AgrC is member of a unique class of histidine kinases, for which the activation 
mechanisms are equally speculative, although several of these receptors function 
in important quorum sensing processes. The aim of this work was to elucidate 
molecular mechanisms of AIP–AgrC signaling, focusing on inhibitor structure–
activity relationships and understanding how ligand binding results in AgrC 
kinase activation. A new Fmoc-based synthetic route to AIPs and -thioester 
peptides was developed and used to construct a series of inhibitor AIPs to define 
the minimal inhibitory pharmacophore. The minimized scaffold should provide 
a foundation for future medicinal chemistry efforts. The AgrC activation 
mechanism was probed via direct biochemical analysis of the receptor, which 
was previously unattainable, and mutagenesis. The results indicate that AgrC is 
a dimer and trans-autophosphorylates and that signal transduction occurs 
symmetrically within the dimer due to intermolecular conformational changes. 
This mechanism may be a general means by which dimeric quorum sensing 
receptors rapidly elicit a response upon signal detection. 
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Chapter 1: Introduction 
1.1 The Regulation of Virulence in a Superbug 
Staphylococcus aureus is an opportunistic pathogen and a major health 
threat worldwide. S. aureus is part of the commensal microbial flora of 
approximately 30% of the adult population and only becomes pathogenic if the 
bacteria are given the opportunity to invade mucous membranes or soft 
tissue (1). Most infections are cleared by the immune system or treatable with 
antibiotics; however, a weakened immune system, surgery, and implanted 
medical devices are risk factors for potentially fatal infections (2). Thus, S. aureus 
thrives in hospitals, where vulnerable patients being treated for an unrelated 
problem may become infected with their commensal strain or with a strain 
spread in the hospital; and infections that advance too quickly for successful 
antimicrobial treatment and/or are resistant to multiple antibiotics often prove 
fatal. Methicillin resistant S. aureus (MRSA) are multidrug resistant bacteria that 
were first isolated in 1961 and are now estimated to be responsible for over 
18,000 deaths in the United States per year (3). Furthermore, while nosocomial 
MRSA are the leading cause of fatal infections, the incidence of community-
acquired MRSA is also increasing at an alarming rate (4). The only antibiotic 
against which S. aureus has not gained widespread resistance is vancomycin; but 
in 1999, the first incidences of S. aureus infection with intermediate vancomycin 
resistance (VISA) were reported in the U. S. (5, 6). Therefore, much attention is 
focused on preventive measures, responsible use of antibiotics to slow the 
development of resistance, and development of new treatments to combat this 
growing problem (7-9). Key to these important efforts is to further our 
understanding of S. aureus virulence and pathogenesis.    
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S. aureus is an especially dangerous pathogen due to the relatively fast 
host-to-host transmission rate of virulent strains compared to avirulent 
strains (10), its ability to acquire antibiotic resistance, and its large, diverse 
arsenal of virulence factors that make it both uniquely adept at evading the host 
immune system and very toxic. Although disease is the very unfortunate 
outcome for the host, the sole function of virulence factors is to enable the 
bacteria to survive in the hostile conditions of the host environment (11). There 
are two main classes of virulence factors, each associated with different phases of 
population growth (Figure 1) (1). During the lag and exponential phases, S. 
aureus cells produce cell wall-associated factors that facilitate tissue attachment 
and evasion of the host immune system, allowing the bacteria to accumulate and 
possibly form a biofilm. For example, microbial surface components recognizing 
adhesive matrix molecules (MSCRAMMS) adhere to the extracellular matrix to 
give the bacteria an attachment point in the host. Protein A binds IgG antibodies 
that form a protective coat and hide them from the immune system. Once the 
population size is sufficient, the cell wall-associated factors are down-regulated 
in late exponential phase and stationary phase, allowing the bacteria to detach 
from their original colonization site and establish an invasive infection. At the 
same time, the bacteria secrete enzymes and toxins, termed exoproteins, to 
degrade host tissue and to promote spread of the infection. The degradative 
enzymes include proteases and hemolysins, which lyse red blood cells by 
creating pores in the cell membranes or by hydrolyzing membrane lipids. 
Enterotoxins are the causative agents of S. aureus food poisoning and contribute 
to toxic shock syndrome and other diseases by stimulating T-cells to produce 
proinflammatory cytokines in excessive amounts (1, 11).  
3
 
Figure 1. Coordination of Virulence Factor Expression with S. aureus 
Population Growth. Adapted from (11). During exponential growth, cell surface-
associated virulence factors are highly expressed in order to promote attachment 
to the host extracellular matrix and evasion of the host immune system. In 
stationary phase, the cell surface-associated virulence factors are down-regulated 
and expression of secreted exoproteins is induced to promote invasion of the 
host and impart toxicity. The bacteria sense the increase in population density 
via the agr system, which is activated at the transition between exponential and 
stationary phases and regulates expression of these two classes of virulence 
factors. 

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The accessory gene regulator (agr) system of S. aureus coordinates 
production of the two main classes of virulence factors with different phases of 
growth, in many cases by directly modulating their expression levels (12, 13). 
While agr is thus considered to be a global regulator of virulence, it is one of 
several genetic loci connected in a complex signaling network that precisely 
regulates the staphylococcal virulon (Figure 2) (14-17). The staphylococcal accessory 
regulator (sar) is an important regulator of virulence that mediates many of its 
effects by influencing agr expression: SarA, SarU, and SarR up-regulate agr 
transcription; contrarily SarR and SarT indirectly down-regulate agr by 
repressing expression of SarA and SarU, respectively; and some Sar proteins 
regulate virulence factors independently of agr. In a variety of infection models, 
loss of function mutations in either agr or sar exhibit reduced virulence, and the 
virulence of double agr- sar- mutants is, in some models, further reduced (18-21). 
However, the precise role of agr in the establishment of infection is unknown. 
Other important loci include S. aureus exoprotein expression (sae) (22), which may 
act downstream of agr to maintain hemolysin and coagulase expression (23), 
staphylococcal respiratory response (srr), which is required for optimal growth in 
anaerobic conditions and inhibits agr output (24), and repressor of toxins (rot), 
which counteracts many effects of agr but also induces expression of some 
exoproteins (25-27).  
The agr response synchronizes virulence factor expression among all 
members of the staphylococcal population via a bacterial communication 
mechanism called quorum sensing. The ability to communicate is essential for 
bacteria to carry out many fundamental group functions, including virulence, 
competence, bioluminescence, and biofilm formation (28). Quorum sensing  
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Figure 2. Network of Genetic Loci that Control Virulence in S. aureus. The 
expression of virulence genes such as -hemolysin (hla), -hemolysin (hld), other 
exotoxins, and Protein A (spa) is modulated by a complex, interactive network of 
many regulatory loci, including agr.  

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systems facilitate these processes by allowing each individual bacterium to sense 
the density of the entire population of which it is a member. Bacteria 
constitutively secrete signaling molecules known as autoinducers that 
accumulate to concentrations proportional to the bacterial population density in 
a closed system. An autoinducer activates its target only after reaching a certain 
threshold concentration, at which point it triggers a specific, coordinated 
response through target gene transcription. Consequently, activation of 
energetically demanding processes is limited to instances in which there are 
enough bacteria present to elicit the desired effect. In Gram-positive bacteria 
such as staphylococci, the autoinducers are short peptides, often bearing post-
translational modifications, called autoinducing peptides (AIPs) (28). At 
concentrations indicating a quorum, each AIP binds its corresponding receptor, 
resulting in either activation or inhibition of target gene transcription. In 
staphylococci, quorum sensing for coordinated virulence factor production is 
mediated by the agr AIP and signaling system (29, 30).  
The agr signaling system is a canonical two-component system (TCS). 
TCSs are ubiquitous in bacteria, allowing them to sense and react to a variety of 
stimuli, including osmolarity, pH, oxygen, chemoattractants, and 
autoinducers (31). Each TCS is typically composed of a receptor histidine protein 
kinase (HPK) that senses the signal and a response regulator (RR) transcription 
factor that modulates gene expression. The HPK receptors are typically dimeric 
and consist of a sensory domain and an histidine kinase (HK) domain, which is 
further divided into two subdomains: an -helical coiled-coil region containing 
the dimerization interface and histidine phosphorylation site (DHp), and the 
catalytic kinase domain (CA) (32). Stimulus perception by the sensory domain 
7
triggers activation of the HK domain, resulting in trans-autophosphorylation of 
the contralateral histidine and phosphotransfer to a conserved aspartate in the 
associated RR.  
The agr locus contains two divergent promoters, P2 and P3, which 
modulate transcription of RNAII and RNAIII, respectively (Figure 3A) (30). 
RNAII encodes the agr TCS and two genes required for AIP biosynthesis. AgrB is 
an integral membrane protein required to process the AgrD propeptide, resulting 
in secretion of a mature AIP that contains a thiolactone macrocycle formed 
between a conserved cysteine sulfhydryl group and the -carboxylate (19, 29). 
AgrC is a polytopic HPK that autophosphorylates and activates the AgrA RR 
upon binding to the AIP. AgrA then binds and activates transcription at the P2 
and P3 promoters (30, 33), resulting in a positive feedback loop and RNAIII 
transcription. RNAIII is the -hemolysin mRNA and a regulatory RNA that 
modulates expression of many virulence factors (13, 34). In addition to RNAII & 
III of the agr locus, AgrA was recently found to directly activate transcription of 
proinflammatory, leukolytic peptides that enhance virulence called phenol-
soluble modulins (PSMs), demonstrating that RNAIII is not the sole effector of 
the agr response (35, 36).  
The agr locus, conserved among the staphylococci and with homologs in 
many other species, has undergone an interesting evolutionary divergence, 
giving rise to variant specificity groups, of which there are four in S. aureus and 
two or more in several other staphylococcal species (37-39). The sequence 
variability of each agr specificity group is contained within agrB, agrD, and the 
transmembrane sensor domain of agrC (Figure 3B), while agrA and the HK 
8
Figure 3. The agr Locus and Variation of the Four Specificity Groups. (A) The 
AgrD propeptide is processed and secreted, in part, by AgrB to form the mature 
AIP. At the appropriate AIP concentration, the AIP binds the sensor domain of 
the receptor histidine kinase, AgrC, resulting in autophosphorylation and 
phosphotransfer to AgrA. Phosphorylated AgrA activates transcription at the agr 
P2 and P3 promoters, resulting in a positive feedback loop of the agr system and 
RNAIII transcription, which mediates many downstream effects. (B) The 
sequence variation among the four agr groups is contained within agrB, agrD, 
and the sensor domain of agrC. The sequences and structures of the four AIPs are 
shown.
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domain of agrC are identical across all four S. aureus agr groups. Each S. aureus 
agr group synthesizes a distinct AIP of seven to nine amino acids, which activates 
the cognate AgrC receptor, and the group identity of the AgrC sensor domain 
alone dictates the specificity of AIP recognition for any given population (40). 
Remarkably, cross-group AIP–AgrC interactions are inhibitory (37), with 
heterologous AIPs acting as competitive antagonists (41) and/or inverse 
agonists (42). The only exception to this intergroup interference is the cross-
activation observed between groups I & IV, the AIP sequences of which differ by 
just a single amino acid. Intraspecies quorum sensing interference may be unique 
to S. aureus, as cross-group inhibition has not been observed among the three 
known agr groups of S. epidermidis (39). The in vivo relevance and therapeutic 
implications of this intriguing phenomenon are poorly understood and the 
subject of ongoing study in several laboratories; nevertheless, cross-group 
antagonism is a valuable tool for studying AIP structure-activity relationships 
and makes agr an especially attractive model system for the study of quorum 
sensing in Gram-positive bacteria.  
1.2 Molecular Mechanisms of the agr System 
 The agr system is one of the most extensively studied quorum sensing 
systems, and the work of several labs has provided a relatively detailed picture 
of the molecular mechanisms of this pathway. The understanding of this system 
is nonetheless a work in progress, and the following section details what is 
known as well as gaps in knowledge that are yet to be filled. 
1.2.1 AIP Biosynthesis 
Significant progress has been made toward elucidating the mechanism of 
AIP biosynthesis since the initial 1997 report that AgrB is involved (29). Given  
10
that the AIP sequences are nested within the AgrD precursors of all four agr 
groups (Figure 4A), processing of each AgrD propeptide to form a cyclic AIP 
requires three chemical transformations: two proteolytic cleavage steps and 
thiolactone formation. The order of the two cleavage events and at least some of 
the proteases involved are now known, but the mechanism of thiolactonization 
remains purely hypothetical.  
The first proteolytic step removes the C-terminal tail of AgrD and is 
mediated by AgrB, as determined by western blot analysis of crude lysates 
containing epitope-tagged versions of AgrD (43). The intermediate 
corresponding to the N-terminal portion of AgrD plus the AIP sequence was 
observed only when AgrB was present, and the C-terminal AIP–AgrD fragment 
was not detected. If AgrB indeed functions as a protease, then one would expect 
to find conserved catalytic residues in the protein. There are in fact several 
conserved histidine, serine, and cysteine residues that potentially fit the bill. 
Mutagenesis experiments found that two of these residues, His77 and Cys84, are 
required for production of an active AIP (43). According to a topological model 
of AgrB (44), His77 and Cys84 are located on or near the cytoplasmic face of the 
protein, making them potentially accessible to AgrD (Figure 4B). Thus, AgrB 
may be a cysteine protease, although definitive proof of this hypothesis awaits 
further biochemical characterization of the purified protein. 
After years of speculation that other proteins in addition to AgrB may be 
involved in AIP production (43-45), a recent study finally revealed that SpsB, a 
type I signal peptidase, carries out the second cleavage event of AgrD-I, 
removing the N-terminal region (46). A synthetic group I peptide substrate, 
NIAAYST tagged with fluorescein, was added to various lysate fractions, and the 
11
Figure 4. AgrD Sequence Alignment and Proposed Mechanism of AIP 
Biosynthesis. (A) AgrD sequences with the AIP portions in green and conserved 
residues shaded yellow. The N-terminal P sites are numbered. (B) Proposed 
mechanism of AIP biosynthesis. The AgrB (38) topology is based on Zhang et al. 
(44). C-terminal cleavage of AgrD (green) is mediated by His77 and Cys84 of 
AgrB to yield an acyl-enzyme intermediate, which is released via intramolecular 
transthioesterification. Translocation by an unknown mechanism allows N-
terminal cleavage by the serine signal peptidase SpsB (44), via a serine/lysine 
catalytic diad (star). The structure is a homologous peptidase from B. subtilis (47). 
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cleavage products were identified by comparing their agarose gel retention times 
to synthetic standards. Through a series of fractionation and inhibition 
experiments, the proteolytic activity was attributed to the type I signal peptidase 
SpsB. The role of SpsB or other peptidases in the processing of the group II, III, 
and IV AIPs is yet to be determined. SpsB is identical in all agr groups, but the 
residues N-terminal to the AIP sequence within AgrD are not (Figure 4A).  
There is a conserved Asp-Glu motif immediately following each 
embedded AIP sequence, and this acidic motif presumably acts as the 
recognition site for cleavage by AgrB. However, the molecular determinants 
underlying N-terminal processing are less obvious from sequence analysis. The 
N-terminal region of each AgrD peptide contains a putative amphipathic helix 
that anchors AgrD to the membrane, and specific processing of AgrD by AgrB is 
maintained even when all residues N-terminal to P10 of AgrD are replaced with 
an unrelated amphipathic helical sequence (48). There is a conserved Ile-Gly 
motif just N-terminal to each AIP sequence, but since the lengths of the AIPs 
vary, it is separated from the site of cleavage by a different number of amino 
acids in AIPs-I/IV, II, and III (Figure 4A). Moreover, the substrate used in the 
study that revealed the involvement of SpsB in N-terminal processing of AIP-I 
did not include the Ile-Gly motif (46). Important sequence requirements for 
cleavage by SpsB are a basic or hydrophobic residue at P2, a proline at P5 that 
induces a helical turn (49), and possibly an alanine at P1 (50). All four N-terminal 
AgrD sequences contain a hydrophobic residue at P2 and a glycine (of the Ile-Gly 
motif) at or adjacent to P5 that might induce a turn (Figure 4A). However, the P1 
and P3 residues are also hydrophobic in most cases, and the position of the 
glycine is not consistent in each AgrD sequence as noted above. Furthermore, 
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only AgrD-I has an alanine at P1. Thus, either AgrD contains additional 
recognition elements that are not evident in its primary structure or proteins 
other than SpsB cleave the N-terminus of AgrD in groups II, III, and IV.  
The group specificity of AgrD processing by AgrB is not as rigid as that of 
AIP–AgrC interactions. While AgrB can only process the cognate AgrD in most 
cases, group III AgrB (AgrB-III) can process AgrD-I to form an activator of AgrC-
I, and AgrB-I can process AgrD-III to form an inhibitor of AgrC-I (37). AgrB-I & -
IV may also be capable of processing both AgrD-I & -IV, as the sequences of 
these two groups are very similar, but this hypothesis has yet to be tested. In an 
effort to understand the basis for AgrB–AgrD specificity, Zhang et al. constructed 
a panel of AgrB-I/II chimeras by swapping homologous segments of the two 
proteins, then determined their ability to synthesize active AIPs from AgrD-I & II 
in a reporter assay (51). The authors narrowed down the determinants of 
specificity in AgrB-I to amino acids 43 to 67 and to residues 126 and 141 in AgrB-
II. While the lack of expression and localization data for the mutant proteins is a 
caveat of this study, it is nonetheless interesting that the specificity determinants 
for AgrB-I and AgrB-II appear to be in different regions of the primary sequence. 
Further study will be needed to reveal the how these patches impart specificity 
and which features of the AgrD propeptides they recognize.   
Based on all of the studies reviewed above, the working model of AIP 
formation is shown in Figure 4B. First, AgrD anchors to the membrane and is 
recognized by AgrB, which generates an acyl-enzyme thioester intermediate 
upon nucleophilic attack by the catalytic cysteine. Transthioesterification by the 
conserved AgrD cysteine mediates release from AgrB. The resulting N-terminal 
AgrD–AIP thiolactone intermediate is transported through the membrane by 
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AgrB or an unknown protein and cleaved by the SpsB signal peptidase, releasing 
the mature AIP into the extracellular milieu. While the proposed concomitant 
amidolysis, transthioesterification mechanism is appealing, the final word on this 
fascinating maturation process awaits the development of a reconstituted 
AgrB/AgrD system. 
1.2.2 AIP Structure-Activity Relationships 
A large effort has been made toward determining the structure–activity 
relationships of the four AIPs by employing synthetic methods and a rapid, 
quantitative agrP3::blaZ reporter assay (19, 29, 40, 41, 52-54). Efficient chemical 
synthesis of AIPs combine solid-phase peptide synthesis (SPPS) and solution 
phase chemistry (19, 52, 53). In the most efficient protocol using Boc chemistry, 
the linear peptide is first synthesized by SPPS on an -thioester-generating resin, 
then cleaved from the solid support, and the final AIP product is obtained by 
spontaneous transthioesterification of the unprotected peptide -thioester in 
neutral aqueous solution (52) (Figure 5). Synthetic AIPs are extremely potent 
agonists and antagonists of cognate and non-cognate AgrC receptors, 
respectively, with EC50 and IC50 values in the low nanomolar range (19). The 
recognition determinants for agonism are much more stringent than those for 
antagonism, consistent with the requirement for group-specific AIP–AgrC 
interactions for activation but not inhibition (19, 40, 53). For example, the 
exocyclic “tail” residues are dispensable for inhibition but not activation (19, 40). 
Indeed, some truncated AIPs consisting of only the pentapeptide macrocycles 
inhibit all four S. aureus AgrC receptors, including the cognate AgrC (Table 1). 
Furthermore, replacement of the AIP thiolactone linkage with a lactam or lactone 
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Table 1. Structure-Activity Relationships of AIPs Made Prior to this Work. 
AgrC Activation AgrC Inhibition AIP 
Derivative 
AIP 
Sequence I II III IV I II III IV 
AIP-I  YSTCDFIM +++ – – + – +++ +++ – 
AIP-II GVNACSSLF – +++ – – +++ – +++ +++ 
AIP-III   INCDFLL – – +++ – +++ +++ – ++ 
AIP-IV  YSTCYFIM ++ – – +++ – +++ +++ – 
AIP-I–II  YSTCSSLF – – – – +++ ++ +++ +++ 
AIP-II–I GVNACDFIM – – – – ++ +++ ++ + 
AIP-II 
Lactone 
GVNASSSLF – – nt nt +++ – nt nt 
AIP-II 
Lactam 
GVNA(Dapa) 
-----SSLF 
– + nt nt +++ – nt nt 
trAIP-II     CSSLF – – – – ++ ++ +++ ++ 
trAIP-I     CDFIM + – – – + +++ ++ – 
trAIP-IV     CYFIM – – – – ++ +++ +++ + 
trAIP-I/IV 
2A 
    CAFIM – – – – +++ +++ +++ +++ 
AIP-II G1A AVNACSSLF – +++ nt nt +++ – nt nt 
AIP-II V2A GANACSSLF – ++ nt nt +++ – nt nt 
AIP-II N3A GVAACSSLF – – – – +++ ++ +++ +++ 
AIP-II S6A GVNACASLF – +++ nt nt +++ – nt nt 
AIP-II S7A GVNACSALF – +++ nt nt +++ – nt nt 
AIP-II L8A GVNACSSAF – – nt nt – – nt nt 
AIP-II F9A GVNACSSLA – – nt nt – – nt nt 
AIP-I Y1A  ASTCDFIM ++ nt nt nt – nt nt nt 
AIP-I S2A  YATCDFIM +++ nt nt nt – nt nt nt 
AIP-I T3A  YSACDFIM ++ nt nt nt – nt nt nt 
AIP-I/IV 5A  YSTCAFIM – – – – +++ +++ +++ +++ 
AIP-I/IV 5N  YSTCNFIM +++ – ++ – – +++ – +++ 
AIP-I/IV 5F  YSTCFFIM +++ – – +++ – +++ +++ – 
AIP-I F6A  YSTCDAIM + nt nt nt – nt nt nt 
AIP-I I7A  YSTCDFAM + nt nt nt – nt nt nt 
AIP-I M8A  YSTCDFIA + nt nt nt – nt nt nt 
AIP-I M8I  YSTCDFII +++ – – ++ – +++ +++ – 
AIP-III 8 AA  YINCDFLL nt nt – nt ++ nt ++ nt 
AIP-III 9 AA AYINCDFLL nt nt – nt nt nt ++ nt 
 
+, ++, +++ = weak to strong activity. – = no activity detected. nt = not tested. 
Dapa = diaminopropanoic acid. trAIP = truncated AIP. AA = amino acids. 
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Figure 5. AIP Synthetic Route via Boc-Based Solid Phase Peptide Synthesis. A 
mercapto-propionic linker is synthesized on resin, and coupling of the C-
terminal amino acid results in thioester formation. Chain elongation is achieved 
with standard Boc-based solid phase peptide synthesis (SPPS) conditions, The 
peptide is cleaved from the resin with anhydrous HF and cyclized via 
intramolecular transthioesterification upon addition of aqueous buffer at neutral 
pH. The synthesis of AIP-II is shown as an example.  
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causes a dramatic reduction in agonistic potency but has virtually no effect on 
antagonism (19, 53). However, linear versions of the AIPs are completely 
inactive, demonstrating that a macrocyclic structure is one requirement for 
inhibition as well as for activation (19). The presence of two bulky hydrophobic 
residues at the C-terminus, a strongly conserved feature of the staphylococcal 
AIPs (Figure 6), also seems to be critical for binding and activity since alanine 
substitutions at either of these positions in AIP-II result in a dramatic reduction 
in agonist and antagonist potency (19). Thus, the macrocycle and hydrophobic 
motif are important for bioactivity, and the thioester and tail residues are 
additionally required for receptor activation but not for binding or inhibition. 
While all four S. aureus AIPs follow the general paradigm described 
above, determinants of specific AIP–AgrC interactions vary considerably among 
the different groups. Alanine scanning mutagenesis revealed that the key 
residues for receptor activation lie in different positions in the sequences of 
different AIPs (19, 53). For example, Asp5 of AIP-I, which lies in the macrocycle, 
and Asn3 of AIP-II, which is in the tail, are critical determinants for specific 
activation of the corresponding AgrC-I & -II receptors. Loss of these side chain 
functionalities in the AIP-I D5A and AIP-II N3A mutants results in loss of 
specificity but not activity, as the mutant peptides maintain antagonism of non-
cognate AgrC receptors and are converted to antagonists of their cognate 
receptors (Table 1). Conversely, substitution of an amide for the acid in AIP-I 
D5N unexpectedly converts the peptide to an AgrC-III agonist (52). Finally, non-
native appendages, such as biotin, can be conjugated to the N-terminus of AIP-I 
without significantly affecting activity, but the addition of one amino acid to the 
N-terminus of AIP-III leads to a loss of agonism (52). 
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Figure 6. Sequence Alignment and Hydrophobicity Profiles of Known and 
Predicted Staphylococcal AIPs. Polar residues are shaded blue and non-polar 
residues are shaded yellow, highlighting the conserved C-terminal hydrophobic 
motif outlined in black. The conserved cysteine is shaded in gray, and note that 
the S. intermedius AIP contains a serine instead of a cysteine that forms a lactone 
instead of a thiolactone. This figure is adapted from Wright et al. (55). 
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The mechanism of intergroup agr interference is thought to be competitive 
antagonism of the AgrC receptor (41). The relaxed AIP sequence requirements 
for antagonism suggest that an AIP binding event is sufficient for blocking 
activation of AgrC by a cognate AIP and that AgrC activation requires an 
additional, specific agonistic interaction. Wash-out and order of addition 
experiments indicated that both agonists and antagonists bind AgrC in a 
reversible manner (41), consistent with competitive antagonism and 
contradictory to an earlier model involving receptor acylation by the thioester-
containing AIP (19). To further test this idea, AgrC was treated with various 
concentrations of antagonistic AIPs to construct a series of AgrC activation 
curves (41). As expected for simple competitive antagonism, the curves shifted in 
dextral fashion in the presence of increasing antagonist. However, the derived 
Schild slopes were significantly less than unity, the value expected for simple 
antagonism. Moreover, inverse agonism was recently observed in constitutively 
active AgrC mutants (42), raising the possibility that some non-cognate AIPs 
induce and/or stabilize an inactive receptor conformation. Ultimately, a direct 
AgrC-AIP binding assay will be needed to fully understand the molecular 
pharmacology of agonism and antagonism of the receptor.  
1.2.3 AIP Recognition by the Receptor Histidine Kinase, AgrC 
 AgrC is a member of the small, unique HPK10 family of quorum sensing 
receptors in Gram-positive bacteria (Figure 7A) (56). These receptors have 
polytopic transmembrane sensor domains and distinctive sequences 
surrounding the phosphorylation site histidine and catalytically important N-box 
and G-box residues. They also lack a D-box motif, typically involved in 
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Figure 7. Histidine Protein Kinase Family 10 Alignment and AgrC Domain 
Structure. (A) Alignment of three conserved motifs among six HPK10 family 
members and two distantly related HPKs of Gram negative bacteria (56). 
Residues that are identical among all HPKs shown are shaded yellow and other 
conserved motifs are shaded turquoise. The H-box histidine is the site of 
phosphorylation, and the N-box and G-box asparagine and glycines are 
important for ATP binding. (B) The domain structure of AgrC, including the 
locations of the residues shaded yellow in (A). The hash marks indicate a 
predicted coiled-coil. The transmembrane topology of AgrC-I is shown (57), 
along with three residues important for recognition of AIP-I (58).  
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nucleotide binding, and a coiled-coil HAMP (histidine kinase, adenylyl cyclase, 
MCP, and phosphotase) domain, which links the sensor and HK domains and 
often plays roles in dimerization and signal transduction in other HPKs (59-61). 
AgrC contains a putative coiled-coil in the DHp subdomain (Figure 7B), which 
may mediate homodimerization; but at the outset of this study, there was no 
definitive proof that AgrC is a homodimer either before or after AIP binding. It is 
generally believed that AIP binding results in trans-autophosphorylation of an 
AgrC dimer and subsequent phosphorylation of AgrA on a conserved aspartate 
residue (33, 57). However, experimental evidence for this model was missing 
prior to this work, and the question of how AgrC transduces the extracellular 
AIP signal to trigger intracellular kinase activation was open.  
While both activation and inhibition determinants of the AIPs have been 
extensively studied as described in Section 1.2.2, work to understand the 
corresponding specificity determinants in the AgrC receptors has just recently 
begun. In the first study to probe this question, AgrC sensor domain chimeras 
were constructed (55). Segments of the proximal and distal halves of the sensor 
domains were switched among different receptor specificity types, 
corresponding to different S. aureus agr groups. These intradomain chimeras 
were then tested for activation and inhibition specificity against synthetic AIPs 
and AIP analogues. This approach facilitated localization of the region of 
receptor–ligand specificity and uncovered a key hydrophobic AgrC–AIP 
recognition, which may explain the mechanism of staphylococcal cross-group 
interference. 
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 The AgrC sensor domain comprises the first ~205 amino acids out of 430 
and contains six predicted transmembrane domains (Figure 7, 8) (57). Although 
the sensor domains of the four AgrC receptors are divergent, the transmembrane 
topology appears to be highly conserved, as judged by the spacing of the 
putative hydrophobic -helices (55). Residues 86-93 within the third 
transmembrane domain are identical in AgrC-I, III, & IV and were chosen as the 
junction site for the AgrC chimeras (Figure 8). The resulting constructs were 
transduced into a -lactamase reporter strain (52) in order to analyze their 
activities. In general, the functionality of each chimera was proportional to the 
degree of sequence conservation between the two contributing receptors. AgrC-I 
& IV sensor domains share 87% sequence identity, and both AgrC-I::IV (N-
terminal portion of AgrC-I fused to C-terminal portion of AgrC-IV sensor 
domain) and AgrC-IV::I were functional. Chimeras involving AgrC-III (~54% 
sequence identity with AgrC-I & IV) were functional but had unpredictable 
activities. Finally, chimeras involving AgrC-II, the receptor of the most divergent 
agr group, were not functional. Attempts to detect AgrC and the chimeras by 
western blot were unsuccessful in this study; thus, it was unclear whether the 
lack of function was due to poor expression or the inability to respond to the AIP 
agonist. The activities of the six functional chimeras, AgrC-I::IV, IV::I, I::III, III::I, 
III::IV, and IV::III, were tested (55).  
 The chimeras of the group I & IV receptors were activated by both AIP-I & 
IV and inhibited by AIP-II and truncated AIP-II (trAIP-II), in line with the trends 
observed with the two native receptors (Table 2). However, AgrC IV::I was 
activated much more strongly by AIP-I than AIP-IV; whereas, the opposite was  
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Figure 8. AgrC Topology. The red line in the third transmembrane region 
represents the chimeric junction used in the study by Wright et al. (55). The 
sequence shown is of AgrC-I, and the shaded residues indicate the amino acids 
that differ in AgrC-IV. Five key residues for group I/IV specificity are 
highlighted (58), and the corresponding amino acids of AgrC-IV are shown. This 
figure is adapted from Geisinger et al. (58), and the topology shown is based on 
Lina et al. (57).  
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Table 2. Activities of AIPs and AIP Derivatives against AgrC Sensor Domain 
Chimeras. 
AIP 
Derivative 
AgrC- 
I::IV 
AgrC-
IV::I 
AgrC- 
III::I 
AgrC-
III::IV 
AgrC-
I::III 
AgrC-
IV::III 
 Activation EC50 (nM), (95% CI) 
AIP-I + 
1220, 
(1050-1410) 
++ 
30, 
(15-45) 
+ 
1700, 
(1500-1900) 
- + ++ 
AIP-II - - - - + 
3100 
+ 
640 
AIP-III - - - - ++ 
48 
++ 
4 
AIP-IV ++ 
6,  
(5-7) 
++ 
120, 
(110-125) 
- + 
340, 
(290-410) 
++ ++ 
AIP-I/IV 5N - + 
440, 
(350-530) 
- - ++ ++ 
AIP-I/IV 5A - - - - ++ ++ 
trAIP-II - - - - ++ 
160 
++ 
50 
AIP-II N3A nt nt nt nt ++ ++ 
AIP-II L8A nt nt nt nt - - 
AIP-II F9A nt nt nt nt - - 
AIP-II F9Nal nt nt nt nt - - 
Linear AIP-I nt nt nt nt + 
3100 
+ 
6700 
Linear AIP-II - nt nt nt - + 
 Inhibition IC50 (nM), (95% CI) 
AIP-I nt nt nt + nt nt 
AIP-II + + + + nt nt 
AIP-III - + + + nt nt 
AIP-IV nt nt + nt nt nt 
AIP-I/IV 5N + nt + + nt nt 
trAIP-II + + + + nt nt 
AIP-II L8A nt nt nt nt nt - 
AIP-II F9A nt nt nt nt nt - 
Linear AIP-II - nt nt nt - nt 
 
Chimeras are notated as AgrC-X::Y, referring to the agr group identities of the N-
terminal (X) and C-terminal (Y) portions of the sensor domain. Precise EC50 and 
IC50 values and 95% confidence intervals are given if known. Number of plus (+) 
symbols indicates the approximate activity. + = EC50 or IC50 value <200 nM. ++ = 
EC50 or IC50 value >200 nM. - = no detectable activity. nt = not tested. 
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true for AgrC-I::IV (Table 2). As previously suggested by Lina et al. (57), this 
result indicates that the major determinant of AIP recognition is in the distal, C-
terminal region of the sensor, at least within agr groups I & IV. The 
corresponding moiety within the AIP that makes the defining group-specific 
contact with the AgrC distal region is the residue at position five within the 
thiolactone ring, as it is the only difference between AIP-I & IV (Figure 3). 
Furthermore, an AIP derivative with asparagine at this position (AIP-I/IV 5N) 
that activates AgrC-I but inhibits AgrC-IV (52), has precisely the same effects 
with the AgrC-IV::I & I::IV chimeras, activating the former and inhibiting the 
latter (Table 2). Nonetheless, the N-terminal, proximal region of AgrC also 
contributes a significant role in receptor specificity, as AIP-I was much more 
potent against AgrC-I::IV than against the native AgrC-IV (Table 1 & 2).  
 The sensor domain chimeras in which the proximal region was derived 
from AgrC-III followed the trend of the AgrC-I/IV chimeras but were much less 
sensitive to activation by the AIPs.  For example, AgrC-III::I was activated by 
AIP-I at concentrations two orders of magnitude higher than that required to 
activate AgrC-IV::I and was not cross-activated by AIP-IV (Table 2). Similarly, 
AgrC-III::IV was activated by AIP-IV but not AIP-I or III. In fact, AIP-IV and 
AIP-I/IV 5N inhibited AgrC-III::I, and AIP-I inhibited AgrC-III::IV, adding 
support to the idea that the proximal region of the AgrC sensor plays a role in 
specificity, albeit inferior to that of the distal region.  
 The results with the final AgrC-I::III & IV::III chimeras were quite 
surprising. Akin to the behavior of the chimeras described above, they were 
preferentially responsive to AIP-III; however, both of these chimeras were also 
strongly activated by many other AIP analogs (Table 2). These included several 
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potent inhibitors of AgrC-III, such as AIP-I, II, & IV (19, 37), and inhibitors of all 
four agr groups, such as AIP-I D5A and trAIP-II (40, 52). Even linear AIP-I & II, 
which are generally inert against AgrC (37, 53), were found to weakly activate 
one or both of these chimeras. Moreover, no AIP or AIP derivative tested could 
inhibit activation of either receptor. Whereas the requirements for activation are 
typically much stricter than those for inhibition, AgrC-I::III & IV::III seemed 
poised for activation by any ligand that can bind. These chimeras appeared to no 
longer be regulated by putative group-specific determinants that are presumed 
to be responsible for activation of native AgrC receptors.   
 One commonality among all the AIPs and AIP derivatives that activated 
AgrC-I::III & IV::III and, in fact, among all known AIPs (Figure 6) is the presence 
of two hydrophobic, usually bulky amino acids at the C-terminus. With the 
exception of the central cysteine, no other positions in the AIPs are so strongly 
conserved. Replacement of the corresponding residues with alanine in the AIP-II 
derivatives L8A & F9A abolished agonism and antagonism of AgrC by these 
peptides (Table 1) (19). These observations, along with the results involving 
AgrC-I::III & IV::III led to the hypothesis that an AIP agonist makes two types of 
interactions with the receptor: a general hydrophobic interaction mediated by at 
least one of the C-terminal nonpolar residues in the peptide; and a sequence-
specific contact that results in activation via change(s) in receptor conformation. 
According to this premise, a distortion within the AgrC-I::III & IV::III chimeras 
bypasses the need for specific contacts, and all that is required for activation is 
the ability to bind. A major prediction of this hypothesis is that removal of one or 
both bulky, hydrophobic C-terminal side chains will eliminate binding and thus 
eliminate activation of the AgrC-I::III & IV::III chimeras. 
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To test this prediction, AgrC-I::III & IV::III were treated with AIP-II L8A & 
F9A and found to be completely insensitive to these peptides (Figure 9 and 
Table 2). In contrast, AIP-II N3A and AIP-I D5A, which contain alanine 
substitutions at sites crucial for activation of native AgrCs and inhibit all four S. 
aureus agr groups (41, 52), were strong activators of AgrC-I::III & IV::III. This 
finding suggests that an alanine replacement at either of the C-terminal positions 
in the hydrophobic patch of the AIP causes a significant defect on receptor 
binding. However, an AIP-II variant with naphthylalanine at position nine, 
designed to increase the C-terminal hydrophobicity and therefore the potency of 
AIP-II failed to activate the native and chimeric AgrC receptors, suggesting that a 
steric constraint superseded the hydrophobic interaction in this case. 
Based on the finding that the determinants for specific recognition of AIP-
I vs. IV are localized to the C-terminal region of the AgrC sensor domain, 
Geisinger et al. (58) set out to find the individual amino acids responsible for the 
ligand specificity. Of the 27 amino acid differences between the AgrC-I & IV 
sensor domains, only seven are located in the C-terminal region of interest 
(Figure 8). According to a topological model of AgrC (57), five of those seven 
residues are located in or near one extracellular loop, while the other two are 
facing the cytoplasm. Thus, the five residues of interest in AgrC-IV were 
systematically replaced with the corresponding amino acids in AgrC-I, and 
reciprocal mutations were made in AgrC-I. The activities of the resulting 
constructs showed that the main specificity determinants between AgrC-I & IV 
are indeed the five divergent residues in the second extracellular loop. 
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Figure 9. Dose-response Curves for AIP-II and Derivatives against AgrC-
IV::III. Data are presented as percent maximal activation of the receptor by AIP-
II expressed as Vmax -lactamase activity. All data points represent two to three 
replicates, and error bars represent standard error measurements (SEM). Nal = 
naphthylalanine. 
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 Initially, all five residues (100, 101, 104, 107, and 116) were swapped 
between AgrC-I & IV, and the activities of the resulting constructs, AgrC-IV (100-
116 C-I) and AgrC-I (100-116 C-IV), were quantified in a -lactamase reporter 
assay (52). The mutations switched the specificities of both receptors almost 
completely (Table 3), indicating that the determinants of AgrC specificity for 
groups I & IV indeed lie in the central extracellular loop (Figure 8). AgrC-IV (100-
116 C-I) was more sensitive to AIP-I than AIP-IV with EC50 values matching 
those for wild type (WT) AgrC-I and vice versa, the only exception being that 
AgrC-I (100-116 C-IV) was more sensitive to AIP-I than WT AgrC-IV.  
 To assess the individual contributions of each residue, many AgrC-I & IV 
mutants were constructed in which one to four of the residues of interest were 
switched between the two receptors. This analysis facilitated further narrowing 
of the major specificity determinants to Thr/Val104, Ser/Val107, and Ser/Ile116, 
although the specificity switch exhibited by these three changes was not quite as 
robust as when all five residues were swapped (Table 3).     
Examination of the key specificity determinants of the AIPs and AgrCs 
revealed an interesting trend. Position five of AIP-I (Asp) and positions 104, 107, 
and 116 in AgrC-I (Thr, Ser, Ser) are all polar amino acids, while the 
corresponding positions in AIP-IV (Tyr) and AgrC-IV (Val, Val, Ile) are all 
nonpolar (Figure 8). Thus, Geisinger et al. (58) hypothesized that polar versus 
nonpolar interactions drive specificity in this case. Position five of AIP-I/IV was 
replaced with different polar and nonpolar residues to test whether these AIP 
derivatives also followed the observed trend. Whereas the activity of AIP-I/IV 
5N was consistent with the hypothesis and activated WT AgrC-I but not AgrC-
IV; surprisingly, AIP-I/IV 5L also activated AgrC-I but not AgrC-IV (Table 3). In  
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Table 3. Activities of AgrC-I/IV Mutants. 
AgrC Variant AIP-I AIP-IV AIP-I/IV 
5N 
AIP-I/IV 
5L 
 Activation EC50 (nM), (95% CI) 
AgrC-I 11, 
(9-12) 
100, 
(86-130) 
85, 
(61-120) 
20, 
(15-28) 
AgrC-IV 1500, 
(1000-2100) 
16, 
(13-20) 
– – 
AgrC-IV (100-116 C-I) 25, 
(22-28) 
140, 
(130-160) 
180, 
(160-200) 
290, 
(170-490) 
AgrC-I (100-116 CI-IV) 44, 
(34-58) 
7, 
(6-8) 
nt nt 
AgrC-IV (104, 107, 116 C-I) 37, 
(31-43) 
45, 
(38-55) 
130, 
(110-160) 
19, 
(17-22) 
AgrC-I (104, 107, 116 C-IV) 520, 
(440-620) 
290, 
(250-330) 
nt nt 
AgrC-IV (107, 116 C-I) 50, 
(40-63) 
56, 
(45-71) 
150, 
(130-170) 
29, 
(23-36) 
AgrC-I (107, 116 C-IV) 450,  
(330-610) 
100, 
(85-120) 
nt nt 
AgrC-IV (100, 101 C-I) 1100, 
(1000-1300) 
620, 
(560-670) 
– nt 
AgrC-I (100, 101 C-IV) 8, 
(7-9) 
15, 
(12-18) 
nt nt 
 
95% CI = 95% confidence interval. – = no activity up to the highest concentration 
tested, > 10 μM. nt = not tested.  
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fact, AIP-I/IV 5F is the only position five substitution that has been shown to 
strongly activate AgrC-IV (Table 1) (52). These results suggest that the ligand 
specificity of AgrC-I is broader than that of AgrC-IV, and further work will be 
required to determine the exact nature of the interaction of position five of AIP-
IV with AgrC-IV.  
In a subsequent, similar study, Jensen et al. (62) swapped the five key 
residues in the middle extracellular loop of AgrC-I & IV plus residues in or near 
the first extracellular loop (Figure 8). When residues 35, 38, 39, 41, 42, 44, and 45 
of AgrC-IV were mutated to the corresponding amino acids of AgrC-I, the 
potency of AIP-IV dropped more than two orders of magnitude, and the 
reciprocal substitutions in AgrC-I abolished the ability of AIP-I to activate it. 
However, inhibition did not appear to be affected by the mutations, as AIP-
I/IV 5A was a potent inhibitor of both mutant receptors. This result suggests that 
the loop one residues contribute important determinants for activation, 
consistent with the earlier findings using AgrC sensor domain chimeras (55). An 
alternative possibility is that the seven replacements in AgrC result in poor 
expression that explains the weakened activation relative to WT receptors. 
1.2.4 The AgrA Response Regulator 
The AgrA RR contains 238 amino acids split into two main domains, as 
predicted by homology modeling (Figure 10A) (63). The putative 
phosphorylation site aspartate is in the N-terminal CheY-like receiver domain, 
which presumably modulates DNA binding by the C-terminal LytTR domain. 
The majority of RRs bind DNA via helix-turn-helix or winged helix motifs, but 
RRs of the LytTR family contain a novel fold (63, 64). Recently, a crystal structure 
of residues 137-238 of AgrA in complex with a 15-base pair DNA duplex showed 
32
Figure 10. AgrA Domain Structure and LytTR Domain Crystal Structure. (A) 
AgrA domain structure. The N-terminal CheY-like receiver domain is 
phosphorylated by AgrC, causing an activating conformational change in the C-
terminal DNA binding LytTR domain. The approximate position of the 
phosphorylation site aspartate based on sequence alignment is shown. (B) The 
structure of the LytTR domain in complex with DNA was recently solved (64), 
demonstrating that AgrA has a novel ten-stranded  fold arranged into three 
antiparallel  sheets. Three key residues that interact with DNA are indicated. 
The  strands are colored blue, and the helices are colored red.  
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that it contains a novel 10-stranded  fold (Figure 10B) (64). His169 and Arg233 
make base-specific contacts with DNA, and subsequent mutagenesis confirmed 
they are essential for DNA binding. However, the structure did not provide an 
explanation for the previous observation that the appropriate length of the C-
terminus is essential for activity (65). A frameshift mutation in agrA resulting in a 
C-terminal amino acid sequence of KKNIIR instead of KKI is the cause of a delay 
in RNAIII production and lack of hemolytic activity in S. aureus strain RN4220. 
Addition of acetyl phosphate promotes homodimerization of AgrA, suggesting 
that the phosphorylated dimer is the active species (33). Thus, the AgrA C-
terminus may be important for homodimerization, stability, or other protein–
protein interactions (33, 64). Additionally, the conformational changes associated 
with phosphorylation and how they regulate the LytTR domain as well as the 
recognition of and interaction with AgrC by AgrA are yet to be characterized. 
1.2.4 Output of the agr Response 
The primary effector molecule of the agr response, RNAIII, acts as both a 
messenger and antisense RNA to carry out multiple functions (13). The 514 
nucleotide transcript contains fourteen hairpin stem loops (Figure 11), including 
three C-rich hairpins, which is unusual for an AT-rich organism such as S. aureus 
(66). Nucleotides 85-165 encode the exotoxin -hemolysin, and 300 nucleotides 
downstream, the 3’-end regulates its expression through a poorly understood 
mechanism (66, 67). The RNAIII 5’-region directly up-regulates hla (-hemolysin) 
by annealing to the mRNA translation initiation region, causing a conformational 
change that unmasks the ribosomal binding site (68). Conversely, the RNAIII 3’-
end binds and occludes the ribosomal binding site of mRNAs targeted for down- 
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Figure 11. RNAIII Structure. The fourteen hairpin loops are numbered, as are 
the nucleotides. This figure is taken from Huntzinger et al., and the line drawn 
through the image pertains to experiments completed in that study (70). 

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regulation, including several cell surface-associated virulence factors and the 
pleiotropic transcription factor rot (26, 69, 70). The expression of other virulence 
genes modulated by agr may also be directly mediated by RNAIII, by regulation 
of transcription factors in addition to Rot, or by undiscovered targets of 
AgrA (35). 
Until recently, the regulation of virulence via induction of transcription at 
the agr P2 and P3 promoters by AgrA was the only known output of the agr 
response. However, Queck et al. observed that genes related to carbohydrate and 
amino acid metabolism and staphyloxanthin pigment biosynthesis are down-
regulated upon agr activation by a mechanism they were unable to 
determine (35). The effect was observed even when RNAIII was deleted, and 
AgrA is unlikely to be involved since the target genes lack consensus AgrA 
binding sequences (35). Furthermore, phenol-soluble modulins (PSMs), virulence 
factors prevalent in community-acquired strains of MRSA (as opposed to 
hospital-acquired strains) (36), were found to be up-regulated by the agr 
response independent of RNAIII expression (35). In this case, the promoter 
regions contain AgrA consensus binding sequences, and AgrA was shown to 
bind and activate transcription of PSMs.  
1.3 Goals of this Work 
The overall goal of this work was to elucidate molecular mechanisms of 
AgrC signaling in order to further develop the understanding of the polytopic 
peptide-sensing HPK10 receptor family and of virulence regulation in S. aureus. 
As described above, the requirements for inhibition of AgrC are significantly less 
stringent than those for activation, and while many AIP derivatives lose the 
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ability to activate, almost all of those tested maintain inhibition. Hence, one aim 
was to determine the minimal determinants within AIPs for inhibition of AgrC. 
This endeavor necessitated a streamlined AIP synthesis; thus, the development 
of a convenient method for the synthesis of Fmoc-based thioester peptides was 
an additional goal. While those efforts were fruitful, the major focus of this work 
was to elucidate the mechanism of AIP-induced activation of AgrC. The 
paradigm for HPK signaling is that they function as dimers and undergo trans-
autophosphorylation (32, 71), but it was not known whether AgrC or other 
HPK10 receptors follow this model. The first step was to resolve this uncertainty, 
and if the hypothesis that AgrC follows this precedence is correct, a further aim 
was to determine whether or not AIP binding affects oligomerization. A related 
goal was to determine the AIP–AgrC stoichiometry. Finally, perhaps the most 
intriguing question regarding the mechanism of AgrC signaling is how 
recognition of the AIP signal is transduced through the receptor to activate the 
kinase domain, and the last aim of this work was to shed light on that issue. 
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Chapter 2: Inhibitors of AgrC Prepared by Fmoc-Based Peptide Synthesis  
2.1 Introduction 
Despite the fact that many AIP derivatives have been synthesized and 
characterized (19, 40, 41, 52-54) (Table 1), linear AIPs and those missing bulky 
hydrophobic side chains at the C-terminus are the only variants found thus far to 
lack inhibitory activity (19, 55). Even substantial modifications, which 
dramatically reduce the ability to activate, compromise inhibitory potency only 
slightly if at all. For example, removal of the four tail residues of AIP-II, nearly 
half of its nine amino acids, has little effect on inhibition of AgrC-I, -III, & -IV, 
and converts the peptide from an agonist of AgrC-II to an antagonist (40). These 
observations raised the question of how much further the AIP structure can be 
minimized before losing the ability to inhibit AgrC, and the truncated AIP-II 
(trAIP-II) pentapeptide provided an ideal starting point. In order to define the 
minimal AIP pharmacophore and discover the minimal determinants for AgrC 
inhibition, ten trAIP-II analogues were synthesized. The peptide backbone, side 
chains, thiolactone linkage, and N-terminus were modified to systematically 
probe each structural element of the molecule. To rapidly synthesize these 
peptides in parallel, an Fmoc-based method was preferred to avoid a bottleneck 
at the cleavage step, which requires use of anhydrous HF in Boc-based methods. 
The synthesis of Fmoc-based thioester peptides has been a longstanding problem 
due to the incompatibility of thioesters with basic Fmoc deprotection conditions. 
While many methods have been reported, none have gained widespread use 
owing to various drawbacks, including lack of generality and low yields (72, 73). 
Therefore, a new Fmoc-based AIP synthesis was developed for this study that is 
also generally useful for the preparation of linear thioester peptides.  
38
2.2 A New Synthetic Method for Thioester Peptides and AIPs via Fmoc-SPPS 
 An attractive starting point from which to develop a more convenient 
method for the generation of thioester peptides by Fmoc-SPPS was the latent 
thioester-linker work of Botti et al. (74) and Warren et al. (75). In these methods, 
C-terminal thioesters are masked as esters during amino acid coupling steps then 
revealed via an intramolecular O to S acyl shift. Whereas the Warren 
methodology requires a solution-phase coupling step with a partially protected 
peptide, the simpler Botti methodology seemed more amenable to adaptation for 
use in an AIP synthesis. In this approach, Fmoc-cysteine (t-butylthio)-OH is first 
coupled to PEGA resin, followed by -amino diazotization and subsequent 
hydrolysis under aqueous conditions to afford an -hydroxy cysteine resin 
(Figure 12A). After chain elongation and cleavage from the resin, reduction of the 
cysteine side-chain disulfide leads to an O to S acyl shift, resulting in -thioester 
formation. The authors chose thiophenol as the reducing agent (Figure 12B), as 
the main motivation of the work was to generate thioesters for use in native 
chemical ligation (76). However, TCEP was used for AIP synthesis (Figure 12D) 
to avoid reduction of the AIP thiolactone. AIPs were successfully generated with 
this slight adaptation of the Botti method, but the isolated yields were very low. 
This result highlights the main drawback of this method: the linker is 
synthesized on resin, consequently limiting the resin options to those that have 
good swelling properties in water that often result in low yields. To overcome 
this limitation, a solution-phase synthesis of 2-(t-butyl-dimethyl-silanyloxy)-3-t-
butyldisulfanyl-propionic acid (5) (Figure 12C) was designed to make a version 
of the linker that can be coupled to any resin using standard approaches.  
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Figure 12. Synthetic Routes for Fmoc-Based Thioester Peptides. (A) Synthetic 
scheme of Botti et al. (74). Diazotization of the -amine on PEGA resin (orange) 
in aqueous conditions yields an -hydroxyl. (B) Thiophenol reduces the linker 
disulfide, and the resulting acyl shift reveals the thioester. (C) New Fmoc-based 
AIP synthesis. The -hydroxy cysteine linker (5) is made from thioglycerol and 
coupled to Rink resin (blue) via standard SPPS. (D) Addition of TCEP results in 
one-pot reduction, O to S acyl shift, and transthioesterificaiton, yielding the AIP.  
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Initial efforts to generate -hydroxy-cysteine-based linkers in solution 
from t-butylthiol protected L-cysteine proved to be unsatisfactory, primarily due 
to the poor yields associated with the diazotization/hydrolysis step. Therefore, 
we adopted an alternate route in which the linker was generated in five steps 
from commercially available thioglycerol, with an overall yield of 31%. As shown 
in Figure 12C, the thiol group was first protected as the t-butyl disulfide to give a 
1,2-diol (1). Attempts to selectively oxidize the primary alcohol directly to the 
carboxylic acid using TEMPO were unsuccessful. Instead, protection of both 
alcohols with t-butyl-dimethyl silanyloxy (TBS) groups, followed by selective 
removal of the primary TBS group facilitated selective oxidation to the acid in 
two steps, using Dess-Martin periodinane and subsequent treatment with 
sodium chlorite. 
An updated version of the synthesis was developed in collaboration with 
Mette Jensen, Maya Bar-Dagan, and Matt Pratt since the initial publication of this 
method (77). The new steps avoid the requirement of addition of a large excess of 
the extremely malodorous t-butylthiol to form the disulfide protecting group 
(Figure 12C and Materials and Methods). Instead, t-butylthiol is first activated 
for disulfide exchange by conjugation to 2,2’-dithiodipyridine, necessitating only 
1.1 equivalents of t-butylthiol relative to thioglycerol as opposed to ten or more. 
trAIP-II was chosen as the first AIP synthesized using the new linker, as it 
is a well characterized peptide (40) and would be useful for the subsequent study 
of minimal inhibitory AIP determinants. The -hydroxy cysteine linker was first 
coupled onto Rink-amide polystyrene resin with HBTU and DIEA (Figure 12B). 
Following a capping procedure and on-resin removal of the TBS group with 
41
TBAF, the C-terminal phenylalanine was double coupled to the linker using 
HBTU in the presence of catalytic DMAP. HPLC–MS analysis of the cleaved 
amino-acylated resin indicated that this loading procedure was highly efficient, 
as no free linker was observed in the crude mixture (data not shown). Peptide 
chain assembly was then performed using standard Fmoc-SPPS protocols, and 
the peptide was cleaved from the resin with TFA and water and TIS as 
scavengers. HPLC–MS analysis of the crude cleavage mixture revealed the 
presence of two closely eluting peaks, both with the mass expected for the 
desired linear peptide–linker product. The first panel in Figure 13A shows the 
crude cleavage mixture obtained for the linear precursor to trAIP-II. The two 
products were presumed to correspond to the two expected diastereomers that 
result from use of the racemic linker. No attempts were made to purify these 
putative stereoisomers since the linker would eventually be cleaved off during 
the cyclization reaction. Indeed, incubation of crude, linear trAIP-II in an 
aqueous buffer containing the reducing agent TCEP resulted in the collapse of 
the two peaks into a single new peak with a mass consistent with the desired 
thiolactone peptide (Figure 13). Homonuclear 1H 2-D NMR analysis confirmed 
that the reaction product was trAIP-II (6), and the 2-D 1H TOSCY spectrum was 
identical to an authentic sample of trAIP-II prepared by the Boc-SPPS route 
(Figure 5) (see Appendix for chemical shift assignments). 
The macrocyclization reaction was found to be the most efficient between 
pH 6.6-6.8, taking approximately 1-2 h to reach completion. If the pH was below 
6.6, the linear, reduced peptide intermediate predominated and proceeded very 
slowly to product, presumably due to a slow rate of O to S acyl shift. At higher 
pH values, hydrolysis of the thioester to give the -carboxy-peptide became 
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Figure 13. HPLC–MS Analysis of the Macrocyclization Reaction. (A) HPLC 
chromatograms of the crude reaction mixture at the time points indicated. S. M. 
is the protected, linear trAIP-II starting material. I. is the reduced (deprotected) 
intermediate(s), and P. is the product, trAIP-II. (B) Mass spectra of the 
corresponding peaks. 
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increasingly problematic. Within the appropriate pH range, analysis of the 
reaction mixture after five minutes revealed the presence of several intermediates 
with a mass consistent with the fully reduced version of linear trAIP-II 
(Figure 13). At least one of these intermediates was presumed to correspond to 
the linear -thioester generated in situ following the O to S acyl shift, although it 
is likely a minor component due to the greater stability of oxyesters over 
thioesters (78). Furthermore, the linear -thioester peptide is an obligatory 
intermediate in the proposed cyclization mechanism (Figure 14B), leading to the 
final transthioesterification step, which acts as a thermodynamic sink in the 
reaction. Given that acyl transfer from a hydroxyl group to a thiol group is 
highly unfavorable, the O to S acyl shift is predicted to occur via the entropically 
preferred five-membered ring as opposed to attack by a distal thiol. To directly 
test whether or not the N-terminal cysteine could attack the oxyester, a trAIP-II 
derivative with an unprotected N-terminal thiol group and protected linker thiol 
group was subjected to the cyclization conditions without TCEP. Consistent with 
the proposed mechanism, cyclization of this peptide was not observed; however, 
upon the addition of TCEP, the peptide cyclized efficiently (Figure 14). Thus, the 
N-terminal thiol attacks only the thioester that is generated by deprotection of 
the linker and subsequent acyl shift. 
2.3 Minimal Determinants for AIP Inhibition of AgrC 
The strategy used to elucidate the minimal determinants of AgrC 
inhibition was to systematically perturb each structural aspect of the already 
partially minimized trAIP-II derivative of AIP-II. Guided by previous SAR 
carried out with AIP-II (19, 40), ten AIP-II analogues based on the trAIP-II
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Figure 14. Testing the Proposed Mechanism of Macrocyclization. (A) Two 
possible products upon treatment of the partially unprotected peptide with the 
macrocyclization buffer minus TCEP. The thiolactone was not observed, only 
disulfide formation. (B) HPLC chromatograms and corresponding mass spectra 
of the reaction. The starting material (S. M.) was nearly completely consumed, 
and the product (P.) was the cyclic disulfide, not the thiolactone. 
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scaffold were synthesized (Figure 15) to test the importance of the peptide 
backbone, side chains, thiolactone linkage, and N-terminus for inhibition. In 
order to compare trends for both cognate and non-cognate inhibition, the 
activities of all analogues were tested against AgrC-II and AgrC-I, respectively. 
This SAR analysis led to the identification of a minimal pharmacophore structure 
with a reduced peptidic character that retains antagonism of AgrC.  
2.3.1 Design and Synthesis of trAIP-II Analogues 
  Previously, alanine scanning of full-length AIP-II showed that the two 
serine hydroxyl groups of residues six and seven are not necessary for biological 
activity (Table 1) (19). Given this observation, the serines were replaced with 
glycines either individually or in combination in the first three trAIP-II analogues 
(Figure 15). The same alanine scanning study showed that the two C-terminal 
hydrophobic side chains are required for both activation and inhibition (19). 
Moreover, the inability of AIP-II L8A and AIP-II F9A to activate the promiscuous 
AgrC-I::III & IV::III sensor domain chimeras (55) confirmed that the conserved 
hydrophobicity of the two C-terminal residues (Figure 6) is required for 
biological activity. Therefore, the leucine and phenylalanine side chains were not 
perturbed in this study. Next, each amide in the macrocycle was N-methylated to 
probe interactions involving the AIP backbone, which had yet to be evaluated in 
any AIP. To test whether these side-chain and backbone modifications could be  
combined, the serines were completely removed and replaced with a methylene 
linker derived from 5-aminopentanoic acid in peptide 14 (Figure 15). 
Additionally, previous SAR studies on full-length AIP-II revealed that the 
thiolactone linkage is a critical determinant in receptor activation, but, 
interestingly, not inhibition (19). For example, a lactam analogue of AIP-II is a  
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Figure 15. Structures of trAIP-II and Derivatives Synthesized for Study of the 
Minimal Inhibitory AIP Pharmacophore. The portions of each molecule colored 
red indicate the residue(s) modified relative to trAIP-II. 
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very poor agonist but potent antagonist of the agr response (19, 52). In contrast, 
the trAIP-II lactam was found to be a very poor inhibitor of AgrC-II (79). To 
confirm this result and to determine whether non-cognate inhibition is 
diminished to the same extent as cognate inhibition, the lactam (15) was 
constructed. Lastly, the acetylated -amino group of the N-terminal cysteine was 
removed to make 16 (Figure 15), allowing determination of any role this vestige 
of the native AIP tail may play in the inhibitory activity of the peptide. 
All but one of the desired thiolactone peptides was generated in good 
yield and purity using the general procedure shown in Figure 12B. The sole 
exception was N-MeF (13), which contains N-methylphenylalanine at the C-
terminus (Figure 15). Attempts to synthesize the linear precursor to this peptide 
by Fmoc-SPPS on the -hydroxy cysteine linker led to low yields, and the crude 
mixture contained significant amounts of deletion products lacking the last two 
residues, Leu and N-Me-Phe. These problems were attributed to 
diketopiperazine (DKP) formation resulting from the presence of the tertiary 
amide at N-Me-Phe, a problem that is well known for C-terminal proline 
containing peptides prepared by Fmoc-SPPS (80) and that has been reported as a 
side reaction in the synthesis of N-methylated peptides (81). Consequently, the -
thioester precursor to peptide N-MeF was generated using the Boc-SPPS strategy 
(Figure 5) employing in situ neutralization chemistry (82) during the chain 
assembly to suppress DKP formation. Finally, the chain elongation for the lactam 
analogue (15) was completed using standard Fmoc-SPPS, as this peptide does 
not contain a thioester. To form the lactam, the cysteine was replaced with 
diaminopropanoic acid, and the serines were deprotected with HF following 
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cyclization of the partially protected linear peptide in solution (Materials and 
Methods) (19). Characterization and analysis of the purity of all AIP analogues 
was completed by HPLC, MS, and NMR (Table 4 and Appendix). 
2.3.2 Structure–Activity Relationships of trAIP-II 
Having obtained all eleven truncated AIP-II analogues, a cell-based 
reporter assay was used to determine the inhibitory activities of each peptide 
(52). S. aureus cultures of strains that cannot produce AIPs but contain the AgrC–
AgrA TCS cassette and -lactamase driven by the agr-dependent P3 promoter 
were treated with the AIP analogues in the presence of the cognate AIP agonist 
at 125 nM, a concentration above the EC90 (19, 52). The extent of agr activation 
was determined by measuring -lactamase activity via a colorimetric readout. To 
test both cognate and non-cognate agr inhibition by the trAIP-II analogues, group 
II & I reporter cell lines RN9372 and RN9222 (Materials and Methods) were used, 
respectively. The resulting dose-response curves and IC50 values against cognate 
(AgrC-II) and non-cognate (AgrC-I) receptors are shown in Figure 16 and Table 
4. Importantly, the IC50 values for trAIP-II prepared by the new Fmoc-SPPS route 
were in good agreement with those previously determined for this peptide (40). 
There are two interesting trends within the activity data summarized in 
Table 4. First, the overall rank order of the peptides, in terms of their inhibitory 
activities, is remarkably similar for the cognate and non-cognate agr groups. 
Second, all of the peptides that exhibited measurable inhibitory activity are more 
potent antagonists of the non-cognate AgrC receptor than of the cognate 
receptor. Furthermore, this difference in inhibitory activities against the two 
receptors increases significantly for the less potent analogues. This trend is more 
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Table 4. Mass Spectrometry and Activity Characterization of trAIP-II and Ten 
trAIP-II Analogues. 
AIP 
Derivative 
Mass 
Expected 
(M+H+) 
Mass 
Observed 
(M+H+) 
AgrC-I IC50 (nM), 
(95% CI) 
AgrC-II IC50 (nM), 
(95% CI) 
trAIP-II (Boc) 579.2 579.0 260, (95-695) 230, (190-270) 
trAIP-II 
(Fmoc) (6) 
579.2 580.0 90, (78-104) 293, (245-350)  
S2G (7) 549.2 550.7 189, (151-237) 1160, (855-1560) 
S3G (8) 549.2 550.0 40, (33-48) 194, (167-225) 
GG (9) 519.2 520.7 77, (66-89) 238, (170-334) 
N-MeS2 (10) 593.3 595.0 639, (534-765) 7880, (4100-15,200) 
N-MeS3 (11) 593.3 595.0 319, (284-357) 1050, (795-1380) 
N-MeL (12) 593.3 595.0 – – 
N-MeF (13) 593.3 595.0 – – 
Meth Link (14) 504.2 505.0 1141, (799-1630) 507,000, (*) 
Lactam (15) 562.3 564.0 1390, (1250-1560) 167,000, (*) 
 N-term (16) 522.2 524.0 1680, (1310-2170) 47,300, (33,700-
66,300) 
 
trAIP-II (Boc) is the version of the peptide made by Boc-SPPS (Figure 5) (40), and 
trAIP-II (Fmoc) is the version of the peptide made by the Fmoc-based synthesis 
described in Section 2.2 (Figure 12C, D). The IC50 values and the corresponding 
95% confidence intervals were computed using nonlinear regression analysis 
(Materials and Methods). – = no inhibition observed up to the highest 
concentrations tested (10-100 μM). (*) = extremely large span of the 95% 
confidence interval (>100,000 nM).  
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Figure 16. Inhibition Curves for trAIP-II Derivatives Against AgrC-I & II. In all 
cases, 125 nM agonist (AIP-I or II) plus varying concentrations of antagonist were 
added to reporter cells. The left panels show inhibitory activities against AgrC-I, 
and the right panels show activities against AgrC-II. trAIP-II is shown in all 
panels as a reference. Data are presented as percent maximal activation of the 
receptor by 125 nM agonist, expressed as Vmax -lactamase activity. All data 
points represent two to three replicates, and error bars represent SEM. 
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clearly seen in Figure 17, which shows a log-log plot of IC50 values. Thus, 
antagonism of the non-cognate agr group is much more tolerant to changes in the 
AIP structure than is antagonism of the cognate group. For instance, replacement 
of the thiolactone with a lactam leads to a modest decrease in the non-cognate 
IC50 (~15-fold) relative to the effect of this change on the cognate activity (~500-
fold). Similarly, replacement of the two serine residues with a methylene linker 
resulted in approximately 13-fold and 1700-fold reductions in non-cognate and 
cognate activities, respectively. 
Modifications to the serine residues were generally well tolerated. Both 
the single and the double glycine mutants (7, 8, and 9) exhibited a minimal loss 
of activity (<5-fold) or actually increased potency (Table 4). N-methylation of the 
serine residues mildly affected inhibition, although cognate inhibition was 
somewhat sensitive to N-methylation of Ser2. In contrast, N-methylation of 
leucine or phenylalanine resulted in a complete loss of activity, indicating that 
the side chains of these amino acids are not the only functionally important 
portions of this region of the AIP.  
The replacement of the sulfur with an NH in the lactam (15) resulted in a 
similar effect on function as replacement of both serines with a methylene linker 
(14), as both peptides have IC50 values of approximately 1 μM against AgrC-I and 
over 100μM against AgrC-II (Table 4). Thus, although the thiolactone linkage is 
not necessary for inhibition by full-length AIP-II (19), it is required for strong 
inhibition in the context of the truncated AIP. The relatively weak activity of the 
Meth Link peptide (14) cannot be explained by the loss of the serine side chains 
in accordance with the activity data for GG (9) (Table 4). It is more likely that the  
52
Figure 17. IC50 Values of trAIP-II Derivatives Against AgrC-I vs. AgrC-II. All 
peptides fall below the y = x (dotted) line, indicative of the fact that all are more 
active against AgrC-I than AgrC-II. The plot also depicts the increasing 
differences in inhibitory activities as the inhibitory potencies decrease. The error 
bars represent 95% confidence intervals.  
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complete loss of an amide bond or the increased flexibility introduced by the 
methylene linker is responsible for the reduced potency.  
Lastly, the removal of the N-terminal amide group caused a dramatic loss 
of inhibitory activity against both cognate (~250-fold) and non-cognate (~55-fold) 
receptors (Table 4). This result shows that the N-terminal vestige of the exocyclic 
“tail” portion of the full-length AIP is in fact important for inhibition. 
2.3.3 NMR Analysis of trAIP-II Analogues 
To explore a possible correlation between the differential activities of the 
trAIP-II analogues and the solution structures of the peptides, full 1H NMR 
chemical shifts were made (Appendix). During this effort, the 1H NMR spectra of 
N-MeS3 (11) was found to contain twice the number of expected resonances. 
Indeed, standard 2-D sequential assignment methods revealed that the sample 
contained two species as a 1:1 mixture in DMSO-d6 at 298 K (Figure 18A). There 
was no evidence for chemical heterogeneity in this peptide by HPLC–MS 
analysis (data not shown). Likewise, the possibility that these extra signals 
resulted from epimerization of the C-terminal Phe during coupling to the 
secondary hydroxyl of the linker was excluded since the same batch of amino-
acylated resin was used for the synthesis of other peptides in the study. Further 
analysis of the ROESY spectrum of N-MeS3 revealed the presence of a strong 
NOE cross-peak between the two serine alpha protons in one of the species but 
not the other (Figure 18B). This cross-peak is consistent with the presence of a cis 
amide bond between Ser2 and N-Me-Ser3. Analogous to the prolyl-tertiary 
amide, N-methylation is known to increase the propensity for trans-cis 
isomerization of an amide bond (83). Two of the other three N-methylated  
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Figure 18. ROESY Spectrum of trAIP-II Derivative N-MeS3. (A) Amide region 
of the ROESY spectrum is color-coded to identify the two spin systems that 
correspond to the FLV (red) and WUDQV (blue) isomers. (B) Alpha region of the 
ROESY spectrum is color-coded as in (A) to show the diagnostic NOE between 
the two alpha protons of the N-MeS3 cis isomer.  
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peptides, N-MeL (12) and N-MeF (13), were also present as two conformers as 
indicated by NMR, with the minor conformer comprising only 10-30% of the 
total sample population. By analogy with N-MeS3, these conformers almost 
certainly stem from cis-trans isomerization of the tertiary amide bond in these 
peptides; however, full assignments were not made for the minor, presumably 
cis, isomers of N-MeL and N-MeF owing to their low abundance. 
The chemical shift assignments of the eleven peptides were used to 
calculate a chemical shift index (CSI) value for each one, allowing comparison of 
their solution structures. The CSI is the average difference in proton ppm 
between the analogue of interest and trAIP-II, including protons directly bonded 
to the macrocyclic scaffold, other than those of the modified residue, plus the 
exocyclic N-terminal amide proton. The CSI values were then plotted against 
relative inhibitory potencies to examine any relationship between differences in 
activity and solution structure among the AIP derivatives compared to trAIP-II 
(Figure 19). According to this simple analysis, there was no observable trend 
between potency and overall chemical shift perturbations. For instance, N-MeL 
(12) and N-MeF (13), which have no measurable activity, have CSI values 
comparable to S3G (8) and GG (9), which are the most potent AIP analogues. 
Similarly, the chemical shifts around the macrocycle in the  N-term peptide (16) 
are largely unperturbed compared to trAIP-II, yet this analogue is one of the least 
potent antagonists. One interpretation of this data is that the exocyclic and two 
C-terminal amides of trAIP-II make specific contacts with the AgrC receptor. 
Alternatively, the modifications may prevent the AIP from assuming a bioactive 
conformation required for receptor binding.  
 
56
Figure 19. Chemical Shift Index Values vs. Inhibitory Potencies. The CSI values 
of each AIP analogues are plotted in order of decreasing potency, from left to 
right. The order of the N-MeS3 isomers is arbitrary since they were not 
separated; and hence, their individual potencies were not determined. 
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The largest CSI was observed for the lactam analogue (15) in which only 
one atom was replaced. In this case, chemical shift changes propagate around the 
entire macrocycle (Figure 19 and Appendix), indicating that this substitution 
induces far-reaching changes in the solution structure of the peptide. A similar 
structural effect was previously observed upon substitution of the thiolactone 
with a lactam in the context of full-length AIP-II (52) and trAIP-II (79). The full-
length AIP-II lactam remains a potent cross-group AgrC antagonist but is an 
extremely weak agonist of AgrC-II (19, 52). Thus, although this major structural 
perturbation differentially affects inhibition of AgrC-I depending on AIP length, 
activity against the cognate AgrC-II is significantly reduced in both contexts.  
2.3.4 Conclusions 
Two prominent trends surfaced in this study regarding AIP inhibition of 
AgrC. First, the overall rank orders of the analogues for inhibition against 
cognate (AgrC-II) and non-cognate (AgrC-I) receptors were almost identical, 
despite the fact that the sensor domains of AgrC-II & I share only 31% sequence 
identity. However, non-cognate antagonism was more resistant to changes in 
AIP structure than cognate antagonism. Of the peptides with measurable 
inhibitory activity, the IC50 values against AgrC-I varied by no more than ~40-
fold, whereas the values against AgrC-II varied by over 3 orders of magnitude 
(Figure 17 and Table 4). This observation is broadly in line with previous SAR 
studies on full-length AIPs, which revealed that cross-group antagonism is more 
tolerant to changes in peptide structure than intra-group agonism (52). 
Pharmacological studies of trAIP-II suggested that both cognate and non-cognate 
antagonism operates through a simple competitive binding mechanism in which 
trAIP-II competes with the group-specific AIP agonist for a common binding site 
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on the sensor domain of AgrC (41). The SAR data presented here are certainly 
consistent with this mechanism, but the details of the cognate and non-cognate 
interactions must differ since certain modifications have a more acute effect on 
the former interaction than the latter one. 
Taken together, these results facilitated identification of the principle 
pharmacophore for agr antagonism by trAIP-II (Figure 20). Roughly one half of 
the molecule, including the cysteine and two C-terminal hydrophobic residues, is 
critical for activity. Conversely, the remainder of the molecule appears to be far 
less important and can even be replaced by an alkyl linker without a dramatic 
loss of non-cognate agr inhibition. Further study is needed to understand the 
basis for inhibition of multiple receptors via so few structural elements. 
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Figure 20. The Minimal Inhibitory AIP Pharmacophore. trAIP-II is color-coded 
to indicate which portions of the molecule are important for inhibition against 
cognate (AgrC-II) and non-cognate (AgrC-I) receptors. 
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Chapter 3: Mechanism of Signal Transduction by AgrC (This work was 
performed in collaboration with Edward Geisinger.) 
3.1 Introduction 
 Knowledge of the mechanism by which AgrC transduces the AIP signal is 
very limited. The importance of particular motifs for ligand recognition and 
specificity within the AgrC sensor domain are beginning to be understood (42, 
55, 58, 62). In a recent study by Geisinger et al. (42), several constitutively active 
AgrC mutants were isolated with single point mutations that mainly localized to 
the C-terminal transmembrane helix of the sensor domain and the putative 
coiled-coil/dimerization (DHp) subdomain (Figure 7). These intriguing findings 
implied that the C-terminal transmembrane helix may move toward the 
cytoplasm in a piston-like movement upon activation and that the DHp 
subdomain is important for regulation of activity. Mathiesen et al. (84) isolated 
constitutive mutants of the L. sakei receptor histidine kinase SppK, another 
member of the HPK10 peptide-sensing family. Although the sites of point 
mutations found to confer constitutive activity upon SppK were not conserved in 
AgrC, they mainly localized to the DHp subdomain. Furthermore, T233I, a 
constitutive mutation in ComD of S. pneumoniae is also in the DHp domain (85); 
and while this residue is conserved in AgrC (T224), the effect of an analogous 
mutation in AgrC is not known. Collectively, these results strongly point to the 
DHp subdomain as the key to the kinase activation mechanism, yet the question 
of how specific ligand binding triggers signal transduction and kinase activation 
via the DHp subdomain is open. 
The goal of this study was to elucidate the AgrC signal transduction 
mechanism and thereby shed light on the mechanism of activation of other 
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members of the HPK10 family. Complementary mutants missing either the 
phosphorylation site histidine of the DHp subdomain or key catalytic residues in 
the CA subdomain exhibited robust activity upon co-expression, revealing that 
AgrC activation occurs through dimerization and trans-autophosphorylation. 
One possible function of the DHp subdomain constitutive mutations was to 
promote dimerization as a mechanism for activation; however, co-
immunoprecipitation analysis demonstrated that dimers are pre-formed. In fact, 
dimerization appeared to be reduced in at least one of the DHp subdomain 
constitutive mutants. By combining the complementary mutants with known 
sensor domain mutations that alter ligand specificity (58), heterodimers were 
constructed in which signal input is primarily received by only one sensor. Not 
only was input from one sensor domain sufficient for activation, but 
additionally, either kinase domain was activated irrespective of whether the 
functional sensor domain was part of the same protomer molecule. Moreover, 
analogous symmetric kinase activation was observed in the absence of ligand in 
mutant heterodimers containing one protomer with a DHp subdomain 
constitutive mutation. Thus, AgrC activation is inherently symmetric via 
bidirectional cross-talk at the dimer interface. 
3.2 AgrC is a Pre-formed Dimer that trans-autophosphorylates 
 The prototypical histidine kinase functions as a dimer and undergoes 
trans-autophosphorylation (32, 71). In order to test whether AgrC follows this 
paradigm, an intermolecular complementation approach was adopted, similar to 
that used to demonstrate functional dimerization and trans-autophosphorylation 
for HPKs in E. coli (86-88). The aim was to create and analyze two 
complementary mutants, one lacking an appropriate phosphorylation site and 
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one with a dysfunctional kinase, neither of which has detectable kinase activity 
when expressed alone. When co-expressed, mutant heterodimers would form in 
which each protomer would complement the other’s defect only if AgrC 
undergoes dimerization and trans-autophosphorylation.  
3.2.1 Design, Characterization, and Testing of Complementary AgrC Mutants 
 Through sequence alignment of the AgrC cytoplasmic domain with that of 
other HPKs, conserved residues representing the putative phosphorylation site 
(His239) and catalytic motifs were identified (Figure 7). The N-box asparagine 
(Asn339) and G-box glycine residues (Gly394 and Gly396) are essential for ATP 
binding in other HPKs (89, 90). Accordingly, these residues were mutated in 
AgrC-I, and the resulting activities were tested in S. aureus -lactamase reporter 
cells (52). As expected, the phosphorylation site mutant H239Q was completely 
inactive (Figure 21). Surprisingly, mutation of the N-box (N339D) resulted in 
only partially reduced receptor activation unlike the effect of the corresponding 
mutation in EnvZ (90). Each individual G-box glycine mutant (G394A and 
G396A) exhibited weaker receptor activation than that observed for AgrC-I 
N339D, while the double mutant (G394A, G396A) was completely inactive up to 
the highest concentration of AIP-I tested (10 μM). Thus, AgrC-IH239Q and AgrC-
IG394A, G396A were selected for subsequent complementation analysis and are 
hereafter referred to as AgrC-IHis and AgrC-IKin, respectively, to indicate the 
particular defect of each mutant. In order to determine the cellular localization 
and expression levels of AgrC-IHis and AgrC-IKin
 C-terminal GFP-fusions of the 
two mutants and WT AgrC-I were constructed. Ligand-dependent kinase 
function was preserved in the AgrC-I-GFP fusion protein, as receptor activation 
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Figure 21. Probing Conserved Catalytic Motifs in the AgrC HK Domain. -
lactamase activity of reporter cells expressing the indicated AgrC-I construct 
following incubation with or without 10 μM AIP-I, as indicated. Data are 
presented as percent maximal activation of WT AgrC-I ± SEM.  
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by AIP-I was nearly as effective as that of WT AgrC (Figure 22 and Table 5). 
Fluorescence microscopy showed that AgrC-I-GFP localized to the cell 
membrane (Figure 23B-D). Images of AgrC-I-GFP expressing cells that produce 
AIP allowed direct observation of the autocatalytic induction of agr expression 
(30) and showed that AgrC is uniformly localized throughout the cell perimeter 
(Figure 23D). Attenuated expression of AgrC-I-GFP in an AIP producing strain 
that lacks agrA confirmed that the observed induction of AgrC expression is 
dependent on the AgrC-A TCS (Figure 23B). The images of cells expressing 
AgrC-I-GFPHis and AgrC-I-GFPKin fusions (Figure 23E, F) resembled those of 
uninduced cells (Figure 23B, C) expressing WT AgrC-I-GFP, suggesting that the 
phosphorylation site and catalytic domain mutations do not adversely affect 
localization.  
Previous attempts to characterize several epitope-tagged versions of AgrC 
by western blot failed, highlighting the difficulties of working with a polytopic 
membrane protein presumed to express at low abundance (55). In this study, a 
protocol for preparation of S. aureus membrane fractions was adapted from 
MRSA Protocols (91), in which the cells were lysed with osmotic shock following 
cell wall removal by treatment with lysostaphin. Four different conditions were 
used for resuspension of membrane pellets, and if the samples were boiled prior 
to gel loading, no definitive bands appeared for either AgrC-GFP or AgrC-HA 
constructs (data not shown). However, when samples were loaded without being 
subjected to denaturing conditions, such as boiling, clear bands attributable to 
AgrC were detected for all resuspension conditions (Figure 24A). Multiple bands 
were detected for AgrC-GFP constructs, including a high molecular weight band 
that may represent an AgrC dimer, but none of the bands matched the expected 
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Figure 22. Functional Characterization of AgrC-GFP. -lactamase activities of 
reporter cells expressing the indicated AgrC-I construct(s) following incubation 
with increasing concentrations of AIP-I. Data are presented as percent maximal 
activation of WT AgrC-I ± SEM.  

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Figure 23. Characterization of AgrC-GFP Constructs by Fluorescence 
Microscopy. (A-L) Fluorescence images of AgrC-GFP constructs used in this 
study. Scale bars equal 2 μm. (K, L) Images with longer exposure than (A-J) for 
an enhanced view of the AgrC truncations, which show lower expression than 
the other constructs.  
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Figure 24. Characterization of AgrC-GFP Constructs by Western Blot. (A) Anti-
GFP western blot of membrane fractions from cells expressing WT AgrC-GFP or 
AgrC-HA solubilized in RIPA (1.0% NP-40, 0.25% DOC), Triton (1.0%), SDS 
(0.1%), or SC (0.1 M sodium carbonate). (B) Anti-GFP western blot of constructs 
shown in Figure 23A-H. Sortase is the loading control. 
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Table 5. Activities of AgrC Mutants and Mutant Heterodimers. 
AgrC Receptor Variants EC50 (nM), (95% CI) IC50 (nM), (95% 
CI) 
WT His 
(H239Q) 
Kin 
(G394A, 
G396A) 
AIP-I AIP-II AIP-III 
(+AIP-I) 
AgrC-I  10, (8.7-13) – nt 
 AgrC-I  – – n/a 
  AgrC-I – – n/a 
 AgrC-I AgrC-I 40, (35-45) – 18, (13-25) * 
AgrC-I-
GFP 
 16, (14-17) – nt 
 AgrC-I-
GFP 
 – – n/a 
  AgrC-I-
GFP 
– – n/a 
 AgrC-I-
GFP 
AgrC-I-
GFP 
36, (31-42) – nt 
 AgrC-ISensor  – – n/a 
  AgrC-ISensor – – n/a 
 AgrC-ISensor AgrC-ISensor 6100, (4200-
9000) 
– nt 
 AgrC-I AgrC-ISensor 200, (170-240) – 140, (88-230) # 
 AgrC-ISensor AgrC-I 310, (260-380) – 320, (150-650) # 
AgrC-II  – 2.9, (2.3-3.6) nt 
 AgrC-II  – – n/a 
  AgrC-II – – n/a 
 AgrC-I AgrC-II 21, (18-25) 17, (13-22) 15, 9.8-21) * 
 AgrC-II AgrC-I 17, (16-19) 4.5, (3.6-5.6) 17, (13-22) * 
 
EC50 and IC50 values and 95% confidence intervals are shown for mutants 
individually and in combination. – = no activity observed up to the highest AIP 
concentration tested (>10 μM). * = 150 nM AIP-I added. # = 1 μM AIP-I added. 
n/a = not applicable, the variant is not active. nt = not tested in this study.  
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molecular weight of 77 kDa. However, treatment with dilute acid resulted in 
appearance of a single band at the appropriate molecular weight (Figure 24B), 
suggesting that the acid denatures the protein to some extent without promoting 
aggregation. In subsequent experiments, lysis was carried out by incubation of 
protoplasts in buffer containing 1.0% nonyl phenoxylpolyethoxylethanol (NP-40) 
and 0.25% deoxycholate (DOC), and the resulting total cell lysates were treated 
with dilute acid prior to gel loading. Having established conditions for 
reproducible western blot analysis of AgrC, the various WT and mutant AgrC-
GFP constructs were analyzed. Importantly, expression of AgrC-IHis is 
comparable to WT AgrC-I, and expression of AgrC-IKin is somewhat reduced but 
sufficient for use in the complementation experiment (Figure 24B).  
Having established that the individual AgrC-IHis and AgrC-IKin mutants 
have no measureable kinase activity and demonstrate adequate expression and 
appropriate localization, they were co-expressed by introducing the compatible 
plasmids, pEG58 and pEG59, into the reporter strain background (52). In cells co-
expressing AgrC-IHis and AgrC-IKin, robust dose-dependent activation by AIP-I 
was observed with a slightly increased EC50 value of 40 nM compared to 10 nM 
for WT AgrC-I (Figure 25B and Table 5). Similar activation was observed with 
the GFP-fused variants (Figure 22). The maximal activity of the mutant 
heterodimers was moderately reduced compared to WT AgrC, consistent with 
the statistical expectation of the formation of inactive mutant homodimers. In 
order to rule out plasmid recombination as a source of active AgrC in this hybrid 
strain, plasmid size was confirmed by agarose gel electrophoresis of whole cell 
minilysates, and each plasmid was backcrossed to a naïve reporter background 
to reconfirm the inactivity of each individual mutant (data not shown).  
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Figure 25. Co-expression of AgrC-I Complementary Mutants. (A) Schematic of 
a heterodimer formed between AgrC-IHis and AgrC-IKin. (B) Activation curves for 
the indicated constructs following treatment with AIP-I. Percent activity is 
relative to maximal activation of WT AgrC-I ± SEM. (C) Inhibition of the 
complementary pair by AIP-III in the presence of a constant concentration (150 
nM) of AIP-I. Percent activity is relative to maximal activation by 150 nM AIP-I ± 
SEM.  
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To ensure that the complementary mutations do not alter ligand 
recognition, the ability of a non-cognate AIP to block AIP-I-induced activation of 
the mutant heterodimer was assessed. Treatment of reporter cells co-expressing 
both mutants with a fixed concentration of AIP-I and increasing concentrations 
of AIP-II or AIP-III resulted in a dose-dependent decrease in activity (Figure 25C 
and Table 5). Thus, AgrC-IHis and AgrC-IKin form functional heterodimers that 
maintain WT ligand specificity. Collectively, these results demonstrate that 
intermolecular complementation occurs between an AgrC-I phosphorylation site 
mutant and a catalytic domain mutant. The possibility that AgrC 
autophosphorylation may occur in cis was not ruled out, but this study 
definitively showed that agr activation can occur via trans-autophosphorylation 
of AgrC dimers or higher order oligomers.  
3.2.2 AgrC Homodimerizes in the Absence and Presence of AIP  
Histidine kinases typically function as dimers (32, 71); however, the 
influence of ligands on the oligomeric state has not been investigated for most 
HPKs. Two exceptions are VirA of A. tumefaciens (92) and the HPK-associated 
aspartate receptor, Tar (93) for which the fundamental dimeric units were shown 
to be independent of ligand binding. In order to determine whether AgrC exists 
as a pre-formed or ligand-induced dimer, co-immunoprecipitation of 
differentially tagged versions of AgrC in the absence and presence of AIP was 
performed. First, cells co-expressing GFP and HA-tagged complementary 
mutants, AgrC-I-GFPHis and AgrC-I-HAKin, were analyzed to ensure that 
heterodimers formed by AgrC-I-GFP and AgrC-I-HA are functional. This pair 
exhibited robust dose-dependent activation by AIP-I, with an EC50 of 31 nM 
(Figure 26A). Next, immobilized GFP antibodies were used to 
72
Figure 26. Co-immunoprecipitation of AgrC-I-GFP and AgrC-I-HA. (A) 
Activity of reporter cells co-expressing AgrC-I-GFPHis and AgrC-I-HAKin 
following treatment with increasing concentrations of AIP-I. Data are presented 
as percent maximal activity of this AgrC-I pair ± SEM. (B) Immunoprecipitation 
of lysates from cells co-expressing WT AgrC-I-GFP and AgrC-I-HA or AgrC-
IR238H-GFP and AgrC-IR238H-HA using an -GFP affinity matrix. Asterisk indicates 
IgG bands, and bracket indicates AgrC-HA bands. (C) Immunoprecipitation, 
including Sortase control, as in (B) except an -HA affinity matrix was used.    
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immunoprecipitate AgrC from total lysates of cells co-expressing WT AgrC-I-HA 
and AgrC-I-GFP. Western blot analysis showed that AgrC-HA is 
immunoprecipitated only when AgrC-GFP is present and that AgrC-HA 
interacts with AgrC-GFP in the absence and presence of AIP (Figure 26B). Similar 
results were obtained when HA antibodies were used to immunoprecipitate the 
complex (Figure 26C).  
In order to rule out the possibility that these results were due to non-
specific interactions with membrane proteins, the immunoprecipitate elutions 
were probed for the presence of Sortase, an unrelated membrane protein 
involved in anchoring proteins to the cell wall. While Sortase appeared in the 
total lysate inputs, it was not present in the samples eluted from the beads 
(Figure 26C). Furthermore, formation of AgrC-GFP/AgrC-HA dimers was not 
observed when a mixture of lysates from cells expressing only AgrC-GFP or 
AgrC-HA was analyzed by immunoprecipitation (data not shown), indicating 
that dimerization occurs only in the cell and not following lysis. These results 
confirm the dimeric nature of AgrC and demonstrate that the dimers form 
independent of ligand binding. 
3.3 The AIP Signal is Transduced Symmetrically within AgrC Dimers  
As the complementary mutants allow isolated detection of the activity of 
AgrC heterodimers vs. homodimers, they could facilitate activity measurements 
of heterodimers containing two different sensor domains. Thus, various aspects 
of AgrC signaling were analyzed by combining the complementary mutants with 
sensor domain mutants. This experimental system proved to be very powerful 
and revealed the surprising result that the AIP signal is propagated both linearly 
within one AgrC molecule and laterally across the dimer interface.  
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3.3.1 One Intact Sensor Domain is Sufficient for Activation  
 First, the AIP:AgrC stoichiometry was evaluated by testing whether one 
complete sensor domain is sufficient for ligand-induced activity in a heterodimer 
containing one truncated sensor domain. N-terminal truncations of both WT 
AgrC-I and AgrC- IKin were constructed by deleting progressive segments of the 
transmembrane sensor domain. When expressed individually, none of the 
resulting homodimers displayed significant activity in response to AIP-I (Figure 
27A). However, co-expression of full-length AgrC-IHis with a truncated mutant 
lacking most of the sensor domain (AgrC-I1-135, Kin) resulted in significant, dose-
dependent activity (Figure 27A, B). The maximal activation was significantly 
reduced compared to the full-length complementary mutants, which may be due 
to poor expression and/or membrane localization of the truncations (Figure 23I- 
L). Nonetheless, one intact sensor domain is sufficient for activation, consistent 
with a model of 1:1 AIP:AgrC stoichiometry.  
In order to overcome the limitation of poor localization, an analogous 
experiment was carried out using a full-length AgrC-I mutant that exhibits 
expression and membrane localization similar to WT but greatly reduced 
sensitivity to AIP-I (Figure 23G, H and 24B) (58). AgrC-I T104V, S107V, S116I is 
approximately 50-fold less sensitive to AIP-I than WT AgrC (58), and for 
simplicity, is hereafter referred to as AgrC-ISensor. The phosphorylation site and 
catalytic mutations were next introduced into AgrC-ISensor; and accordingly, co-
expression of AgrC-ISensor, His and AgrC-ISensor, Kin resulted in very weak activity with 
an EC50 value of 6.1 μM (Figure 28C and Table 5). However, when AgrC-IHis was 
combined with AgrC-ISensor, Kin, activation by AIP-I was restored close to that 
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Figure 27. Activities of N-terminally Truncated Variants of AgrC. (A) Activities 
of the indicated AgrC-I truncation mutants following treatment with a saturating 
concentration (10 mM) of AIP-I. The gray bars represent the activities upon co-
expression with full-length AgrC-IHis. (B) Schematic of AgrC-IHis + AgrC-I1-135, Kin 
and the activity of that pair following treatment with AIP-I. Individual mutants 
and the full-length AgrC-IHis/AgrC-IKin pair are shown for reference. Data are 
presented as percent maximal activation of WT AgrC-I ± SEM.  
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Figure 28. Analysis of AgrC Mutant Heterodimers Containing Sensor Domains 
with Different Ligand Recognition Properties. (A) Schematic of AgrC-
IHis/AgrC-ISensor, Kin heterodimer with a WT sensor domain linked to a functional 
kinase domain. (B) Schematic of AgrC-IKin/AgrC-ISensor, His heterodimer with a WT 
sensor domain linked to a dysfunctional kinase domain. (C) Activities of reporter 
cells co-expressing the constructs indicated following treatment with AIP-I. 
Percent activity is relative to maximal activation of WT AgrC-I ± SEM. (D) 
Activities of reporter cells indicated following treatment with increasing 
concentrations of AIP-III in the presence of 1 μM AIP-I. Percent activity is relative 
to maximal activation of AgrC-IHis/AgrC-IKin by 1 μM AIP-I ± SEM.  
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observed for the AgrC-IHis /AgrC-IKin pairing with WT sensor domains (Figure 
28A, C and Table 5), consistent with the above observation that only one WT 
sensor is required for activation of an AgrC dimer. Additionally, the maximal 
activities of heterodimers involving AgrC-ISensor were similar to that observed 
with the AgrC-IHis /AgrC-IKin pair, unlike the result with the truncated receptors. 
3.3.2 Both AIP-dependent and Constitutive AgrC Signaling is Symmetric  
Having established that only one functional sensor domain is required for 
activation, the AgrC-ISensor heterodimers were used to test the simple hypothesis 
that each receptor protomer transduces the activating signal directly to its own 
kinase. In this proposed mechanism of asymmetric activation, only the kinase 
domain linked to the functional sensor domain is predicted to be activated. For 
example, in the AgrC-IHis/AgrC-ISensor, Kin heterodimer, AgrC-IHis contains WT 
sensor and kinase domains and phosphorylates AgrC-ISensor, Kin (Figure 28A, C). In 
contrast, the reciprocal pair of AgrC-ISensor, His and AgrC-IKin is predicted to be 
inactive since the functional sensor and kinase domains are located in different 
protomers of the dimer and therefore separated (Figure 28B). Surprisingly, AgrC-
IKin/AgrC-ISensor, His exhibited robust dose-dependent activation that was nearly 
indistinguishable from that observed for AgrC-IHis/AgrC-ISensor, Kin, as reflected in 
the EC50 values of 310 and 200 nM, respectively (Figure 28C and Table 5). The 
AIP-I-induced activation of both heterodimeric pairs was inhibited by AIP-III in 
a dose-dependent fashion (Figure 28D and Table 5), demonstrating that 
antagonism by non-cognate AIPs is maintained and the heterodimers are not 
artificially poised for activation. Thus, instead of following the predicted linear 
signaling mechanism, AgrC activation appears to be symmetric. Ligand binding 
to one functional sensor domain stabilizes or induces conformational changes 
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that may be propagated across the dimer interface to activate either kinase 
domain. Alternatively, a composite AIP binding pocket formed by both sensor 
domains could account for the result, as a 1:2 AIP:AgrC stoichiometry has not 
been formally excluded, but this possibility is not supported by the results 
obtained with the truncated AgrC variants.   
To further test the idea of symmetric signaling by AgrC, heterodimers 
were constructed in which the two receptors belong to two of the most divergent 
agr specificity groups, I & II. The sensor domains of AgrC-I & II share only 31% 
sequence identity, and AIP-I & II are potent cross-group inhibitors (Table 1). The 
histidine and CA subdomain mutations were added to AgrC-II, and as with 
AgrC-I, the AgrC-IIHis and AgrC-IIKin mutants were completely inactive 
individually (Table 5). In this case, the asymmetric, linear model of activation 
predicts that only the AIP specific for the sensor domain attached to a functional 
kinase would activate an AgrC-I/II heterodimer. For example, only AIP-I would 
be expected to activate AgrC-IHis/AgrC-IIKin since only AgrC-I has a functional 
kinase (Figure 29A). Conversely, the symmetric model predicts that both AIP-I & 
II would activate an AgrC-I/-II heterodimer equally well, regardless of which 
protomer harbors the functional kinase domain. In fact, AgrC-IHis/AgrC-IIKin was 
activated to approximately the same extent by AIP-I & II, as represented by EC50 
values of 21 and 17 nM, respectively (Figure 29C and Table 5). The same result 
was obtained upon treatment of the reciprocal AgrC-IKin/AgrC-IIHis heterodimer 
with AIP-I or AIP-II (Figure 29B, D and Table 5). Thus, receptors of two 
divergent agr groups formed functional heterodimers activated by both cognate 
AIPs, lending additional evidence to the conclusion that input from one sensor 
domain leads to activation of either kinase domain. 
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Figure 29. Analysis of Mutant Heterodimers Containing AgrC Receptors of 
Two Different agr Groups. (A, B) Schematics of AgrC-I/II mutant heterodimers. 
(C, D) Activities of the constructs shown above (A, B) treated with AIP-I or AIP-
II as indicated. (E, F) Activities of (A) and (B) treated with 150 nM AIP-I and 
increasing AIP-III. Percent activity is relative to maximal activation of WT AgrC-I 
or AgrC-II (C, D) or of AgrC-IHis/AgrC-IKin (E, F) ± SEM.       
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To ensure that the ligand recognition by the unnatural AgrC-I/II sensor 
domain pairings was not fundamentally changed, inhibition by AIP-III, an 
antagonist of both AgrC-I & II, was tested. Indeed, the two complementary 
AgrC-I/II mutant heterodimers were potently inhibited by AIP-III  (Figure 29E, F 
and Table 5).  
The model taken from the above results involves propagation of 
activating conformational changes across the dimer interface within the 
intracellular HK domain, downstream of the ligand-receptor interaction. To test 
this model, a recently isolated constitutive DHp subdomain mutant, AgrC-IR238H 
(42), was incorporated into complementary mutant heterodimers. R238 is 
adjacent to the phosphorylation site histidine (H239) in the predicted 
dimerization domain. In the absence of ligand, AgrC-IR238H exhibits full activity, 
equivalent to that observed upon treatment of WT AgrC-I with a saturating 
concentration of AIP-I (Figure 30C). Like WT AgrC-I, the constitutive mutant 
exists as a pre-formed dimer (Figure 26B, C); however, the level of 
homodimerization was less than that of the WT receptor, a finding that may be 
relevant to the mechanism of the constitutively active receptor.  
  Provided that AgrC-IR238H assumes the conformational state associated 
with normal ligand-dependent receptor activation, the symmetric signaling 
mechanism predicts that this conformation can be transduced to a WT AgrC 
protomer in a heterodimer configuration, resulting in constitutive trans-
autophosphorylation. To test this prediction, the histidine and G2-box mutations 
were introduced to AgrC-IR238H. Individually, the AgrC-IR238H, His and AgrC-IR238H, Kin 
mutants were inactive (Figure 30C), confirming that ligand-independent activity 
depends on these critical residues. When co-expressed, complementation  
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Figure 30.  Ligand-independent Signaling by AgrC Mutant Heterodimers 
Containing One Constitutive R238H Mutant. (A) Schematic of AgrC-IR238H, 
His/AgrC-IKin in which the protomer with the constitutive mutation also has a WT 
kinase domain. (B) Schematic of AgrC-IHis/AgrC-IR238H, Kin in which the protomer 
with the constitutive mutation has a dysfunctional kinase domain. (C) Activities 
of reporter cells expressing the indicated AgrC-I constructs following treatment 
with or without AIP-I, as indicated. Data are presented as percent maximal 
activation of WT AgrC-I ± SEM. 
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between the mutants was observed, with constitutive activity reaching a level 
similar to that seen with AIP-I-induced activation of the AgrC-IHis/AgrC-IKin 
complementary pair (Figure 30C). Next, mutant heterodimers composed of one 
constitutive and one non-constitutive receptor were analyzed. The combination 
of AgrC-IR238H, His and AgrC-IKin, as illustrated in Figure 30A, resulted in ligand-
independent activation at a magnitude nearly as high as that observed with the 
homologous AgrC-IR238H, His/AgrC-IR238H, Kin pairing (Figure 30C). The key 
reciprocal combination of AgrC-IHis and AgrC-IR238H, Kin (Figure 30B), in which the 
receptor with a functional kinase is missing the constitutive mutation, also 
exhibited activity in the absence of AIP-I (Figure 30C), In this case, the 
magnitude of activation was about one third of that seen with AgrC-IR238H, 
His/AgrC-IKin, indicating that the symmetry was imperfect. Nonetheless, an 
activating conformational change imparted by one point mutation was 
transferred between protomers of an AgrC dimer. 
3.4 Model of AgrC Signaling 
On the basis of these results, a working model of AgrC signal transduction 
has been developed in which cognate ligand binding to one or both 
transmembrane sensor domains of an AgrC homodimer stabilizes or induces an 
active conformational state, in turn stabilizing or inducing a conformational 
change in the corresponding cytoplasmic DHp subdomain(s). Intermolecular 
interactions across the coiled-coil dimer interface result in functionally parallel 
conformational changes in both protomers whether or not they are ligand-
bound. The concerted adoption of the activated conformational state in both 
protomers leads to concurrent phosphorylation of both histidines by the 
contralateral kinase subdomains. While the nature of the conformational changes 
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responsible for symmetric signaling by AgrC is yet to be determined, they are 
likely mediated by coiled-coils in the predicted dimerization (DHp) domain. 
There is one published study demonstrating symmetric signaling in an HPK, in 
which various chimeras of the aspartate receptor, Tar, and the E. coli osmosensor, 
EnvZ, were analyzed (60). The HAMP domain, a small coiled-coil linking the 
sensor and HK domains in many HPKs, was determined to be the site of 
symmetric signaling within the chimeras, based on the observation that 
homologous HAMP domain pairings enabled symmetric signal transduction 
through the receptors, whereas heterologous HAMP pairings resulted only in 
linear, asymmetric receptor signaling. AgrC and other HPK10 members do not 
contain HAMP domains, but their DHp subdomains contain putative coiled-
coils. One feasible way a conformational shift could be transmitted between 
dimeric receptors is via concerted rotation of the coiled-coils. Structural analysis 
of an archaeal HAMP domain by NMR implied that signaling involves a 
concerted, gear-like rotational transition between distinct helical packing mode 
(61). A rotational activation mechanism has also been suggested for the A. 
tumefaciens VirA and yeast Sln1 HPKs, in which the effects of altering the coiled-
coil domain helical register were analyzed using N-terminally fused leucine-
zipper insertions (94, 95). 
Stimulus modulation by cross-talk within dimeric receptors may be 
adaptive for particular biological functions. Regarding AgrC dimers in 
staphylococci, symmetric activation may act as a mechanism for signal 
amplification that is important for the physiological process of quorum sensing, 
in which a swift, exponential response to a particular concentration of ligand is 
desired. 
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Chapter 4: Discussion 
4.1 Summary and Implications of this Work  
 In this work, the tools of chemistry and biology were used to extend the 
understanding of signal transduction in the agr system of S. aureus. First, a new, 
convenient method for the synthesis of AIPs and -thioester peptides was 
developed and used to facilitate an analysis of the inhibitory AIP 
pharmacophore. While previous AIP structure–activity relationships (SAR) had 
revealed that many substantial perturbations do not prevent AgrC inhibition 
even though minor changes often result in loss of AgrC activation, the limit of 
plasticity of the inhibitory AIP structure was not known. In fact, only two bulky, 
hydrophobic amino acids at the C-terminus and an acylated N-terminus must be 
present within the thiolactone macrocyclic scaffold to block activation by cognate 
AIPs (Figure 20). Second, genetic and biochemical approaches led to the 
discovery that AgrC is a pre-formed dimer that transduces activating 
conformational change(s) upon AIP binding both linearly within one protomer 
and laterally across the dimer interface to the sister protomer, resulting in 
symmetric trans-autophosphorylation. This study was the first direct 
investigation of the activation mechanism of AgrC, the S. aureus receptor 
histidine kinase of the agr quorum sensing system that controls virulence.  
The new synthetic route to AIPs via Fmoc-SPPS described in Section 2.2 is 
based on the handle design of Botti et al. (74) but extends this latent thioester 
linker concept to any resin type. The thiolactone-containing AIP structure can be 
obtained by simply incubating the corresponding protected peptide -oxyester 
precursor in aqueous buffer in the presence of a non-nucleophilic reducing agent 
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such as TCEP (Figure 12D). Collectively, the data support the cascade-type 
mechanism shown, in which the reducing agent first triggers the O-to-S acyl 
transfer at the C-terminus, thereby setting up a transthioesterification reaction 
between the nascent -thioester and the cysteine sulfhydryl, yielding the 
thiolactone with concomitant expulsion of the linker.  
In addition to AIP synthesis, the -hydroxy cysteine linker (5) is generally 
useful for the preparation of peptide -thioesters for use in native chemical 
ligation (76) and expressed protein ligation (96) studies. Most of the AIPs and 
AIP derivatives used in this work were synthesized via the -hydroxy cysteine 
linker, and in some cases, an automated microwave-assisted peptide synthesizer 
was used, highlighting the stability of the linker (Materials and Methods). The 
linker was also successfully used in the Fmoc-SPPS synthesis of phosphopeptide 
-thioesters for use in protein semisynthesis (Mette Jensen, unpublished). 
However, one important limitation is that the stability of the linker is somewhat 
sequence dependent. An N-methylated residue (Section 2.3.1) or Gly-Gly 
sequence (Kyle Chiang and Maya Bar-Dagan) at the C-terminus of the peptide 
prevented attainment of the desired sequences, presumably via diketopiperazine 
formation during deprotection of the second amino acid coupled to the resin (80, 
81). Nonetheless, this method appears amenable to most peptide sequences and 
offers an improved route to Fmoc-based -thioester peptides and AIPs. In 
comparison to the method of Botti et al. (74) upon which the linker was based, 
this method circumvents the need to repeat the linker installation on every batch 
of resin used and avoids the exclusive use of resins that swell in water, which are 
difficult to handle and have low loading capacities, resulting in low yields.  
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The ability to prepare AIPs via the new Fmoc-SPPS route enabled a 
systematic SAR analysis of truncated AIP-II (6), which was previously found to 
inhibit S. aureus virulence of all four agr groups (40). The inhibitory activities of 
ten trAIP-II analogues were tested against AgrC-II and AgrC-I to evaluate 
cognate and non-cognate inhibition, respectively. The rank order of the peptides 
according to potency was roughly the same for both receptors, but as potency 
decreased, selectivity of the molecules for AgrC-I over AgrC-II increased (Table 4 
and Figure 17). Although the main mode of inhibition is still hypothesized to be 
competitive antagonism at the orthosteric agonist binding site (41), recent work 
demonstrated that some non-cognate AIPs are inverse agonists of some 
constitutively active AgrC mutants (42). Of the four S. aureus agr groups, group II 
is the most divergent from the others, and inverse agonism was only observed in 
AIP–AgrC pairings that included either AIP-II or AgrC-II. Thus, the behavior of 
inhibitory AIPs may be more complex than that of neutral antagonists, and the 
mode(s) of inhibition may differ depending on the agr groups involved. One or 
both of these possibilities may explain why the weakest trAIP-II derivative 
antagonists inhibited AgrC-I much more strongly than AgrC-II.  
Cross-group antagonism of the agr response by non-cognate AIPs has 
been used to attenuate the spread of an infection in an animal model (19). Thus, 
understanding the minimal determinants of inhibition by AIP analogues may be 
directly applicable to development of an antimicrobial if AgrC proves to be a 
viable therapeutic target. The Meth Link analogue (14) of trAIP-II (Figure 15) 
encompasses only the elements determined to be required for inhibition in this 
study (Figure 20) and may represent a good starting point for further medicinal 
chemistry efforts. Although Meth Link is a very poor inhibitor of AgrC-II, it is a 
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modest inhibitor of AgrC-I, with an IC50 of approximately 1 μM (Table 4). The 
peptidic character of this molecule has already been reduced compared to the 
trAIP-II parent peptide via the removal of one amide bond, and its molecular 
weight of 504 Da is comparable to small molecule therapeutics. The stability of 
the molecule may be significantly improved if a substitute can be found for the 
thioester that does not greatly sacrifice inhibitory potency. Notably, such an 
analogue could provide important clues to solve the longstanding mystery of the 
basis for the importance of the thioester. The results obtained with the Lactam 
analogue (15) (Table 4) suggest that an amide is not a good choice. Construction 
of a trAIP-II lactone derivative was attempted via a route analogous to that used 
to construct full-length AIP-II lactone (19), but the NMR spectra were not 
consistent with the expected structure although the product had the expected 
mass. The discrepancy was unfortunately not resolved, leaving open the 
question of whether an ester is a viable substitution for the thioester in this 
context. Nonetheless, the lactone variant may not be worth pursuing considering 
that the full-length AIP-II lactone structure differs dramatically from that of 
native AIP-II (79), as seen with the lactam derivatives (52, 77, 79). A thioether 
linkage, which has been proposed as a stabilizing substitute for the thioester (79), 
may be a better option. Another alternative to the thioester may be an N-
methylated amide, as such a substitution in the non-ribosomal peptide 
thiocoraline was recently shown to have no effect on the molecule’s antitumor 
activity, while the oxyester substitution greatly reduced it (97). Finally, work to 
further reduce the peptidic character of the scaffold and explore SAR of the 
region lacking important inhibition determinants may prove to increase the 
drug-like properties and potencies of these AIP-derived antagonists. 
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As noted above, the reasons for the presence of the thioester linkage in 
staphylococcal AIPs and the specific requirement of the thiolactone for 
significant AgrC activation are unknown. These questions are particularly 
intriguing given the fact that thioesters are rarely found in bioactive natural 
products. With few known exceptions, such as thiocoraline (98), most thioesters 
in biology are used as reactive handles to transfer molecules from one protein to 
another protein. Thus, thioester-containing molecules and protein adducts are 
typically transient intermediates in biosynthesis or conjugation pathways. In the 
cases of at least two thioester-containing natural products, largazole (99) and 
lactacystin (100), the parent molecules are inactive and undergo spontaneous or 
enzyme-catalyzed modifications to yield active molecules that do not contain 
thioesters. Overall, these observations are consistent with the intuitive 
hypothesis that thioester linkages are better suited for biological intermediates 
than for end products, as thioesters are relatively unstable compared to amides 
and esters. In contrast to amides and esters, thioesters lack resonance 
stabilization due to the poor overlap between the non-bonding electrons of the 
sulfur spd hybrid orbitals and the electrons of the p orbitals of the carbonyl 
carbon. Additionally, thiols have lower pKa values then the corresponding 
hydroxyls and are therefore better leaving groups.  Given this backdrop of 
information, a very appealing hypothesis is that the thiolactone AIPs represent 
transient intermediates. Indeed, Lyon et al. proposed that the AIPs may acylate 
AgrC (40); however, the results of order-of-addition and wash-out experiments 
were not consistent with covalent binding to the receptor (41). As AIPs appear to 
be a rare example of bioactive, thioester-containing final products, perhaps the 
inherent instability of the thiolactone is advantageous from the perspective of 
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staphylococci in vivo. Spontaneous AIP hydrolysis may contribute to the 
temporal control of AIP concentration by preventing excessive accumulation of 
AIP at low bacterial population density and/or persistent AgrC activation. 
Additionally, RNAIII expression and toxin production decrease in alkaline pH (> 
8.0) (101, 102), and AIP hydrolysis may be the mechanism for the observed pH 
dependence of agr output.   
The role of the AIP thiolactone in AgrC activation in vitro may be related 
to structural differences among thioesters, esters, and amides that are subtler 
than the pronounced differences in stability. The resonance stabilization of 
amides and esters imparts rigidity, whereas thioesters are more flexible. The 
differences in NMR chemical shifts observed among AIP-II lactam and AIP-II 
lactone derivatives and native AIP-II suggest that the rigid amide and ester 
substitutions may change the overall structure of the AIP macrocycle such that it 
can no longer activate AgrC (52, 77, 79). If so, a thioether linkage may be the ideal 
thioester substitute to test this possibility and to improve the therapeutic 
potential of AIP antagonists by imparting stability without sacrificing flexibility.  
The mechanistic analysis of AgrC in Chapter 3 yielded the first definitive 
insights into the activation mechanism of a polytopic, peptide-sensing receptor 
histidine kinase. Intermolecular complementation of histidine phosphorylation 
site and kinase domain mutants and co-immunoprecipitation of differentially 
tagged AgrC variants demonstrated that AgrC is a pre-formed dimer that 
undergoes trans-autophosphorylation. The mechanistic link between AIP 
binding to an AgrC dimer and the consequential signal transduction to the 
kinase domains was investigated by further elaborating the robust 
complementation scheme. Several sensor domain variants were combined with 
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the complementary mutants to construct AgrC heterodimers in which signaling 
by individual protomers could be tracked. The observation of ligand-induced 
activation by a pairing between a truncated receptor and an intact one suggested 
that one AIP binding event per dimer is sufficient for activation and that the 
AIP:AgrC stoichiometry is 1:1. Activation in this configuration was rather weak, 
possibly due to poor expression and incomplete membrane localization of the 
truncated mutant. To circumvent these limitations, full-length AgrC-ISensor 
mutants were used in which only three sensor domain residues are changed, 
resulting in a 50-fold reduction in the response to AIP-I (58). Accordingly, 
activation levels of pairings between one AgrC-ISensor mutant and one WT sensor 
domain were restored to the magnitude observed with the initial complementary 
heterodimers containing two WT sensor domains. Remarkably, receptor 
activation was unaffected by whether or not the sensor domain directly linked to 
the functional kinase was mutated. Thus, a signal received by one sensor led to 
activation of either kinase domain, indicating that the mechanism of signal 
transduction is symmetric within AgrC dimers. Further support for this concept 
was provided by constructing heterodimers of receptors belonging to the two 
most divergent agr specificity groups, I & II. Although AIP-I is an antagonist of 
AgrC-II and vice versa, both AIP-I & II activated mutant AgrC-I/II heterodimers 
equally well. Finally, using a constitutive mutant with a single amino acid 
change in the DHp domain, activation of a non-constitutive receptor in the 
heterodimeric configuration was observed, demonstrating that ligand-
independent activity is also symmetrically transduced within a dimer. 
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One key to these results was the ability to directly detect AgrC expression 
and localization, which had previously been elusive (55). A few important 
technical considerations enabled the use of fluorescence microscopy and western 
blot of epitope-tagged variants of AgrC to characterize the mutants used in the 
study and analysis of AgrC dimers by co-immunoprecipitation. Despite the 
hypothesis that low abundance of AgrC prevented its visualization (55), past 
difficulties in detecting AgrC by western blot are most likely attributable to 
incompatibility of standard denaturation procedures with AgrC, a polytopic 
membrane protein. Boiling samples prior to gel loading reproducibly resulted in 
a lack of bands in the western blot, possibly due to aggregation of AgrC (data not 
shown). Similarly, certain lysis procedures could result in a failure to recover an 
adequate amount of AgrC for detection. In this study, osmotic shock and 
detergents were both successfully used to lyse S. aureus cells and subsequently 
detect AgrC in samples that were either treated with dilute acid or that did not 
undergo any denaturation step at all (Materials and Methods). There are 
innumerable potential applications for techniques that enable monitoring of 
AgrC protein levels and localization, and these new tools are expected to greatly 
aid in future investigations of AgrC (see Section 4.2).  
The efficacy and potency of AIP-I toward the initial AgrC-IHis/AgrC-IKin 
complementary pair was moderately reduced compared to WT AgrC (Figure 25 
and Table 5). The drop in efficacy is consistent with the possibility of a statistical 
mixture of dimers that includes inactive mutant homodimers and the loss of one 
out of two potential phosphorylation sites per heterodimer. The explanation for 
the modest change in potency indicated by the change in EC50 from 10 to 40 nM 
is less readily apparent. The EC50 values depend on three unknown quantities, as 
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described in the following equation from Black and Leff’s operational model of 
agonism (103): 
EC50 = KA/(1 + ([RT]/KE)). 
KA is the agonist (AIP) affinity for the receptor (AgrC), [RT] is the total receptor 
concentration, and KE is the concentration of agonist-bound receptor that elicits a 
half-maximal response. This equation is used for standard sigmoidal curves with 
Hill Slopes equal to one, as is the case for the AgrC reporter assay results. 
Presumably, the KA of AIP-I for WT AgrC is the same as that for the 
complementary AgrC mutants, as the sensor domains are identical in WT AgrC, 
AgrCHis, and AgrCKin. According to the analysis of AgrC expression levels by 
fluorescence microscopy and western blot (Figures 23 and 24), there is little to no 
difference in expression between WT AgrC and the complementary mutants, 
suggesting that [RT] also remains relatively constant in these experiments. 
However, the total concentration of agonist-bound AgrC that elicits a half-
maximal response, KE, is predicted to increase due to AIP-I binding to the 
inactive mutant homodimers and the availability of only one out of two 
phosphorylation sites per active heterodimer. The KE would change further if the 
complementary mutations alter events downstream of AgrC activation, such as a 
change in the affinity between AgrC and AgrA. Thus, both the observed decrease 
in efficacy and increase in EC50 are most likely due to an increase in KE caused by 
formation of inactive AgrC homodimers and the loss of one phosphorylation site 
per active mutant heterodimer.    
In the mutant heterodimers formed by AgrC-I & II, the maximal activation 
levels were further decreased, reaching maximum levels of approximately 40-
60% of that observed for AgrC-IHis/AgrC-IKin (Figure 29C, D). This result could 
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reflect a decreased propensity for the divergent receptors to form dimers, 
especially if the sensor domains interact at the dimer interface. Co-
immunoprecipitation analysis of complementary AgrC-I/II mutant heterodimers 
could be used to test this possibility. The differential effects of the ligand on each 
protomer could also result in submaximal signaling by the receptor complex. For 
example, if AIP-I, an inverse agonist of a constitutive AgrC-II mutant (42), 
stabilizes or induces an inactive state of AgrC-II, this effect could interfere with 
an activating conformational change transduced by AgrC-I. Nonetheless, the 
agonist-induced activation outweighs any interfering effects as evidenced by the 
robust activation of AgrC-I/II mutant heterodimers by AIP-I and AIP-II. 
Inhibition tests of the heterodimers using AIP-III confirmed that the 
artificial pairings maintained native ligand recognition. However, there was an 
unexpected subtlety to some of the dose-response curves in which AIP-III 
appeared to act as a partial agonist at low concentrations. For example, 
concentrations of AIP-III between 0.5 and 50 nM increased activation of AgrC-
IHis/AgrC-IIKin by AIP-II (Figure 31A) but not by AIP-I (Figure 31B). To a lesser 
extent, the same effect was observed for AIP-III inhibition of AgrC-IKin/AgrC-
ISensor, His (Figure 31C). In both cases, AIP-III slightly increased activation at low 
concentrations only when the mutated kinase was linked to the sensor domain 
that could perceive the AIP agonist, although AgrC-IIHis/AgrC-IKin did not follow 
this trend when AIP-I was used as the agonist (Figure 31B). The biphasic dose-
response curves may be indicative of an allosteric binding site for AIP-III that 
remained undetected until now since this effect is only observed when the linear 
pathway for receptor signaling is blocked. An analogous effect called functional 
selectivity, in which the same ligand acts as a partial agonist or antagonist of the  
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Figure 31. Inhibition of AgrC Mutant Heterodimers by AIP-III. (A, B) AIP-III 
inhibition of AgrC-I-II heterodimers activated with AIP-II (A) or AIP-I (B). (C) 
Inhibition of AgrC-ISensor heterodimers activated by AIP-I as in Figure 28D. Error 
bars represent SEM. 
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same receptor depending on the context, is attributed to allosteric binding sites in 
G-protein coupled receptors (GPCRs) (104). Moreover, in some cases, particular 
effects of the allosteric agonists are only observed in the presence of an 
orthosteric agonist (104, 105). Alternatively, the apparent partial agonism of AIP-
III could be an artifact of the heterodimeric pairings. The development of a direct 
AgrC binding assay would be an invaluable tool to test for allostery and to better 
understand the mechanisms of inhibition and inverse agonism. 
The ligand-independent activation level of the heterodimer in which the 
receptor with the R238H mutation had a mutated kinase domain (Figure 30B) 
was approximately one third that of the heterodimer in which the receptor with 
the R238H mutation had a WT kinase domain and mutated phosphorylation site 
(Figure 30A). This imperfect symmetry of signaling by the AgrC R238H mutant 
may be a clue to the mechanism of this mutant’s constitutive activity. Since the 
AgrC activity was weaker when the R238H mutation was directly adjacent to the 
H239 phosphorylation site of the same protomer, the constitutive effect of the 
R238H mutation is neither to recruit the kinase domain to the H239 
phosphorylation site nor to cause a conformational change that exposes the 
adjacent H239 for phosphorylation. Instead, the R238H mutation appears to 
confer constitutive activity mainly via a direct, cis effect on the C-terminal kinase 
domain of its own protomer and secondarily via an indirect, trans effect on the 
kinase domain of the sister protomer mediated by intermolecular interactions 
between the two coiled-coils. A second, less favorable possibility is that the 
R238H mutation mainly promotes an activating conformational change in the 
sister protomer, which is indirectly transduced to its own coiled-coil and kinase 
domain via intermolecular interactions at the dimer interface. Although the 
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former is simpler and ostensibly more likely than the latter, both hypothetical 
mechanisms could contribute to the low ligand-independent activity observed 
when the receptor harboring the constitutive mutant lacks a functional kinase 
domain.  
Based on all of the results presented in Chapter 3, the working model of 
AgrC signaling is that AIP binding to a pre-formed dimer triggers symmetric 
conformational changes in both protomers directly and/or by intermolecular 
interactions at the dimer interface (Figure 32). Thus, whether one or both 
protomer(s) is ligand-bound, they are both activated, resulting in trans-
autophosphorylation by both kinase domains. This activation mechanism is 
predicted to be mediated by the putative coiled-coil in the DHp subdomain, the 
probable site of dimerization. Most of the point mutations within the cytoplasmic 
HK domains of AgrC and other HPK10 receptors found to confer constitutive 
activity were localized at or very near the putative coiled-coils of the receptors 
(42, 84, 85). Together, these results suggest that symmetric signaling via 
concerted conformational changes at the coiled-coil dimer interface may be a 
general mechanism of activation by quorum sensing HPK10 receptors. Beyond the 
HPK10 family, evidence for symmetric signaling via the coiled-coil HAMP linkers 
of distantly related HPKs was obtained using chimeric mutants of aspartate 
receptor, Tar, and the osmosensor, EnvZ (60). However, in the case of HPKs such 
as EnvZ, which sense a general property of the extracellular environment as 
opposed to discrete chemical ligands, the role of symmetric signaling would 
necessarily be something other than activating an unliganded sister protomer 
within a dimer. Perhaps, symmetric signaling could serve to reinforce activating 
conformational changes and stabilize the activated state. Further study will be  
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Figure 32. Model of AgrC Signal Transduction. Upon binding of one AIP 
molecule to an AgrC dimer, a conformational change (orange arrow) is 
transferred both linearly, to the kinase domain of the liganded protomer, and 
laterally, across the dimer interface (top). As a result, both kinase domains are 
activated and trans-autophosphorylate. Additionally, a second AIP binding event 
may occur (bottom), reinforcing the conformational changes in both protomers 
and thereby further stabilizing the active state. 

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required to probe the extent to which symmetric signaling is a general 
mechanism of HPK activation. 
In the eukaryotic GPCRs, another class of polytopic receptors in which 
dimerization is important (106), conformational changes transduced across the 
dimer interface have been recently observed. In analyses of purified leukotriene 
B4 GPCR dimers labeled with spectroscopic probes, intermolecular 
conformational changes were shown to be transmitted between a ligand-bound 
protomer and an unbound one (107). However, these conformational changes 
were asymmetric (107) and not sufficient to activate the G-protein associated 
with the unliganded protomer (108). In another study, FRET experiments used to 
track specific ligand-induced conformational changes within μ-opioid and 2A-
adrenergic receptor heterodimers revealed that interprotomer cross-talk resulted 
in inhibition of G-protein activation (109). Finally, co-expression of two inactive 
somastatin-5 (SSTR5) receptor mutants, one that hampered ligand binding and 
one that disabled signaling, restored activity (110), indicative of symmetric 
signaling analogous to that observed by AgrC.  
The various concerted conformational changes observed in different 
GPCRs and AgrC may be indicative of an adaptive value of fine-tuned, concerted 
conformational changes within dimeric receptors for particular biological 
functions. The ability to modulate stimuli by this type of mechanism may be a 
major reason why some receptors dimerize or oligomerize instead of simply 
functioning as monomers. In bacteria, amplification of the autoinducing signal 
by this mechanism may be particularly beneficial for cell density-dependent 
processes regulated by quorum sensing receptors, such as virulence, competence, 
and bacteriocin production (31). 
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4.2 Future Directions 
4.2.1 AIP–AgrC Cross-linking 
 Previous investigations of the AIP binding determinants within the AgrC 
sensor domain relied on powerful and readily available genetic methods: site-
directed mutagenesis (58, 62); construction of chimeric receptors between 
different agr groups (55); and error-prone PCR followed by activity 
screening (42). Individual residues responsible for inhibition of AgrC-I (42) and 
group-specific interactions of agr groups I & IV (58, 62) were identified, as well as 
a putative hydrophobic pocket essential for AIP binding (55) (see Section 1.2.3). 
In order to build on these findings, work is underway to precisely locate the AIP 
binding site(s) via covalent AIP–AgrC cross-linking. To this end, AIP-I & II 
derivatives containing photo-activatable cross-linkers at the N-terminus or in 
place of a natural amino acid were designed and constructed (Figure 33). First, 
benzophenone was chosen as the cross-linking moiety, and the amino acid p-
benzoylphenylalanine (Bpa) was added to AIP-II. Two opposing considerations 
guided the placement of Bpa within the AIP-II amino acid sequence. Installment 
of the cross-linker in place of or adjacent to residues known to be critical for 
AgrC activation may maximize the probability that it will contact the receptor 
and form a productive cross-link at the binding site. However, this benefit is lost 
if the cross-linker reduces the AIP affinity for the receptor, suggesting that the 
cross-linker should be positioned away from critical activation determinants. 
Thus, Bpa was installed at various positions in the AIP-II sequence, namely Ala4, 
Ser6, Ser7, and the N-terminus. Although Phe9 is both a key residue for 
activation and the amino acid that most closely resembles Bpa, AIP-II F9Bpa was  
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Figure 33. Structures of AIP Derivatives Containing Cross-linkers.  
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not made since a similarly bulky naphthylalanine substitution at that position 
rendered the peptide inactive (55). A biotin handle was added to the N-terminus 
of each peptide for detection, and control peptides lacking the biotin 
modification were also prepared to assess its effect on activity. The linear 
versions of the cross-linker AIP-II analogues were obtained, but the cyclization 
reactions of AIP-II Ala4Bpa, Ser6Bpa, and Ser7Bpa were low yielding, likely due 
to interference by the bulky benzophenone side chain (data not shown). Only 
AIP-II with Bpa coupled to the N-terminus (AIP-II-Bpa-Biotin (17), Figure 33) 
was successfully cyclized and subsequently tested for its ability to activate AgrC-
II. Although the control peptide AIP-II-Bpa (18) exhibited moderate activation of 
AgrC-II as compared to that of AIP-II, AIP-II-Bpa-Biotin (17) was completely 
inactive (Table 6) and therefore could not be used in cross-linking experiments.  
Subsequent AIP cross-linkers were designed using a photo-reactive 
analogue of methionine, photo-Met (pMet) (111). The photo-reactive moiety is a 
diazirine that replaces the thioether sulfur of methionine (Figure 33) and 
decomposes to a carbene upon irradiation with 330–370 nm light. pMet is 
sterically similar to methionine; thus, replacement of methionine by pMet in an 
AIP was anticipated to be a minor perturbation that would not impede AIP 
cyclization and permit genuine interactions with AgrC. In AIP-I, methionine is 
the C-terminal amino acid, one of the two hydrophobic residues hypothesized to 
interact with a hydrophobic pocket in the receptor (55). Thus, AIP-I M8pMet was 
constructed with and without biotin (19, 20) and tested for activity against AgrC-
I (Figure 33 and Table 6). Unlike Bpa, pMet was not commercially available, and 
Fmoc-pMet was synthesized by Frej Tulin and Matthew Pratt of the Muir Lab 
(112). Cyclization reactions of AIP-I M8pMet and AIP-I M8pMet-Biotin 
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Table 6. Activities of AIP Derivatives Containing Cross-linkers 
 
AIP Derivative 
 
 
AgrC Activation EC50 (nM), (95% CI) 
 
AIP-II 12, (4.9-27) 
AIP-II-Bpa-Biotin (17) – 
AIP-II Bpa (18) 59, (23-150) 
AIP-I 15, (13-18) 
AIP-I M8pMet-Biotin (19) 144, (37-565) 
AIP-I M8pMet (20) 2.5, (1.4-4.3) 
 
– = no activity up to the highest concentration of AIP tested, >10 μM. 
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proceeded without difficulty, and the substitution of pMet for methionine 
actually improved potency against AgrC-I (Table 6). The additional biotin handle 
caused a reduction in activity, but with an EC50 value of 140 nM, AIP-I M8pMet-
Biotin (19) was determined to be suitable for further use in cross-linking studies. 
Work is currently underway to cross-link 19 to AgrC-I.  
Methionines are only present in AIP-I & IV (Figure 3), but cross-linkers 
that resemble other natural amino acids are also available. For example, photo-
leucine and photo-isoleucine, two additional diazirine containing 
analogues (111), could be used in place of leucine in AIP-II & III and isoleucine in 
AIP-I, III, & IV; and azido and nitro-phenylalanine analogues (113) could be used 
in place of phenylalanine or tyrosine in all four AIPs. Use of these additional 
cross-linking AIP analogues, in which positions of the cross-linking amino acids 
are varied, may facilitate more complete mapping of the AIP binding site(s) on 
AgrC as well as enable comparison of cognate and non-cognate binding sites in 
the four S. aureus AgrC receptors.    
4.2.2 Inhibition of AgrB (This work was performed in collaboration with 
Matthew Pratt.) 
 In addition to inhibition of cognate AIP–AgrC interactions, another 
possible mode of agr interference is targeting of AgrB processing of its 
propeptide substrate. Based on evidence that AgrB is a cysteine protease (43), the 
enzyme may be inhibited by epoxysuccinyl derivatives known to target this class 
of enzymes (114). A bona fide AgrB inhibitor of this type would provide strong 
support for the proposal that AgrB is in fact a cysteine protease, and perhaps the 
identity of the catalytic cysteine could be confirmed (43). Furthermore, AgrB is a 
potential therapeutic target, perhaps more promising than AgrC since prevention 
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of AIP biosynthesis may be a more effective way to block agr activation than 
administering competitive AgrC antagonists. Thus, an epoxysuccinyl peptide 
(26) designed to inhibit AgrB was constructed (Figure 34). 
Like many other cysteine protease inhibitors (114), the AgrB inhibitor 
design was based on the natural product E-64 (Figure 34), the first reported 
epoxysuccinyl peptide cysteine protease inhibitor (115). In order to be recognized 
by AgrB, the conserved Asp-Glu dipeptide at the P1’ and P2’ positions (Figure 4) 
was incorporated in the molecule, and the electrophilic epoxysuccinyl moiety 
was appended at the P1 position (Figure 34). The carboxylic acid functionalities 
were protected as esters to promote passage across the cell membrane where 
they would presumably be removed by non-specific esterases. In order to 
synthesize desired product 26, each N-Boc-protected amino acid was activated as 
a pentafluorophenyl ester (21 and 22). An azide handle was appended to the 
resulting glutamate (22) by acylation with N,3-dibromopropan-1-ammonium 
(23), followed by displacement of the bromide with sodium azide to form 
intermediate 24. Following deprotection of the glutamate Boc group with TFA, 
the aspartate ester (22) and glutamate 24 were coupled to form dipeptide 25. 
Finally, the epoxysuccinyl pentafluorophenyl ester, which was synthesized by 
Matt Pratt, was coupled to the dipeptide to form the final product (26). 
AgrB inhibition by epoxysuccinyl peptide 26 was assessed by testing its 
ability to block AIP biosynthesis. S. aureus cultures of agr group I strains were 
grown in the presence of various concentrations of 26, and the supernatants were 
collected and added to -lactamase reporter cells. Unfortunately, the addition of 
the peptide inhibitor had no effect on the supernatants’ ability to activate AgrC 
(data not shown), indicating that it did not block AIP biosynthesis and secretion  
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Figure 34. Synthesis of Cysteine Protease Inhibitor Designed for AgrB. The 
natural product E-64, the first reported epoxysuccinyl peptide cysteine protease 
inhibitor is shown. 
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into the medium. In order to rule out the possibility that AIP production occurs 
before the peptide passes through the membrane, is deprotected by esterases, 
and reacts with AgrB, the experiment was repeated with cells that received two 
treatments of peptide 26. After the first treatment, the supernatants were 
removed, and the cells were re-suspended in medium containing the inhibitor a 
second time. However, the same result was obtained. In future efforts, direct 
labeling of an epitope-tagged version of AgrB in cells or in vitro could be probed 
by western blot with an azide-reactive detection agent such as phosphine-biotin. 
The most definitive experiment would be to purify AgrB and add the inhibitor 
without the ester protecting groups in vitro. Alternatively, if AgrB purification 
proved prohibitive, labeling of AgrB could be attempted in S. aureus lysates.  
 4.2.3 Quantitative AIP–AgrC Binding Assay 
 While the agr -lactamase reporter assay (52) has been an incredibly 
powerful and useful tool in the study of agr, it has limitations nonetheless. 
Specifically, direct investigation of the receptor–ligand interactions are not 
possible since the output is a transcriptional read-out downstream of AgrC 
activation. The development of a direct AIP–AgrC binding assay would 
immediately help resolve several outstanding questions in the field. First, the 
binding constants of cognate and non-cognate AIPs could be determined with 
WT and mutant variants of AgrC missing important determinants for group-
specific activation (58, 62). Accordingly, any cooperative effects exerted upon 
AIP binding to AgrC dimers may be delineated. A direct binding assay would 
also facilitate definitive determination of the mode(s) of inhibition by non-
cognate AIPs (competitive, non-competitive, or uncompetitive) using classical 
techniques. Finally, the ability to detect AIP–AgrC cross-links (Section 4.2.1) may 
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be a useful tool to ensure that AgrC is properly folded following isolation for a 
binding assay; and conversely, a binding assay system could be a useful tool to 
increase the yield of AIP–AgrC cross-linking. These advances would be a 
tremendous complement to previous investigations and significantly increase 
understanding of the agr system. 
 Thus far, a major obstacle to developing a direct AIP–AgrC binding assay 
has been the isolation of AgrC. Attempts in the lab to over-express and purify 
AgrC from E. coli have been unsuccessful. However, AgrC dimers were 
successfully isolated by co-immunoprecipitation (Section 3.2.2). These 
experimental conditions, in which AgrC intermolecular interactions are 
maintained, are a key step toward the development of conditions to isolate AgrC 
for a binding assay. Future efforts are aimed at inducing expression of AgrC in 
S. aureus and incorporating the receptor into nanoscale apolipoprotein bound 
bilayer (NABB) particles, as done previously with GPCRs (116, 117).  
4.2.4 AgrC Structure and Further Mechanistic Insights 
 Although AgrC was shown to be activated via symmetric signaling (see 
Section 3.3), the structural consequences accompanying this mechanism remain 
unknown. Thus, the successful application of NMR or crystallographic methods 
to determine the structure of AgrC in different activation states would be 
extremely informative. As AgrC is a polytopic membrane protein, determination 
of the structure of the full-length protein is expected to be very challenging. Even 
elucidation of the entire cytoplasmic HK domain structure could be equally 
difficult, as the first complete HK domain crystal structure of a sensor histidine 
kinase was only recently determined (118). Nonetheless, a structure of only one 
subdomain may provide great insight into remaining mechanistic questions 
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regarding AgrC. For example, dimerization plays a key role in the function of 
AgrC (see Section 3.2), and a crystal structure of the putative coiled-coil 
dimerization (DHp) subdomain could reveal the location and intermolecular 
contacts of the dimerization interface. Computational programs that predict the 
presence of coiled-coils in proteins are available (119) and could be used to 
design constructs for crystallization. In addition to the WT DHp subdomain, 
structural studies of a construct containing the R238H constitutive mutant may 
provide insight into the mechanism of ligand-independent activity and reduced 
propensity for homodimerization (Figure 26) imparted by the mutation.  
 As proposed above, symmetric signaling by AgrC may be important for 
efficient kinase activation at the appropriate AIP concentration. This possibility 
could be tested by comparing WT AgrC activity in the -lactamase reporter assay 
with that of an AgrC mutant that can undergo only asymmetric signaling. In this 
way, the effect of symmetric signaling on activation efficacy and EC50 may be 
determined. The biggest challenge in this experiment would be to find an AgrC 
mutant containing change(s) in the coiled-coil sequence that disrupt 
intermolecular interactions required for symmetric signaling but not 
dimerization or asymmetric signaling. One good starting point for finding such 
mutants would be an AgrC coiled-coil structure, if available. Alternatively, the 
library of AgrC-I mutants already generated via error-prone PCR by Geisinger et 
al. (42) could be used. In this experiment, AgrC mutants that signal 
asymmetrically would be isolated by a process of elimination. First, the mutants 
would be screened for activity in the presence of AIP-I, and any mutants 
previously identified as constitutively active (42) would be eliminated. Next, 
variants that signal symmetrically would be eliminated by testing for 
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complementation between the remaining AgrC-I mutants and AgrC-IIKin in the -
lactamase reporter assay. Those that can signal symmetrically would be activated 
by AIP-II and eliminated, while AgrC-I mutants that can signal only 
asymmetrically would not form functional heterodimers with AgrC-IIKin and fail 
to be activated by AIP-II. In the final elimination step, co-immunoprecipitation 
analysis would be performed to remove mutants that are not pre-formed dimers. 
Notably, the discovery of any mutants that fail to exhibit dimerization would not 
be useful in this experiment, but they would be extremely interesting for further 
study, as they may undergo cis-autophosphorylation. Finally, the contribution of 
symmetric signaling to overall AgrC activity may be determined by comparing 
the AIP-I-induced activities of the selected mutants to that of WT AgrC. One 
caveat to this experiment is that symmetric signaling may contribute only to the 
kinetics of activation, and this effect would not be observed in the reporter assay. 
Thus, the potential result of no change between the activities of WT AgrC and 
asymmetric signaling mutants would be uninterpretable. Secondly, the 
asymmetric signaling mutants may alter signaling in unpredictable ways 
independent of blockage of symmetric signaling. In this case, the activities of 
different asymmetric signaling mutants would vary and prevent determination 
of the specific contribution of symmetric signaling to AgrC activity.  Nonetheless, 
such an outcome may lead to new insights into the AgrC signaling mechanism. 
 A second hypothesis generated from the results described in Chapter 3 is 
that symmetric signaling may be a general phenomenon among quorum sensing 
receptors, especially those of the HPK10 family of AgrC. In order to test this 
possibility, the predicte coiled-coil region of AgrC could be replaced with that of 
other HPK10 family members in the context of the complementary mutant 
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schemes and tested for symmetric signaling as described in Chapter 3. 
Furthermore, mixed combinations could be used to determine whether a 
heterodimer containing two different coiled-coils still signals symmetrically.  
 A major outstanding question regarding the mechanism of AgrC 
activation is whether, in the ground state, the phosphorylation site histidine is 
occluded from the catalytic (CA) kinase domain or the CA domain is held an 
inactive conformation, apart from the phosphorylation site. In other words, does 
AIP binding trigger solvent exposure of the phosphorylation site histidine or 
release of the CA domain, or both? One experiment that may delineate between 
these possibilities is co-expression of a construct containing the sensor and DHp 
domains with a construct containing the CA subdomain in trans in the -
lactamase reporter assay (Figure 35). If, in WT AgrC, the phosphorylation site 
histidine is occluded from the kinase prior to ligand binding, activation would 
only occur upon addition of AIP. Alternatively, if the kinase is held in an inactive 
conformation or apart from the phosphorylation site prior to activation, co-
expression of the constructs would be predicted to result in constitutive activity. 
In a similar experiment involving EnvZ of E. coli, kinase activity was successfully 
reconstituted via trans expression of the DHp and CA subdomains (120), 
although the sensor domain was absent. A critical assumption in this experiment 
is that native conformational changes triggered by AIP binding will be 
transduced from the sensor domain to the DHp subdomain regardless of 
whether a CA subdomain is present in cis or trans. Nonetheless, if this 
assumption is incorrect, the outcome would likely be lack of activity, and an 
alternative approach could be to co-express the full-length AgrC-IKin mutant and 
the WT CA subdomain. 
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Figure 35. Experimental Scheme for trans Expression of AgrC Domains. (A) 
Two possible mechanisms of AgrC activation. Either the CA subdomains are 
held away from the target phosphorylation sites or the phosphorylation site 
histidines are occluded from CA subdomains. Upon addition of AIP, the restraint 
is removed. (B) If AgrC is split between the DHp and CA subdomains and 
expressed in trans, activity is predicted to be constitutive or ligand-dependent, 
based on the two hypothetical mechanisms.  
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4.2.5 The in vivo Role of agr in Virulence 
The role of agr activation and cross-group interference in establishment 
and maintenance of S. aureus infection is a critical, unresolved problem in the 
field (121). Certain diseases such as toxic shock syndrome are correlated with a 
certain agr group (122), while others such as cystic fibrosis are associated with all 
four agr groups (123), and indeed some patients are colonized with two or three 
different groups. There are also varying results regarding the influence of agr 
group identity on host colonization. In one study of patients infected with 
S. aureus, a significant number of individuals were colonized with multiple agr 
groups (124). In contrast, a separate analysis of the nasal flora of healthy 
volunteers yielded no incidences of multiple agr group colonization of S. aureus, 
although many participants harbored multiple agr groups of S. epidermidis (125). 
Since cross-group interference has no direct effect on growth, it is unlikely to 
impact commensal colonization. Instead, certain agr groups may have a survival 
advantage in certain niches. In an insect model of virulence, a correlation was 
found between relative fitness and specific agr groups by monitoring their 
population densities before and after infection within a mixed culture (126). 
Thus, there is a plausible role for interference in infection, but it is also 
conceivable that certain agr groups have an enhanced ability to carry out a 
particular disease process unrelated to cross-group inhibition.
The temporal regulation of agr in vivo has been examined by Wright et 
al. (127) who used an agr P3::lux reporter system to monitor agr activation in real 
time in a mouse abscess model of S. aureus infection. As expected, agr was 
activated a few hours after injection of the bacteria, and this initial burst of 
activity lasted only a few hours. Remarkably, a second burst of agr activity was 
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observed approximately 72 hours after the initial infection. This behavior does 
not represent a temporary diminishment of the bacterial population based on 
consistent cell density; although it may be indicative of low metabolic activity or 
phagocytosis by neutrophils. Co-injection of a non-cognate AIP with the bacteria 
led to a reduction in agr activation at the early time points and, importantly, no 
abscess formed over five days. Interestingly, the second burst of agr activity did 
not occur in this case, suggesting that the initial burst of agr activity is required 
for the resurgence. This result was especially surprising considering that the AIP 
half-life is a few hours in serum (127). Analogous experiments in which mice 
were injected with agr- strains confirmed that agr activation is required to 
establish an infection in this experimental model. 
Despite considerable evidence that virulence of S. aureus strains lacking a 
functional agr locus is attenuated and are not competent to establish infection 
(18-21, 127), many drug-resistant strains and clinical isolates are paradoxically 
missing a functional agr locus (16, 128-130). At least some of these dysfunctional 
agr mutations arise following the initial establishment of infection (131), and 
mixed populations of agr+ and agr- strains have been isolated from the same 
individual (131, 132), raising the possibility that agr activation by part but not all 
of the bacterial population is required for infection. Perhaps a subsequent loss of 
agr function confers an advantage for long-term survival in the host due to the 
metabolic demand of agr activation. In any case, the fundamental question of 
whether S. aureus can cause an infection without agr activation has yet to be 
definitively answered. Thus, the viability of agr as a prophylactic or therapeutic 
target is promising but unknown pending future work in this area.    
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4.3 Conclusion 
The work presented here elucidated several mechanistic features of the agr 
system and produced methods expected to aid greatly in future studies. The 
identification of the minimal determinants for AIP inhibition of AgrC lays a 
foundation for future medicinal chemistry efforts to increase the physiological 
stability and efficacy of potential AIP-based therapeutics. The finding that AgrC 
activation occurs via symmetric signaling by pre-formed dimers represents a 
significant advance in the mechanistic understanding of AgrC, and the 
development of fluorescence imaging and western blot analysis of AgrC 
provides the long awaited ability to monitor receptor expression. Intriguing 
future directions for investigation of agr include analysis of AIP–AgrC 
interactions by cross-linking and direct binding assays, elucidation of the 
structural basis for AgrC symmetric signaling, and clarification of the 
significance of agr in infection. 
Whether or not agr proves to be therapeutically relevant, a deeper 
understanding of the mechanisms that contribute to virulence will increase 
knowledge of S. aureus infections and provide the foundation for new discoveries 
and eventual advances in treatment. The insights described in this work will 
hopefully be applicable to other quorum sensing receptors and serve to build 
connections between the molecular mechanisms of AgrC activation and 
inhibition and S. aureus virulence in vivo. 
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Chapter 5: Materials and Methods 
Materials. Amino acids, HBTU, HATU, PyBop, and Rink and MBHA resins were 
purchased from Novabiochem (San Diego, CA) with the exceptions of Boc-N-
methylphenylalanine (Fluka, Buchs, Switzerland) and Fmoc-DAPA(Boc)-OH 
(Neosystem Laboratoire, Strasbourg, France). All solvents were obtained from 
Fisher (Pittsburgh, PA), and trifluoroacetic acid was obtained from Halocarbon 
(River Edge, NJ). All other chemical reagents, including DNase and poly-lysine 
solution, were purchased from Sigma Aldrich (Milwaukee, WI). Oligonucleotide 
primers were synthesized by Integrated DNA Technologies (Coralville, Iowa). 
QuikChange kits for site-directed mutagenesis were obtained from 
Stratagene/Agilent (Cedar Creek, TX). Lysostaphin was purchased from AMBI 
Products LLC (Lawrence, NY), and Criterion Tris-HCl gels were purchased from 
Bio-Rad (Hercules, CA). Immuno Elution Buffer and BCA assay kit were 
obtained from Pierce (Rockford, IL). Protease inhibitors and mouse anti-GFP 
antibodies were obtained from Roche (Indianapolis, IN). Mouse anti-HA 
antibodies and anti-HA affinity matrix were purchased from Covance 
(Emeryville, CA), rabbit anti-Sortase antibodies from Abcam (Cambridge, MA) 
and anti-mouse horse radish peroxidase (HRP) and anti-rabbit HRP antibodies 
from Bio-Rad (Hercules, CA). ECL and ECL Plus were obtained from Amersham 
(Buckinghamshire, UK), and glass slides and coverslips were obtained from 
Fisher (Pittsburgh, PA). 
Reversed-Phase HPLC and Mass Spectrometry. Analytical and semipreparative 
HPLC was performed using a Hewlett-Packard 1100 series instrument with 
diode array detection. A Vydac C-18 column (5 μm, 4.6 x 150 mm) with a 1 
mL/min flow rate was used for analytical scale HPLC, a Vydac C-18 column (10 
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μm, 10 x 250 mm) with a 4 mL/min flow rate was used for semipreparative 
HPLC, and a Vydac C-18 column (10 μm, 22 x 250 mm) with an 18 mL/min flow 
rate was used for preparative HPLC. A Waters 2795 Separations Module plus 996 
photodiode array detector with a Vydac C18 column (3μm, 2.1 x 150 mm) and a 
0.2 mL/min flow rate was used for LC-MS. In all cases, linear gradients of 0.1% 
aqueous TFA (solvent A) versus 90% acetonitrile, 10% water, and 0.1% TFA 
(solvent B) were utilized. ESI-MS was performed on a PE Sciex API-100 single 
quadrupole electrospray mass spectrometer. ESI-HRMS was performed on a Q–
TOF Ultima hybrid quadrupole time-of-flight electrospray mass spectrometer 
(University of Illinois at Urbana-Champaign Mass Spectrometry Laboratory).  
NMR Spectroscopy. Compounds 12-16 were dissolved in CD3-OD or CDCl3, and 
1H and 13C NMR spectra were recorded with a Bruker 400 MHz spectrometer. 
Measurements were taken at 298 K, and chemical shift values are relative to 
methanol (1H 3.31 ppm, 13C 49.00 ppm) or chloroform (1H 7.26 ppm, 13C 77.16 
ppm). Peptides 6-16 were dissolved in DMSO-d6, and 1-D 
1H, homonuclear 1H 
TOCSY, and ROESY experiments were performed on a Bruker 400 MHz 
spectrometer, Bruker 600 MHz spectrometer with cryoprobe, or Bruker Avance 
700 MHz spectrometer with cryoprobe, respectively. The mixing times were 77 
and 200 ms for TOCSY and ROESY experiments, respectively. In all cases, the 
sample temperature was 298 K, and the reported chemical shift values are 
relative to DMSO at 2.50 ppm. The chemical shift index (CSI) of each peptide was 
calculated using the formula 
CSI =  (|ai-6i|)/n 
where a is the peptide of interest, 6 is peptide 6, i is the proton type (e.g., Cys1 
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NH), and n is the total number of protons included in the calculation. Protons 
directly bonded to the macrocyclic scaffold plus the exocyclic N-terminal amide 
proton were included in each CSI (Cys1 NH, H, H; Ser2 NH, H; Ser3 NH, 
H; Leu NH, H; and Phe NH, H). The protons of the modified residue(s) were 
excluded. 
Synthesis. 3-t-Butyldisulfanyl-propane-1,2-diol (1). A solution containing 1-
mercapto-ethane-1,2-diol (3.0 g, 27.7 mmol, 1.0 equiv), 2-methyl-propane-2-thiol 
(25 g, 277 mmol, 10.0 equiv), and triethylamine (7.0 g, 69.3 mmol, 2.5 equiv) 
dissolved in methanol (55 mL) was stirred at room temperature with bubbling O2 
overnight (>10 h). Methanol and excess 2-methyl-propane-2-thiol were removed 
in vacuo, and the crude product was purified by flash chromatography using 3:2 
hexanes/ethyl acetate to give 5.4 g of 1 (99%) as a clear oil. 1H NMR (400 MHz, 
CD3OD)  3.83 (m, 1H),  3.58 (dd, 1H, J = 11.3, 4.8 Hz),  3.52 (dd, 1H, J = 11.3, 
5.8 Hz),  2.90 (dd, 1H, J = 13.3, 5.3 Hz),  2.78 (dd, 1H, J = 13.3, 7.3 Hz),  1.34 (s, 
9H); 13C NMR (100 MHz, CD3OD)  72.33,  65.90,  48.45,  45.64,  30.25, ESI-MS 
m/z calcd for C7H16O2S2 196.3, found 393.0 ([2M + H
+]). 
In an updated route to 1 in two steps, a solution containing 2-methyl-
propane-2-thiol (4.5 g, 49.9 mmol, 1.1 equiv), 2,2-dithiodipyridine (10.0 g, 45.4 
mmol, 1.0 equiv), and triethylamine (4.6 g, 45.4 mmol, 1.0 equiv), dissolved in 
methanol (230 mL) was stirred at room temperature overnight (>10 h). Methanol 
and excess 2-methyl-propane-2-thiol were removed in vacuo, and the crude 
product was purified by flash chromatography using 1:1 dichlorometane 
/methanol to give 9.1 g of 2-(tert-butyldisulfanyl)pyridine (99%). 1H NMR (400 
MHz, CDCl3)  8.42 (m, 1H),  7.79 (m, 1H),  7.63 (m, 1H),  7.05 (m, 1H),  1.34 
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(s, 9H). In the subsequent step, a solution containing 2-(tert-
butyldisulfanyl)pyridine (9.1 g, 45.4 mmol, 1.0 equiv), 1-mercapto-ethane-1,2-diol 
(5.4 g, 50.2 mmol, 1.2 equiv), and triethylamine (9.3 g, 91.4 mmol, 2.0 equiv), 
dissolved in methanol (150 mL) was stirred at room temperature overnight (>10 
h). Methanol was removed in vacuo, and the crude product was extracted with 
ethyl acetate, washed with 1 N HCl, 1 N NaOH, brine, and dried over Na2SO4, 
filtered, and further dried in vacuo. Purification by flash chromatography using 
3:2 hexanes/ethyl aectate to give 6.7 g of 1 (75%).   
1,2-Bis-(t-butyl-dimethyl-silanyloxy)-3-t-butyldisulfanylbutyldisulfanyl-
propane (2). t-Butyl-chloro-dimethyl-silane (11 g, 72 mmol, 3.0 equiv), imidazole 
(9.8 g, 144 mmol, 6.0 equiv), and 4-dimethylaminopyridine (170 mg, 1.4 mmol, 
0.06 equiv) were added on ice to a solution of 1 (4.7 g, 24 mmol, 1.0 equiv) 
dissolved in 240 mL of anhydrous DMF. The reaction was stirred under N2 at 
room temperature overnight at which point 0.5 N NaOH was added to quench 
the reaction, and the product was extracted with ethyl acetate, washed with 1 N 
HCl, dried over Na2SO4, filtered, and dried in vacuo. Excess DMF was removed 
by an azeotrope with hexanes to yield 10 g (99%) of 2, which was taken on to the 
next step without further purification. 1H NMR (400 MHz, CDCl3)  3.89 (m, 1H), 
 3.61 (dd, 1H, J = 10.1, 5.0 Hz),  3.53 (dd, 1H, J = 10.1, 6.3 Hz),  2.99 (dd, 1H, J = 
13.1, 4.9 Hz),  2.73 (dd, 1H, J = 13.1, 6.7 Hz),  1.33 (s, 9H),  0.90 (s, 18H),  0.08 
(m, 12H); 13C NMR (100 MHz, CDCl3)  72.70, 66.40, 47.81, 46.00, 30.06, 26.10, 
26.04, 25.86, 25.82, 18.50, 18.30, -2.79, -3.41, -4.39, -4.20, -5.20, -5.18, ESI-MS m/z 
calcd for C19H44O2S2Si2 424.2, found 423.0 ([M
-]). 
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2-(t-Butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propan-1-ol (3). A cold 1:1 
mixture of TFA and water (18 mL) was added dropwise to a solution of 2 (4.4 g, 
10 mmol, 1.0 equiv) in 45 mL of THF. The reaction was stirred at 0 °C for 4.5 h, 
and then it was slowly poured into a separation funnel containing an ice cold 
solution of NaHCO3 to bring the pH above 7. The product was extracted with 
ethyl acetate, washed with water and brine, dried over Na2SO4, and filtered, and 
the solvents were removed in vacuo. Purification by flash chromatography with 
15:1 hexanes/ethyl acetate yielded 2.0 g (65%) of 3. 1H NMR (400 MHz, CD3Cl)  
3.97 (m, 1H),  3.70 (dd, 1H, J = 11.3, 3.5 Hz),  3.62 (dd, 1H, J = 11.3, 4.0 Hz),  
2.87 (dd, 1H, J = 13.4, 7.2 Hz),  2.79 (dd, 1H, J = 13.4, 5.4 Hz),  1.34 (s, 9H),  0.91 
(s, 9H),  0.13 (s, 3H),  0.10 (s, 3H); 13C NMR (100 MHz, CDCl3)  72.14, 65.01, 
48.06, 44.05, 29.98, 25.93, 18.19, -4.29, -4.48, -4.62, ESIMS m/z calcd for 
C13H30O2S2Si2 310.2, found 309.0 ([M
-]). 
2-(t-Butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionaldehyde (4). Dess-
Martin periodinane (1.3 g, 3.1 mmol, 1.2 equiv) was added to a solution of 3 (800 
mg, 2.6 mmol, 1.0 equiv) in 26 mL of CH2Cl2 under N2. The reaction was stirred 
at room temperature for 2 h, then diluted with CH2Cl2 and ethyl acetate. The 
product was washed with 0.1 N HCl, 1 N NaOH, and brine, dried over Na2SO4, 
and filtered, and the solvents were removed in vacuo. Purification by flash 
chromatography using 19:1 hexanes/ethyl acetate yielded 590 mg (73%) of 4. 1H 
NMR (400 MHz, CDCl3)  9.64 (s, 1H),  4.22 (m, 1H),  2.99 (dd, 1H, J = 13.4, 4.2 
Hz),  2.80 (dd, 1H, J = 13.4, 7.9 Hz),  1.31 (s, 9H),  0.91 (s, 9H),  0.12 (s, 3H),  
0.10 (s, 3H); 13C NMR (100 MHz, CDCl3)  202.17, 76.57, 48.22, 43.66, 29.97, 25.84, 
18.30, -4.55, -4.63, ESI-MS m/z calcd for C13H28O2S2Si 308.1, found 309.0 ([M+H
+]). 
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2-(t-Butyl-dimethyl-silanyloxy)-3-t-butyldisulfanyl-propionic Acid (5).  
Compound 4 (227 mg, 0.74 mmol, 1.0 equiv) was dissolved in 4 mL of t-butyl 
alcohol. 2-Methyl-2-butene (3.02 g, 42.9 mmol, 58 equiv) was added to the 
solution on ice, followed by a pre-dissolved solution of monobasic sodium 
phosphate (225 mg, 1.63 mmol, 2.2 equiv) and 80% sodium chlorite (251 mg, 2.22 
mmol, 3.0 equiv) in water (4 mL). The reaction was stirred vigorously to ensure 
mixing of the two phases at room temperature for 2 h. The reaction mixture was 
diluted with ethyl acetate, washed with 0.1 N HCl and brine, dried over Na2SO4, 
and filtered, and the solvents were removed in vacuo. Purification by flash 
chromatography using 19:1 CH2Cl2/methanol yielded 160 mg (66%) of 5 as a 
clear oil. 1H NMR (400 MHz, CDCl3)  4.47 (m, 1H),  3.12 (dd, 1H, J = 13.4, 3.6 
Hz),  2.93 (dd, 1H, J = 13.4, 7.9 Hz),  1.33 (s, 9H),  0.92 (s, 9H),  0.15 (s, 3H),  
0.13 (s, 3H); 13C NMR (100 MHz, CDCl3)  176.60, 71.27, 48.23, 45.77, 30.00, 25.82, 
18.29, -4.80, -4.86, ESI-HRMS m/z calcd for C13H28O3S2Si [M + H
+] 325.1327, 
found 325.1329. 
Fmoc-SPPS of AIPs. Native AIPs and peptides 6-12, 14, 16, 19, and 20 were 
synthesized manually or with a Liberty microwave-assisted automated peptide 
synthesizer (CEM). Linker 5 (188 mg, 0.61 mmol, 1.1 equiv relative to resin 
substitution) was added to a solution of HBTU (207 mg, 0.55 mmol, 1.0 equiv 
relative to resin loading) in DMF (1.2 mL), followed by DIEA 
(diisopropylethylamine) (0.25 mL, 1.44 mmol, 2.6 equiv relative to resin) to pre-
activate the acid. After 3 min, the solution was added to Rink amide resin and 
stirred by bubbling N2 through the vessel at room temperature for 4 h. 
Remaining free amines were acetylated by two treatments with a 1:1:8 solution of 
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acetic anhydride/DIEA/DMF for 10 min. Deprotection of the TBS group was 
accomplished by the addition of tetrabutyl ammonium fluoride (10 mL of a 1.0 M 
solution in THF) overnight at room temperature. 4-Dimethylaminopyridine (0.1 
equiv relative to the C-terminal amino acid) was used in addition to HBTU and 
DIEA to double couple the C-terminal amino acid to the hydroxyl group of the 
linker. For automated syntheses, the resin was loaded onto the peptide 
synthesizer at this point. Subsequent steps were completed with standard 
HBTU/DIEA activation and piperidine deprotection protocols for Fmoc solid-
phase peptide chemistry with a few exceptions. N-Methylated amino acids were 
double coupled, once with HBTU and once with HATU. Other unnatural 
monomers were coupled with standard methods. Finally, peptides 6–12, 14, and 
16 were acetylated at the N-terminus with a 1:1:8 solution of acetic 
anhydride/DIEA/DMF for 10 min. Each peptide was cleaved from the solid 
support by treatment with 95:2.5:2.5 TFA/TIS/water for 3-4 h at room 
temperature, followed by filtration and washing of the beads with the TFA 
cleavage cocktail. The peptides were either purified by semipreparative or 
preparative HPLC or taken on to the cyclization step without purification. 
The cyclization buffer contained 20% acetonitrile and 80% 6 M 
guanidinium chloride in 0.1 M sodium phosphate buffer pH 6.5. TCEP (tris-(2-
carboxy)ethyl phosphine) (70 mM) was added to this solution, and the pH was 
brought back up to 6.6-6.8 with 4 M NaOH. Each linear peptide was dissolved in 
this solution to a final concentration of 100 μM and rocked at room temperature 
for 2-24 h, and the reaction was monitored by analytical HPLC. The desired AIP 
product was then purified by semipreparative or preparative HPLC. 
122
Data for trAIP-II (6). 1H NMR (400 MHz, DMSO-d6)  8.68 (d, 1H, J = 8.8 Hz),  
8.46 (d, 1H, J = 8.2 Hz),  8.12 (m, 2H),  7.60 (d, 1H, J = 8.7 Hz),  7.25 (m, 2H),  
7.21 (m, 3H),  5.12 (t, 1H, J = 5.4 Hz),  5.03 (t, 1H, J = 5.4 Hz),  4.56 (m, 1H),  
4.39 (m, 1H),  4.28 (m, 1H),  4.22 (m, 1H),  3.92 (m, 1H),  3.64 (m, 1H),  3.58 
(m, 2H),  3.52 (m, 1H),  3.31 (obsc 1H),  3.16 (m, 1H),  2.84 (m, 2H),  1.86 (s, 
3H),  1.38 (m, 1H),  1.30 (m, 1H),  1.22 (m, 1H),  0.74 (d, 3H, J = 6.3 Hz),  0.71 
(d, 3H, J = 6.3 Hz), ESI-MS m/z calcd for C26H37N5O8S 579.2, found 580.0 ([M + 
H+]). See appendix for chemical shift assignments of peptides 6–16. 
Data for S2G (7). 1H NMR (400 MHz, DMSO-d6)  8.67 (d, 1H, J = 9.0 Hz)  8.44 
(d, 1H, J = 7.9 Hz),  8.21 (m, 1H),  7.99 (d, 1H, J = 7.7 Hz),  7.59 (d, 1H, J = 8.3 
Hz),  7.26 (m, 2H),  7.20 (m, 3H),  5.21 (t, 1H, J = 5.5 Hz),  4.59 (m, 1H),  4.32 
(m, 1H),  4.21 (m, 1H),  3.98 (m, 1H),  3.89 (m, 1H),  3.62 (m, 1H),  3.52 (m, 
1H),  3.32 (obsc, 1H),  3.31 (obsc, 1H),  3.16 (m, 1H),  2.84 (m, 2H),  1.86 (s, 
3H),  1.31 (m, 2H),  1.18 (m, 1H),  0.74 (d, 3H, J = 6.2 Hz),  0.69 (d, 3H, J = 6.2 
Hz), ESI-MS m/z calcd for C25H35N5O7S 549.2, found 550.0 ([M+H
+]).  
Data for S3G (8). 1H NMR (400 MHz, DMSO-d6)  8.46 (m, 1H),  8.36 (d, 1H, J = 
7.4 Hz),  8.30 (d, 1H, J = 8.0 Hz),  8.02 (m, 2H),  7.24 (m, 5H),  4.64 (m, 1H),  
4.41 (m, 2H),  3.99 (m, 1H),  3.79 (dd, 1H, J = 14.0, 3.6 Hz),  3.57 (m, 3H),  3.35 
(obsc, 1H),  3.13 (m, 1H),  2.91 (m, 1H),  2.62 (m, 1H),  1.86 (s, 3H),  1.49 (m, 
1H),  1.12 (m, 2H),  0.78 (d, 3H, J = 6.5 Hz),  0.71 (d, 3H, J = 6.5 Hz); ESI-MS 
m/z calcd for C25H35N5O7S 549.2, found 550.0 ([M+H
+]).  
Data for GG (9). 1H NMR (400 MHz, DMSO-d6)  8.39 (m, 1H)  8.29 (m, 2H),  
8.15 (d, 1H, J = 9.4 Hz),  8.08 (m, 1H),  7.23 (m, 5H),  4.67 (m, 1H),  4.42 (m, 
1H),  4.10 (m, 1H),  3.98 (m, 1H),  3.79 (m, 1H),  3.58 (dd, 1H, J = 14.2, 6.4 Hz), 
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 3.28 (obsc, 1H),  3.18 (m, 1H),  2.87 (m, 1H),  2.72 (m, 1H),  1.86 (s, 3H),  
1.43 (m, 2H),  1.10 (m, 1H),  0.78 (d, 3H, J = 6.5 Hz),  0.71 (d, 3H, J = 6.5 Hz); 
ESI-MS m/z calcd for C24H33N5O6S 519.2, found 520.3 ([M+H
+]).  
Data for N-MeS2 (10). 1H NMR (400 MHz, DMSO-d6)  8.73 (d, 1H, J = 8.3 Hz),  
8.56 (d, 1H J = 9.0 Hz),  7.98 (d, 1H J = 7.4 Hz),  7.49 (d, 1H, J = 8.1 Hz),  7.25 
(m, 2H),  7.18 (m, 3H),  5.25 (m, 1H),  4.95 (m, 3H),  4.38 (m, 1H),  4.16 (m, 
1H),  4.08 (m, 1H),  3.80 (m, 1H),  3.73 (m, 2H),  3.33 (obsc, 1H),  3.12 (m, 
1H),  3.00 (s, 3H),  2.90 (m, 1H),  2.83 (m, 1H),  1.87 (s, 3H),  1.26 (m, 3H),  
0.73 (m, 6H); ESI-MS m/z calcd for C27H39N5O8S 593.3, found 595.0 ([M+H
+]).   
Data for N-MeS3 (11a and 11b). (cis and trans amide isomers ~50% each): 1H 
NMR (400 MHz, DMSO-d6)  8.66 (d, 1H, J = 7.4 Hz),  8.47 (d, 1H, J = 7.6 Hz),  
8.24 (d, 1H, J = 8.6 Hz),  8.10 (m, 3H),  7.48 (m, 2H),  7.25 (m, 5H),  7.14 (m, 
5H),  4.90 (m, 1H),  4.83 (m, 1H),  4.59 (m, 1H),  4.51 (m, 1H),  4.45 (m, 1H),  
4.35 (m, 1H),  4.26 (m, 1H),  4.12 (m, 2H),  3.99 (m, 1H),  3.88 (m, 1H),  3.77 
(m, 1H),  3.63 (m, 1H),  3.56 (m, 3H),  3.34 (obsc, 1H),  3.29 (obsc, 1H),  3.26 
(obsc, 1H),  3.24 (obsc, 1H),  3.14 (m, 2H),  3.02 (m, 1H),  2.97 (m, 2H),  2.66 
(s, 6H),  2.49 (obsc, 1H),  1.86 (s, 6H),  1.39 (m, 5H),  1.29 (m, 1H),  0.77 (m, 
6H),  0.73 (m, 6H); ESI-MS m/z calcd for C27H39N5O8S 593.3, found 595.0 
([M+H+]). 
Data for N-MeL (12). 1H NMR (400 MHz, DMSO-d6)  8.45 (d, 1H, J = 8.2 Hz),  
8.25 (d, 1H, J = 9.9 Hz),  8.05 (d, 1H, J = 8.5 Hz),  7.76 (d, 1H, J = 9.1 Hz),  7.25 
(m, 3H),  7.21 (m, 2H),  5.15 (m, 1H),  4.82 (m, 1H),  4.75 (m, 1H),  4.67 (m, 
1H),  4.44 (m, 1H),  4.22 (m, 1H),  3.63 (m, 2H),  3.50 (m, 1H),  3.45 (m, 1H),  
3.37 (obsc, 1H),  3.36 (obsc, 1H),  3.11 (m, 1H),  3.01 (s, 3H),  2.89 (m, 1H),  
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2.70 (m, 1H),  1.90 (m, 1H),  1.85 (s, 3H),  1.37 (m, 1H),  1.25 (m, 1H),  0.75 (d, 
3H, J = 6.5 Hz),  0.69 (d, 3H, J = 6.4 Hz); ESI-MS m/z calcd for C27H39N5O8S 593.3, 
found 595.0 ([M+H+]). 
Data for Meth Link (14). 1H NMR (400 MHz, DMSO-d6)  8.24 (d, 1H, J = 7.8 Hz), 
 8.09 (m, 1H),  7.94 (d, 1H, J = 8.9 Hz),  7.74 (d, 1H, J = 9.2 Hz),  7.26 (m, 3H),  
7.20 (m, 2H),  4.67 (m, 1H),  4.34 (m, 1H),  4.20 (m, 1H),  3.43 (m, 1H),  3.28 
(obsc, 1H),  3.21 (obsc, 1H),  2.90 (m, 1H),  2.76 (m, 2H),  2.11 (m, 1H),  2.01 
(m, 1H),  1.84 (s, 3H),  1.50 (m, 3H),  1.32 (m, 1H),  1.20 (m, 2H),  0.97 (m, 
1H),  0.75 (d, 3H, J = 6.5 Hz),  0.68 (d, 3H, J = 6.5 Hz); ESI-MS m/z calcd for 
C25H36N4O5S 504.2, found 505.0 ([M+H
+]). 
Data for   N-term (16). 1H NMR (400 MHz, DMSO-d6)  8.76 (d, 1H, J = 8.4 Hz),  
8.18 (d, 1H, J = 7.5 Hz),  8.06 (d, 1H, J = 7.8 Hz),  7.34 (d, 1H, J = 8.7 Hz),  7.26 
(m, 3H),  7.20 (m, 2H),  5.09 (t, 1H, J = 5.0 Hz),  4.98 (t, 1H, J = 5.3 Hz),  4.54 
(m, 1H),  4.26 (m, 1H),  4.18 (m, 1H),  3.88 (m, 1H),  3.64 (m, 4H),  3.33 (obsc, 
1H),  3.21 (m, 1H),  2.85 (m, 2H),  2.62 (obsc, 1H),  2.34 (m, 1H),  1.42 (m, 1H), 
 1.24 (m, 2H),  0.74 (d, 3H, J = 6.3 Hz),  0.70 (d, 3H, J = 6.3 Hz); ESI-MS m/z 
calcd for C24H34N4O7S 522.2, found 523.0 ([M+H
+]). 
Data for AIP-I M8pMet-Biotin (19). ESI-MS m/z calcd for C54H74N12O15S2 1195.4, 
found 1195.9 ([M+H+]). 
Data for AIP-I M8pMet (20). ESI-MS m/z calcd for C44H60N10O13S 969.1, found 
969.9 ([M+H+]). 
trAIP-II Lactam (15) Synthesis. The peptide was synthesized similarly to the 
full-length AIP-II lactam (19). Chain elongation was completed using Fmoc-SPPS 
protocols. Fmoc-Serine(benzyl)-OH was used in residue positions two and three. 
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Fmoc-DAPA(Boc)-OH was used in place of cysteine in position one. Once 
cleaved from the resin with TFA, the partially protected linear peptide was 
cyclized with PyBop and DIEA, purified by semipreparative HPLC, and treated 
with 25:1 HF:4-methyl-phenol (p-cresol) for 1 h at 0 oC to remove the benzyl 
groups. The final product was purified with semipreparative HPLC. 1H NMR 
(400 MHz, DMSO-d6)  8.67 (m, 1H),  8.11 (m, 1H),  8.04 (m, 1H),  7.72 (m, 1H), 
 7.59 (m, 1H),  7.49 (m, 1H),  7.20 (m, 5H),  4.38 (m, 2H),  4.31 (m, 1H),  3.94 
(m, 1H),  3.84 (m, 1H),  3.79 (m, 1H),  3.71 (m, 1H),  3.62 (m, 3H),  3.21 (obsc, 
1H),  3.00 (m, 1H),  2.85 (m, 1H),  1.84 (s, 3H),  1.37 (m, 1H),  1.25 (m, 1H),  
1.10 (m, 1H),  0.76 (d, 3H, J = 6.5 Hz),  0.69 (d, 3H, J = 6.2 Hz); ESI-MS m/z calcd 
for C26H38N6O8S 562.3, found 563.5 ([M+H
+]). 
Boc-SPPS of AIPs. AIP-II N3A, L8A, F9A, F9Nal, native AIPs, and peptides 13, 
17, and 18 were manually synthesized. Manual solid phase peptide synthesis 
with standard in situ neutralization/HBTU activation protocol for Boc chemistry 
(82) was used for chain elongation on a mercaptopropionamide MBHA resin.
Leucine was double-coupled to N-methylated phenylalanine with HBTU, then 
HATU. Peptides were cleaved from the resin by treatment with 25:1 HF:p-cresol 
for 1 h at 0 oC, precipitated and washed with diethyl ether, and purified by 
semipreparative or preparative HPLC. After lyophilization, the linear peptides 
were dissolved again in MeCN, water, and 0.1% TFA and cyclized in solution by 
the addition of 4x volume of 0.1 M sodium phosphate buffer, pH 7, for 2 h at 
room temperature. The final products were purified by semipreparative or 
preparative HPLC. 
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Data for AIP-II N3A. ESI-MS m/z calcd for C37H57N9O11S 836.0, found 836.9 
([M+H+]). 
Data for AIP-II L8A. ESI-MS m/z calcd for C35H52N10O12S 836.9, found 837.9 
([M+H+]). 
Data for AIP-II F9A. ESI-MS m/z calcd for C32H54N10O12S 802.9, found 803.9 
([M+H+]). 
Data for AIP-II F9Nal. ESI-MS m/z calcd for C42H60N10O12S 929.1, found 929.9 
([M+H+]). 
Data for N-MeF (13). 1H NMR (400 MHz, DMSO-d6)  8.50 (d, 1H, J = 8.3 Hz),  
8.25 (d, 1H, J = 8.6 Hz),  7.86 (d, 1H, J = 9.2 Hz),  7.80 (d, 1H, J = 9.1 Hz),  7.25 (m, 
3H),  7.14 (m, 2H),  5.16 (m, 1H),  5.00 (m, 1H),  4.63 (m, 1H),  4.39 (m, 1H),  
4.28 (m, 1H),  4.25 (m, 1H),  4.20 (m, 1H),  3.63 (m, 1H),  3.53 (m, 3H),  3.21 
(obsc, 2H),  3.19 (obsc, 1H),  2.89 (m, 1H),  2.64 (s, 3H),  1.88 (s, 3H),  1.52 (m, 
2H),  1.32 (m, 1H),  0.86 (d, 3H, J = 6.0 Hz),  0.81 (d, 1H, J = 6.1 Hz); ESI-MS m/z 
calcd for C27H39N5O8S 593.3, found 595.0 ([M+H
+]). 
Data for AIP-II Bpa-Biotin (17). ESI-MS m/z calcd for C64H85N13O16S2 1356.6, 
found 1357.9 ([M+H+]). 
Data for AIP-II Bpa (18). ESI-MS m/z calcd for C54H71N11O14S 1130.3, found 1131.6 
([M+H+]). 
(S)-4-methyl 1-perfluorophenyl 2-(tert-butoxycarbonylamino)succinate (21). 
Boc-Glu(OMe)-OH.DCHA (5.0 g, 11.3 mmol, 1.0 equiv) was added to 1.5 M 
H2SO4 (9 mL), extracted with ethyl acetate (35 mL), washed with H2O, dried over 
Na2SO4, filtered, and solvent was removed in vacuo to give 3.0 g Boc-Glu(OMe)-
OH (99%) as a yellow oil. Boc-Glu(OMe)-OH (3.0 g, 11.3 mmol, 1.0 equiv) was 
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next dissolved in DMF (76 mL) and pyridine (1.10 mL, 13.7 mmol, 1.2 equiv) 
under Ar. Pentafluorophenyl trifluoroacetate (2.46 mL, 14.3 mmol, 1.25 equiv) 
was added slowly, the reaction was stirred at room temperature 1 h, then diluted 
with ethyl acetate. The product was washed with 1 N HCl, NaHCO3, H2O, and 
brine, dried over Na2SO4, filtered, and the solvent was removed in vacuo to give 
4.6 g of 21 as a yellow oil (94%). The product was taken onto the next step 
without further purification.  
(S)-5-methyl 1-perfluorophenyl 2-(tert-butoxycarbonylamino)pentanedioate 
(22). Boc-Asp(OMe)-OH (3.7 g, 14.9 mmol, 1.0 equiv) was next dissolved in DMF 
(65 mL) and pyridine (1.44 mL, 17.8 mmol, 1.2 equiv) under Ar. 
Pentafluorophenyl trifluoroacetate (3.2 mL, 18.6 mmol, 1.25 equiv) was added 
slowly, the reaction was stirred at room temperature 1 h, then diluted with ethyl 
acetate. The product was washed with 1 N HCl, NaHCO3, H2O, and brine, dried 
over MgSO4, filtered, and the solvent was removed in vacuo to give 4.9 g of 22 as 
a yellow oil (79%). The product was taken onto the next step without further 
purification. 
(S)-methyl 5-(3-bromopropylamino)-4-(tert-butoxycarbonylamino)-5-oxopenta-   
noate (23). A solution of 21 (4.6 g, 10.7 mmol, 1.2 equiv) dissolved in DIEA (1.86 
mL, 10.7 mmol, 1.2 equiv) and DMF (24 mL) was stirred at room temperature 30 
min under Ar. A solution of 3-bromopropyl ammonium bromide (1.95 g, 8.9 
mmol, 1.0 equiv) in DIEA (1.55 mL, 8.9 mmol, 1.0 equiv) and DMF (8 mL) was 
added to the reaction mixture, which was stirred at room temperature 5 h, 
diluted with ethyl acetate, washed with H2O, dried over Na2SO4, filtered, and the 
solvent was removed in vacuo. The product was purified by flash 
chromatography using 2:5 ethyl acetate/hexanes to give 1.8 g of 23 (52%).  
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(S)-methyl 5-(3-azidopropylamino)-4-(tert-butoxycarbonylamino)-5-oxopenta- 
noate (24). (This step was completed by Matthew Pratt.) Bromide 23 (1 g, 2.6 
mmol, 1.0 equiv) was dissolved in DMF (20 mL) and the mixture was heated to 
45 °C.  NaN3 (660 mg, 13.1 mmol, 5.0 equiv) was added, and the reaction was 
stirred for 16 h.  At this time, the reaction was cooled to room temperature, 
diluted with ethyl acetate (100 mL) and washed with H2O (50 mL) two times.  
The organic layer was dried over Na2SO4, filtered, and concentrated.  Silica gel 
chromatography (50% ethyl acetate in hexanes) yielded 620 mg of 24 (70%) as a 
clear oil. The reaction was repeated to give 1.3 g of 24 for the next step. 
(S)-methyl 5-(3-azidopropylamino)-4-((S)-2-(tert-butoxycarbonylamino)-4-  
methoxy-4-oxobutanamido)-5-oxopentanoate (25). A solution of 24 (1.3 g, 3.82 
mmol, 1.0 equiv) in 95:5 TFA/H2O (21 mL) was stirred at room temperature 1 h. 
The solvent was removed by azeotrope with toluene, and the product ((S)-
methyl 4-amino-5-(3-azidopropylamino)-5-oxopentanoate, 928 mg, 3.82 mmol, 
1.0 equiv), was then added to a solution of 22 (1.9 g, 4.43 mmol, 1.2 equiv) in 
DIEA (664 μL, 3.82 mmol, 1.0 equiv) and DMF (13 mL). The reaction was stirred 
at room temperature 21 h, diluted with ethyl acetate, washed with 1 N HCl, 
NaHCO3, H2O, and brine, dried over MgSO4, filtered, and the solvent was 
removed in vacuo. The product was purified by flash chromatography using 4:1 
ethyl acetate/hexanes to give 406 mg of 25 (23%) as a clear oil. 
(2S,3S)-2-ethyl 3-perfluorophenyl oxirane-2,3-dicarboxylate. (This step was 
completed by Matthew Pratt.) First, the epoxide, (2S,3S)-3-
(ethoxycarbonyl)oxirane-2-carboxylic acid, was synthesized by the route 
reported by Meara et al. (126). This expoxide (1 g, 6.25 mmol) was dissolved in 
DMF (20 mL) and pyridine (560 uL, 6.88 mmol) under an inert atmosphere.  
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Pentafluorophenyl trifluoroacetate (1.24 mL, 7.19 mmol) was then added slowly, 
and the reaction was stirred for 16 h.  Dilution with ethyl acetate (50 mL) was 
followed by washes with 1 N HCl, H2O, and brine.  The organic layer was dried 
over Na2SO4, filtered, and concentrated.  The resulting pink solid was used in the 
next reaction without further purification. 
(2R,3R)-ethyl 3-((S)-1-((S)-1-(3-azidopropylamino)-5-methoxy-1,5-dioxopentan-
2-ylamino)-4-methoxy-1,4-dioxobutan-2-ylcarbamoyl)oxirane-2-carboxylate 
(26). A solution of 25 (100 mg, 0.212 mmol, 1.0 equiv) in 95:5 TFA/H2O (18 mL) 
was stirred at room temperature 1 h. The solvent was removed by azeotrope 
with toluene, and the product, ((S)-methyl 4-((S)-2-amino-4-methoxy-4-oxobut- 
anamido)-5-(3-azidopropylamino)-5-oxopentanoate, 79 mg, 0.212 mmol, 1.0 
equiv), was then added to a solution of (2S,3S)-2-ethyl 3-perfluorophenyl 
oxirane-2,3-dicarboxylate (83 mg, 0.254 mmol, 1.2 equiv) in DIEA (37 μL, 0.212 
mmol, 1.0 equiv) and DMF (4.5 mL). The reaction was stirred at room 
temperature 19 h, diluted with ethyl acetate, washed with 1 N HCl, NaHCO3, 
H2O, and brine, dried over MgSO4, filtered, and the solvent was removed in 
vacuo. The product was purified by flash chromatography using 15% hexanes in 
ethyl acetate to give 52 mg of 26 (48%) as a white solid. 1H-NMR (100 MHz, 
CDCl3)  7.58 (d, 1H, J = 7.2 Hz),  7.07 (d, 1H, J = 7.9 Hz),  6.73-6.70 (m, 1H),  
4.72 (q, 1H, J = 6.0 Hz),  4.38-4.33 (m, 1H),  4.32-4.23 (m, 2H),  3.89 (s, 1H),  
3.73 (m, 7H),  3.34 (m, 4H),  3.05 (dd, 1H, J = 17.2, 4.3 Hz),  2.79 (dd, 1H, J = 
17.3, 6.1 Hz),  2.59 (m, 1H),  2.46-2.39 (m, 1H),  2.14-2.08 (m, 2H),  1.81-1.78 
(m, 2H),  1.32 (t, 3H J = 7.1 Hz); 13C-NMR (101 MHz, CDCl3)  175.30, 172.13, 
171.04, 170.29, 167.06, 166.96, 62.72, 54.17, 53.80, 53.04, 52.66, 52.55, 49.84, 49.45, 
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37.40, 36.11, 30.70, 28.91, 26.75, 14.43; ESI-MS m/z calcd for C20H30N6O10 514.5, 
found 537.0 ([M+Na+]) and 515.0 ([M+H+]). 
AgrB Inhibition Assay. Cultures of strains RN7206 (agr null) and RN6734 (agr 
group I) were grown to early exponential phase, pelletted and washed with 
media, and the supernatants were discarded. The cultures were re-suspended in 
media containing 0.5 nM–100 μM compound 26 or only DMSO vehicle and 
grown 1 h. Cells were pelleted, and the supernatants were recovered, filtered, 
and tested for AIP activity in the reporter assay. The cell pellets were then re-
suspended in media containing 0.5 nM–100 μM compound 26 or only DMSO 
vehicle a second time and grown for 40 min. The supernatants were recovered 
and tested for activity as in the first test. 
Reporter Assays. AIP activities were analyzed using a previously described 
method with a -lactamase reporter gene read-out (52). Strains RN9222, RN9372  
containing plasmid-borne agrC and P3-blaZ (assays performed in Chapters 2 & 
4), or derivatives of RN10829 containing plasmid-borne agrC and chromosomal 
P3-blaZ (assays performed in Chapter 3) were grown to mid-exponential phase 
and transferred to microtiter plates. In experiments involving constitutive 
mutants, growth proceeded without transfer to microtiter plates. 80 μL aliquots 
were treated in duplicate with synthetic AIPs or supernatants for 1 h with 
shaking at 37 oC in a THERMOmax microplate reader (Molecular Devices). Cell 
density was monitored by OD650 readings taken every 1 min. Immediately 
following Nitrocefin addition, hydrolysis was monitored by OD490 readings taken 
every 20 seconds over 20 min. All peptide stock solution concentrations were 
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determined by amino acid analysis (AAA) at the Keck AAA and Protein 
Sequencing Lab (Yale University, New Haven, CT). 
Assay data were normalized to percent maximal activation and plotted as 
initial -lactamase reaction velocity versus log peptide concentration. PRISM 4.0 
(GraphPad, San Diego) was used to fit individual agonist or antagonist dose-
response curves via nonlinear regression to the following four-parameter logistic 
equation: 
E = basal+
Emax  basal
1+10logEC50 log[A]nH
 
in which E denotes effect, [A] denotes the agonist concentration, nH denotes the 
midpoint slope, EC50 denotes the midpoint location parameter, and Emax and 
basal denote the upper and lower asymptotes, respectively. For inhibition curves, 
the midpoint location parameter from the above equation reflects the IC50. Each 
data point represents two or three replicates, and error bars represent standard 
error measurements. All curves shown in the same graph correspond to 
experiments performed on the same day.  
Bacterial Strains and Growth Conditions. The S. aureus strains used in this 
study (Table 7) are derivatives of NCTC8325. RN7206 is a derivative of the 
standard agr group I laboratory strain, RN6734, in which the agr locus has been 
replaced by tetM. Cloning was performed using E. coli strain DH5. All clones 
were first transformed into RN4220, the standard recipient for E. coli DNA, 
before transduction to other strains. S. aureus cells from overnight plates 
containing the appropriate selective antibiotics (chloramphenicol, 10 mg/ml 
and/or erythromycin, 10 mg/ml) were used as inocula for all experiments. 
Subsequent growth in CYGP or MH broth without antibiotics was performed at  
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Table 7. Strains and Plasmids Used in this Study. 
Strain or 
Plasmid 
Genotype or Description Reference 
S. aureus strains 
RN4220 Restriction-deficient mutant of strain 8325-4 (127) 
RN6734 Standard agr-I laboratory strain (13) 
RN7206 agr::tetM replacement in RN6734 (13) 
RN9222 RN6911 (agr::tetM replacement in agr-I strain) 
containing pRN7062 (P2-agrCA-I; P3-blaZ) (Group I 
-lactamase reporter strain) 
(40) 
RN9372 RN9120 (agr::tetM replacement in agr-II strain) 
containing pRN7035 (P2-agrCA-II; P3-blaZ) (Group II 
-lactamase reporter strain) 
(40) 
RN10828 RN7206 containing pRN9253 (P2-agrBDA; P3-
RNAIII) integrated into the SaPI1 att site (hemolysis 
assay strain) 
(58) 
RN10829 RN7206 containing pRN9254 (P2-agrA; P3-blaZ) 
integrated into the SaPI1 att site (-lactamase reporter 
strain) 
(58) 
EG61 RN7206 containing pRN9256 (P2-agrBD; P3-RNAIII) 
integrated into the SaPI1 att site ( agrA strain) 
This work 
E. coli strains 
DH5 Standard recipient for plasmid cloning Promega 
XL1-Blue Supercompetent cells Stratagene 
Plasmids 
pRN9256 Shuttle/suicide vector pJC1111 (58) containing SaPI1 
integration cassette and agrA construct (P2-agrBD; 
P3-RNAIII) 
This work 
pRN9231 Shuttle vector with promoter P2, insertion site for 
agrC, P2 terminator, pT181 replicon, and Em marker 
(58) 
pEG54 pRN9231 containing replacements by pC194 replicon 
and Cm marker 
This work 
pRN9232 pRN9231 with agrC-I (58) 
pEG55 pEG54 with agrC-I This work 
pEG58 pRN9231 with agrC-IKin (G394A,G396A) -HA This work 
pEG59 pEG54 with agrC-IHis (H239Q) -PKA This work 
pEG60 pRN9231 with agrC-I G394A This work 
pEG61 pRN9231 with agrC-I G396A This work 
pEG62 pRN9231 with agrC-I N339D This work 
pEG63 pRN9231 with agrC-I-gfp This work 
pEG64 pRN9231 with agrC-IKin-gfp This work 
pEG65 pEG54 with agrC-IHis-gfp This work 
pEG66 pRN9231 with agrC-I 1-204 This work 
pEG67 pRN9231 with agrC-I 1-175 This work 
pEG68 pRN9231 with agrC-I 35-175 This work 
pEG69 pRN9231 with agrC-I 1-135 This work 
pEG70 pRN9231 with agrC-I 1-72 This work 
pEG71 pRN9231 with agrC-IKin 1-204 This work 
pEG72 pRN9231 with agrC-IKin 1-175 This work 
133
Table 7. (continued) 
pEG73 pRN9231 with agrC-IKin 35-175 This work 
pEG74 pRN9231 with agrC-IKin 1-135 This work 
pEG75 pRN9231 with agrC-IKin 1-72 This work 
pEG78 pRN9231 with agrC-I 1-204-gfp This work 
pEG79 pRN9231 with agrC-I 1-175-gfp This work 
pEG80 pRN9231 with agrC-I 35-175-gfp This work 
pEG81 pRN9231 with agrC-I 1-135-gfp This work 
pEG82 pRN9231 with agrC-I 1-72-gfp This work 
pRN9248 pRN9231 with agrC-ISensor (T104V, S107V, S116I) (58) 
pEG83 pRN9231 with agrC-ISensor, Kin This work 
pEG84 pEG54 with agrC-ISensor, His This work 
pEG85 pRN9231 with agrC-ISensor-gfp This work 
pEG86 pRN9231 with agrC-I R238H (42) This work 
pEG87 pRN9231 with agrC-IKin R238H  This work 
pEG88 pEG54 with agrC-IHis R238H This work 
pEG89 pRN9231 with agrC-I R238H-gfp This work 
pEG90 pEG54 with agrC-I R238H-HA This work 
pEG97 pRN9231 with agrC-II This work 
pEG99 pEG54 with agrC-IIHis This work 
pEG100 pRN9231 with agrC-IIKin This work 
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37 °C with shaking. Cell density was determined using a THERMOMax 
microplate reader (Molecular Devices) to measure the OD650 of 100 μL culture 
samples.  
Plasmid and Reporter Construction. The plasmids used in this study (Table 7) 
were prepared by cloning PCR products obtained from oligonucleotide primers 
(Table 8). Clones were sequenced by the Skirball DNA Sequencing Core Facility 
or Genewiz. Plasmid pRN9231 was used as the backbone vector for WT agrC and 
G-box mutant constructs and contains the agrP2 promoter, an erythromycin 
resistance cassette, and the pT181 replicon (58). Compatible plasmid pEG54, 
which served as the backbone vector for H-box mutant agrC constructs, was 
created by replacing the resistance cassette and replicon of pRN9231 with a 
chloramphenicol resistance cassette and the pC194 replicon, cloned with ApaI  
and NarI sites.  These plasmids contain an insertion site for agrC, formed by PstI 
and KpnI restriction sites, such that agrC expression is driven by agrP2.  Point 
mutations in agrC were introduced via QuikChange (Stratagene) or by two-step 
PCR.  agrC truncation and deletion mutants were constructed by inverse PCR on 
pUC18 subclones, closing on silent AflII or BglII sites. A C-terminal AgrC 
translational fusion to GFP was constructed using an in-frame XbaI site, and 
subsequent GFP-tagged mutants were created either by site-directed 
mutagenesis as above or using a ClaI site endogenous to agrC to swap in the 
mutant sequences.  A chromosomal agr locus derivative lacking agrC, B, and D 
was constructed by deleting agrB and D from pRN9254. 
Fluorescence Microscopy. Cultures were grown to high optical density (OD650 
>0.5), pelleted, and re-suspended in PBS, concentrating the cells up to 50-fold 
relative to the liquid culture density. 5 mL aliquots of cells were added to # 1.5  
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Table 8. Oligonucleotide Primers Used in this Study. 
Primer Sequence (5’ – 3’)* RE 
site 
used 
AgrC-I-F CCAGCTGCAGGAAGTACCAAAAGAATTAACACAA PstI 
KpnI-R GAGCTCGGTACCTTCATACATTCACATCCTTATGGCTAGTTG KpnI 
H239Q-F GCGCAAGTTCCGTCAGGATTATGTCAATATC  
H239Q-R GATATTGACATAATCCTGACGGAACTTGCGC  
G394A-F GGTGAAGGTCGTGCTTTAGGTCTATCAAC  
G394A-R GTTGATAGACCTAAAGCACGACCTTCACC  
G396A-F GGTGAAGGTCGTGGTTTAGCTCTATCAAC  
G396A-R GTTGATAGAGCTAAACCACGACCTTCACC  
G394, 6A-F GGTGAAGGTCGTGCTTTAGCTCTATCAAC  
G394, 6A-R GTTGATAGAGCTAAAGCACGACCTTCACC  
N339D-F GGTATTATTCTTGATGATGCAATTGAGGCATC  
N339D-R GATGCCTCAATTGCATCATCAAGAATAATACC  
 1-175-F ACTCGCTTAAGGCTAAAGTAATAAGGCAGTATTC Afl-II 
 35-175-F ACTCGCTCGAGGCTAAAGTAATAAGGCAGTATTC XhoI 
 35-175-R AATACTCGAGTTTACTGTACTTAATACCACTAATTATAGCTG XhoI 
 1-135-F GAGTTCTTAAGAAAATTAGCACACCATATCTAATAC AflII 
 1-72-F ATTTTCTTAAGATCAAATGGTATTCTATTTTGTTG AflII 
aflII-R TAACTATTTAACTTAAGCACCTACTATCACACTCTC AflII 
AgrCI-I 
H239Q-R GACATAATCCTGACGGAACTTGCGCATTTCATTATTAATTG 
 
AgrC-II-
H239Q-F GCGCAAGTTCCGTCAGGATTATGTCAATATCTTAACGACAC 
 
AgrC-I-GFP-
Xba-R 
CTTATCTAGAATTGTTAATAATTTCAACTTTTTGAATAAAGAAAC
C 
XbaI 
AgrC-I-GFP-
Kpn-F 
TAAGGGTACCTGCAGAAGTACCAAAAGAATTAACACAATTACA
CG 
PstI, 
KpnI 
R238H, 
H239Q-R 
GTAGCCCGGGCATGTCATCTTCTCGAATGTATTCTGAAAGTGTC
GTTAAGATATTGACATAATCCTGATGGAACTTGCGCATTTCGTTG
TTG 
XmaI 
XmaI-F GACATGCCCGGGCTACGTGATTATTTCAATAAAAATATTGTACC XmaI 
R238H-HA-F GCGCAAGTTCCATCATGATTATGTCAATATC  
R238H-HA-R GATATTGACATAATCATGATGGAACTTGCGC  
R238H-GFP-F GCGCAAGTTCCATCATGATTATGTC  
R238H-GFP-R GACATAATCATGATGGAACTTGCGC  
Restriction sites are underlined. Overlapping restriction sites in AgrC-I-GFP-
Kpn-F are underlined (KpnI) and italicized (Pst1).  
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coverslips that were previously coated with poly-lysine solution and placed on 
glass slides. Imaging was immediately carried out on a DeltaVision image 
restoration microscope (Applied Precision/Olympus). Images were deconvolved 
with SoftWoRx (Applied Precision).  
Western Blotting. Cultures were grown to high optical density (OD650 >0.5), 
pelleted, and washed with buffer containing 10mM Tris-HCl, pH 7.4, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, and 1.1 M sucrose (wash buffer). Cells 
were lysed by treatment with 100 μg/mL lysostaphin in wash buffer containing 
protease inhibitors, followed by rocking for 10 min at 37 oC, high speed spin (30 
min, 8,000g), removal of supernatant, and resuspension in lysis buffer (50 mM 
Tris-HCl, pH 7.4, 0.5% NP-40, 5 mM MgCl2; or 50 mM Tris-HCl, pH 7.4, 1.0% NP-
40, 0.25% DOC, 150 mM NaCl, and 1 mM EGTA) containing 10 μg/mL DNase 
and protease inhibitors. Lysates were incubated on ice 10 min, and the soluble 
fractions were removed following 30 min spin at 10,000g. Total protein 
concentrations of the soluble fractions were determined by BCA assay. SDS 
loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 1 mg/mL bromophenol blue, 
10% glycerol) was added to samples, which were then untreated or acidified 
with Immuno Elution buffer (Pierce) prior to loading on 10-20% Criterion Tris-
HCl gel. Protein transfer to nitrocellulose membrane was followed by 
immunoblotting with mouse anti-GFP, mouse anti-HA, or rabbit anti-Sortase 
primary antibodies and anti-mouse HRP or anti-rabbit HRP secondary 
antibodies. Visualization was carried out with ECL or ECL Plus. 
Immunoprecipitation. Cultures of derivatives of RN10306 containing GFP 
and/or HA-tagged AgrC were grown to high optical density (OD650 >0.5). Each 
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culture was split into two subcultures, one treated with 1 uM AIP-I and one with 
buffer. All subcultures were grown for an additional 15 minutes. Cells were then 
pelleted, washed, and lysed, as for western blotting. 250 μg aliquots of total 
protein, diluted with lysis buffer to uniform final volumes, were added to 25 μL 
aliquots of anti-HA affinity matrix washed with lysis buffer. Samples were 
incubated 1 h at 4 ªC, with mixing by slow rotation. Unbound material was 
removed following centrifugation. Beads were washed gently three times with 
lysis buffer, and bound proteins were eluted with Immuno Elution buffer 
(Pierce) by gentle mixing for three minutes. Analysis of samples was completed 
by western blot, as above. 
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Appendix: NMR Chemical Shift Assignments of trAIP-II and Derivatives. 

AIP 
Derivative NH  H H Other 
6 trAIP-II           
Cys 8.46 4.39 3.16, 2.85     
Ser  8.11 4.22 3.64, 3.52   5.03 
Ser  7.60 4.28 3.58   5.12 
Leu 8.13 3.92 1.38, 1.30 1.22 0.74, 0.71 
Phe 8.68 4.56 3.31, 2.83   7.25, 7.21 
Ac         1.86 
7 S2G           
Cys 8.44 4.32 3.16, 2.87     
Gly 8.21 3.89, 3.52       
Ser 7.59 4.21 3.62, 3.32   5.21 
Leu 7.99 3.98 1.31 1.18 0.74, 0.69 
Phe 8.67 4.59 3.31, 2.81   7.26, 7.20 
Ac         1.86 
8 S3G           
Cys 8.30 4.44 3.13, 2.62     
Ser 7.99 4.39 3.57   4.94 
Gly 8.46 3.79, 3.58       
Leu 8.36 3.99 1.12 1.49 0.78, 0.71 
Phe 8.02 4.64 3.35, 2.91   7.24, 7.20 
Ac         1.86 
9 GG           
Cys 8.30 4.42 3.18, 2.72     
Gly 8.39 4.10, 3.29       
Gly 8.08 3.79, 3.58       
Leu 8.28 3.98 1.43 1.10 0.78, 0.71 
Phe 8.15 4.67 3.28, 2.87   7.26, 7.22 
Ac         1.86 
10 N-MeS2           
Cys 8.56 5.00 3.12, 2.83     
N-MeSer   4.14 3.79   OH 4.92, Me 3.01 
Ser 7.49 4.95 3.73   5.25 
Leu 7.98 4.08 1.26 1.15 0.73 
Phe 8.73 4.38 3.33, 2.90   7.25, 7.19 
Ac         1.87 
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NMR Chemical Shift Assignments (continued). 
 
 NH  H H Other 
11a N-MeS3 
(trans)           
Cys 8.47 4.12 3.13, 2.96     
Ser 8.11 4.90 3.57, 3.26     
N-MeSer   4.11 3.77, 3.63   Me 2.66 
Leu 7.48 4.35 1.41, 1.34 1.29 0.77, 0.76 
Phe 8.66 4.26 3.24, 2.97   7.14 
Ac         1.86 
11b N-MeS3 
(cis)           
Cys 8.24 4.45 3.15, 2.49     
Ser 8.09 4.83 3.56, 3.34     
N-MeSer   4.51 3.88, 3.55   Me 2.66 
Leu 7.48 3.99 1.35 1.46 0.74, 0.72 
Phe 8.08 4.59 3.29, 3.02   7.25 
Ac         1.86 
12 N-MeL           
Cys 8.45 4.44 3.11, 2.89     
Ser 8.05 4.22 3.63, 3.50   4.82 
Ser 7.76 4.67 3.63, 3.36   5.15 
N-MeLeu   3.45 1.90, 1.37 1.25 0.75, 0.69, Me 3.01 
Phe 8.25 4.75 3.37, 2.70   7.25, 7.21 
Ac         1.85 
13 N-MeF           
Cys 8.50 4.39 3.19, 2.89     
Ser 8.25 4.20 3.55   5.16 
Ser 7.80 4.28 3.63, 3.51   5.00 
Leu 7.86 4.63 1.52 1.32 0.86, 0.81 
N-MePhe   4.25 3.21   
Ar 7.25, 7.14, Me 
2.64 
Ac         1.86 
14 Meth 
Link           
Cys 8.24 4.34 3.21, 2.90     
Pent 8.09 3.43, 2.73 2.11, 2.01 1.55, 1.32 1.50 
Leu 7.74 4.20 1.25, 1.14 0.97 0.75, 0.68 
Phe 7.94 4.67 3.28, 2.79   7.26, 7.20 
Ac         1.84 
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NMR Chemical Shift Assignments (continued). 
 
 NH  H H Other 
15 Lactam           
Dapa 8.11 4.38 3.62, 2.85   7.59 
Ser 8.04 4.31 3.79, 3.71   5.32 
Ser 8.67 3.84 3.62     
Leu 7.72 3.94 1.10, 1.25 1.37 0.69, 0.76 
Phe 7.49 4.36 3.21, 3.00   7.20 
Ac         1.84 
16  N-term           
Mercap   2.62, 2.34 2.87, 3.21     
Ser 8.06 4.18 3.64   4.98 
Ser 7.34 4.26 3.64   5.09 
Leu 8.18 3.88 1.24 1.42 0.74, 0.70 
Phe 8.76 4.54 3.33, 2.83   7.26, 7.20 

Ac = N-terminal acetyl group. Pent = 5-aminopentanoic acid.  
Dapa = 2,3-diaminopropanoic acid. Mercap = 3-mercaptopropanoic acid. 
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